

## GLOSSARY RESOURCES

The resources listed below were used as sources for the lists of terms at the end of each chapter:

Bulletin of Experimental Treatments for AIDS. Glossary. San Francisco AIDS Foundation.  
<http://www.thebody.com/sfaf/summer01/glossary.html> (accessed on 2 June 2004).

Carlton Hogan and the University of Minneapolis. Glossary of Medical, Statistical and Clinical Research Terms.  
<http://www.specialweb.com/aids/glossary.html> (accessed on 3 June 2004).

Dorland's Medical Dictionary.  
[http://www.mercksource.com/pp/us/cns/cns\\_hl\\_dorlands.jspzQzpgzEzzSzppdocszSzuszSzcommonzSzdorlandzSzdorlandzSzdmd\\_m\\_05zPzhtm](http://www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspzQzpgzEzzSzppdocszSzuszSzcommonzSzdorlandzSzdorlandzSzdmd_m_05zPzhtm) (accessed on 3 June 2004).

Gay Men's Health Crisis. Glossary.  
<http://www.gmhc.org/health/glossary3.html> (accessed on 3 June 2004).

National Center for Toxicogenomics. Glossary. National Institutes of Health.  
<http://www.niehs.nih.gov/nct/glossary.htm> (accessed on 4th June 2004)

## ENDNOTES: Volume I

- Abbott Laboratories. Kaletra® (lopinavir/ritonavir). Package insert. 2001.  
[www.fda.gov/cder/foi/label/2001/21251s2lbl.pdf](http://www.fda.gov/cder/foi/label/2001/21251s2lbl.pdf) (accessed on 26 May 2004).
- Abbott Laboratories. Norvir, (ritonavir capsules). Package insert. 2003.  
[www.rxabbott.com/pdf/norpi2a.pdf](http://www.rxabbott.com/pdf/norpi2a.pdf) (accessed on 22 May 2004).
- Abdel-Hamid M, El-Daly M, El-Kafrawy S, et al. Comparison of second-and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus.  
*J Clin Microbiol* 40(5):1656-59. 2002.
- Abdulkarim AS, Zein NN, Germer JJ, et al. Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from Syria: identification of two novel hepatitis C virus subtypes.  
*Am J Trop Med Hyg* 59(4):571-76. 1998.
- Abergel A, Bonny C, Martineau N, et al. (abstract 342) Treatment of severe hepatitis C (METAVIR fibrosis score = 3 or 4) with peginterferon and ribavirin. Results from a French multicenter randomized controlled study. American Association for the Study of Liver Disease. Boston, Massachusetts. 2003.
- Accapezzato D, Fravolini F, Casciaro MA, et al. Hepatitis C flare due to superinfection by genotype 4 in an HCV genotype 1b chronic carrier. *Eur J Gastroenterol Hepatol* 14(8):879-81. 2002.
- Aceti A, Pasquazzi C, Zechini B, et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. *J Acquir Immune Defic Syndr* 29 (1):41-48. 2002.
- Adams NJ, Chamberlain RW, Taylor LA, et al. Complete coding sequence of hepatitis C virus genotype 6a. *Biochem Biophys Res Commun* 234(2):393- 96. 1997.
- Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology* 33(6):1358- 64. 2001.
- Agouron Pharmaceuticals. Rescriptor® (delavirdine mesylate). Package insert. 2002.  
[www.fda.gov/cder/foi/label/2002/20705slr009lbl.pdf](http://www.fda.gov/cder/foi/label/2002/20705slr009lbl.pdf) (accessed on 24 May 2004).
- Agouron Pharmaceuticals. Viracept® (nelfinavir mesylate). Package insert. 2004.  
[www.fda.gov/cder/foi/label/2004/20778se5-022,20779se5-042,21503se5-001\\_viracept\\_lbl.pdf](http://www.fda.gov/cder/foi/label/2004/20778se5-022,20779se5-042,21503se5-001_viracept_lbl.pdf) (accessed on 24 May 2004).
- Ahmad J, Dodson SF, Demetris AJ, et al. Recurrent hepatitis C after liver transplantation: a non-randomized trial of interferon alfa alone versus interferon alfa and ribavirin.  
*Liver Transpl* 7(10):863-69. 2001.

Ahmed F, Rovner D, Jacobson IM, et al. (abstract 1195) Seizures during pegylated interferon and ribavirin therapy for chronic hepatitis C in the WIN-R trial. American Association for the Study of Liver Disease. Boston, Massachusetts. 2003a.

Ahmed F, Jacobson IM, Chen ST, et al. (abstract 1196) Serious ophthalmologic events during pegylated interferon and ribavirin therapy for chronic hepatitis C: observations from the WIN-R trial. American Association for the Study of Liver Disease. Boston, Massachusetts. 2003b.

AIDS Clinical Trials Group. Table for Grading Severity of Adult Adverse Experiences. Division of AIDS, National Institute of Allergy and Infectious Diseases. Rockville, Maryland 1992.

Aitken C, Bowdon S, Hellard M, et al. Indications of immune protection from hepatitis C protection. *J Urban Health* 81 (1):58-60. 2004.

Aizawa A, Shibamoto Y, Takagi I, et al. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. *Cancer* 89(1):53-59. 2000.

Alvarez W, Li DS, Shah N, et al. (abstract 1013) Interferon treatment outcomes in patients with decompensated HCV+ cirrhosis. American Association for the Study of Liver Disease. Boston, Massachusetts. 2003.

Alberti A, Chemello L, Benvegna L. Natural history of hepatitis C. *J Hepatology* 31(Suppl 1):17-24. 1999.

Alberti A, Boccato S, Vario A, et al. Therapy of acute hepatitis C. *Hepatology* 36 (5 Suppl 1):S195-S200. 2002.

Allen SA, Spaulding AC, Osei AM, et al. Treatment of chronic hepatitis C in a state correctional facility. *Ann Intern Med* 138(3):187-90. 2003.

Allory Y, Charlotte F, Benhamou Y, et al. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. *Human Pathology* 31(1):69-74. 2000.

Alter HJ. Descartes before the horse: I clone, therefore I am: the hepatitis C virus in current perspective. *Ann Intern Med* 115(8):644-49. 1991.

Alter HJ. Discovery of non-A, non-B hepatitis and identification of its etiology. *Am J Med* 107(6B):16S-20S. 1999.

Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. *JAMA* 264(17):2231-35. 1990.

Alter MJ, Margolis HS, Krawczynski FN, et al. The natural history of community-acquired hepatitis C in the United States. The sentinel counties chronic non-A, non-B hepatitis study team. *N Engl J Med* 327:1899-1905. 1992.

Alter MJ. (editorial) Transmission of hepatitis C virus—route, dose and titer. *N Engl J Med* 330:784-86. 1994.

Alter MJ, Moyer LM. The importance of preventing hepatitis C virus infection among injection drug users in the United States. *J Acquir Immune Deficiency Syndromes and Human Retrovirology* 18(S1):S6-S10. 1998.

Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med* 341:556-62. 1999.

Alter MJ. Prevention of spread of hepatitis C. *Hepatology* 36(5, Suppl 1): S93-S98. 2002.

Amin J, Kaye M, Skidmore S, et al. HIV and hepatitis C coinfection within the CAESAR study. *HIV Med* 5(3):174-179. 2004.

Amoroso P, Rapicetta M, Tosti ME, et al. Correlation between virus genotype and chronicity rate in acute hepatitis C. *J Hepatol* 28(6):939-44. 1998.

Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside-and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. *Clin Infect Dis* 38:743-53. 2004.

Anthony KB, Yoder C, Metcalf JA, et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. *J Acquir Immune Defic Syndr* 33(2):125-33. 2003.

Anton C, Trifan A, Stanciu C, et al. Seizures during the treatment with interferon for chronic C hepatitis. *Rev Med Chir Soc Med Nat Iasi* 104(2): 135-7. 2000.

Arizcorreta C, Martinez C, Diaz F, et al. (abstract WePeB6036) Natural history of chronic hepatitis C: unusually rapid progression to liver fibrosis and cirrhosis in human immunodeficiency virus co-infected patients. XIV International AIDS Conference. Barcelona, Spain. 2002.

Armstrong GL, Alter MJ, McQuillan GM, et al. The past burden of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. *Hepatology* 31(3):777-82. 2000.

Asch SM, Kilbourne AM, Gifford AL, et al. Underdiagnosis of depression in HIV. *J Gen Intern Med* 18(6):450-60. 2003.

Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. *Amer J Gastroenterol* 95(6):1545-50. 2000.

Augenbraun M, Goedert JJ, Thomas D, et al. Incident hepatitis C in women with human immunodeficiency virus infection. *Clin Infect Dis* 37:1357-64. 2003.

Australasian Society for HIV Medicine. Dore G, Sasadeusz J, editors. Coinfection. HIV & Viral Hepatitis. A Guide for Clinical Management. 2003.  
<http://www.ashm.org.au/index.php?PageCode=1305&SD=10&DExpand=1> (accessed on 22 May 2004).

Azzam H, Ahmed F, Peterson B, et al. (abstract 1227) Delayed recovery of pegylated interferon and ribavirin induced anemia. American Association for the Study of Liver Disease. Boston, Massachusetts. 2003.

Azzari C, Resti M, Moriondo M, et al. Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection. *Blood* 96 (6):2045-48. 2000.

Backmund M, Meyer K, Von Zielonka M, et al. Treatment of hepatitis C infection in injection drug users. *Hepatology* 34(1):188-93. 2001.

Backus L, Phillips B, Boothroyd D, et al. (abstract 800) Hepatitis C co-infection increases mortality in HIV-infected U.S. veterans treated with highly active antiretroviral therapy. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2004.

Badizadegan K, Jonas MM, Ott MJ, et al. Histopathology of the liver in children with chronic hepatitis C viral infection. *Hepatology* 28(5):1416-23. 1998.

Baldo V, Floreani A, Dal Vecchio L, et al. Occupational risk of blood-borne viruses in healthcare workers: a 5-year surveillance program. *Infect Control Hosp Epidemiol* 23(6):325-327. 2002.

Ballesteros A, Tural C, Fuster D, et al. (abstract WePeB6045) Haematological toxicity, effect on CD4 cell count and on body mass index (BMI) of combined treatment with Peg-Intron® (1.5 µg/kg/week) + ribavirin (400 mg/bid) for hepatitis C virus (HCV) infection in HIV+ patients on antiretroviral therapy (ART). XIV International AIDS Conference. Barcelona, Spain. 2002.

Ballesteros A, Franco S, Fuster D, et al. Early HCV dynamics on peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. *AIDS* 18(1):59-66. 2004.

Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. *J Acquir Immune Defic Syndr* 26 (5):435-42. 2001.

Barbaro G, Di Lorenzo G, Asti A, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. *Am J Gastroenterol* 94(8):2198-205. 1999.

Barkhuizen A, Rosen HR, Wolf S, et al. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. *Am J Gastroenterol* 94(5):1355-60. 1999.

- Barrett S, Goh J, Coughlan B, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. *Gut* 49:423-30. 2001.
- Barry M, Wild M, Veal G, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. *AIDS* 8(8):F1-5. 1994.
- Bartlett JG. (abstract 19) Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois. 2001
- Bass NM. Is there any use for nontraditional or alternative therapies in patients with chronic liver disease? *Curr Gastroenterol Rep* 1(1):50-56. 1999.
- Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr* 21(2):114-19. 1999.
- Batise D, Van Huyen, J P, Piketty C, et al. (letter) Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues. *AIDS* 16(17): 2370-2371. 2002.
- Batki SL, Gruber VA, Bradley JM, et al. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. *Drug Alcohol Depend* 66(3):283-93. 2002.
- Bedossa P, Poynard T for the METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. *Hepatology* 24 (2):289-93. 1996.
- Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology* 38(6):1449-57. 2003.
- Bejarano PA, Koehler A, Sherman KE. Second opinion in liver biopsy. *Am J Gastroenterol* 96(11):3158- 64. 2001.
- Bell TM, Bansal AS, Shorthouse C, et al. Low-titre auto-antibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C. *J Gastroenterol Hepatol* 14(5):419-22. 1999.
- Beld M, Penning M, van Putten M, et al. Low levels of hepatitis C virus RNA in serum, plasma and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. *Blood* 94(4):1183- 91. 1999.
- Beltrami EM, Williams IT, Shapiro CN, et al. Risk and management of blood-borne infections in health care workers. *Clin Microbiol Rev* 13(3): 385-407. 2000.

- Benci A, Caremani M, Taconi D. Thrombocytopenia in patients with HCV-positive chronic hepatitis: efficacy of leucocyte interferon-alpha treatment. *Int J Clin Pract* 57(1):17-19. 2003.
- Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C coinfecting patients. *Hepatology* 30(4):1054-58. 1999.
- Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfecting patients: impact of protease inhibitor therapy. *Hepatology* 34(2):283-7. 2001.
- Benvegnù L, Pontissop P, Cavaletto D, et al. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. *Hepatology* 25(1):211-215. 1997.
- Benvegnù L, Chemello L, Noventa F, et al. Retrospective analysis of the effect of interferon therapy on the clinical outcomes of patients with viral cirrhosis. *Cancer* 83(5):901-9. 1998.
- Berenguer J, González J, Miralles P, et al. (abstract 960) Interferon alpha and ribavirin therapy for chronic hepatitis C in HIV-infected patients (GESIDA 28-02 Study). 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France. 2003a.
- Berenguer J, González J, Miralles P, et al. (abstract V-1726) Predictive value of early virologic response (EVR) in HIV-infected patients with chronic hepatitis C (CHC) treated with interferon alpha (IFN- $\alpha$ ) and ribavirin (RBV). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. 2003b.
- Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *Hepatology* 37(3):600-609. 2003.
- Berggren R, Jain M, Hester J, et al. (abstract 562) False-negative hepatitis C antibody is associated with low CD4+ cell counts in HIV/HCV-coinfecting individuals. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois. 2001.
- Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. *Clin Infect Dis* 33(10):1795-97. 2001.
- Bienvenu L, Burel F, Hofman V, et al. [A rare etiology of hepatic steatosis associated with lactic acidosis: the toxicity of antiviral nucleoside analogues]. *Ann Pathol* 21(2):160-63. 2001.
- Bini EJ, Currie S, Shen H, et al. (abstract 106426) Interferon and ribavirin therapy in patients coinfecting with HIV and hepatitis C. Abstracts of Digestive Disease Week. New Orleans, Louisiana. 2004.
- Bizollon T, Ahmed SN, Radenne S. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. *Gut* 52(2):283-87. 2003.

- Bjorkander J, Cunningham-Rundles C, Lundin P, et al. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. *Am J Med* 84(1):107-11. 1988.
- Bjoro K, Froland SS, Zhibing Y, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. *N Engl J Med* 331(24):1607-11. 1994.
- Blatt LM, Mutchnick MG, Tong MJ, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. *J Viral Hepat* 7(3):196-202. 2000.
- Bochet M, De Torres M, Valantin A, et al. (abstract 574) Efficacy and tolerance of IFN $\alpha$  plus ribavirin for chronic hepatitis C in HIV-infected patients. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois. 2001.
- Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. *Hepatology* 26(2):473-77. 1997.
- Bodsworth NJ, Cunningham P, Kaldor J, et al. Hepatitis C virus infection in a large cohort of homosexually active men: independent associations with HIV-1 infection and injecting drug use but not sexual behavior. *Genitourin Med* 72(118):118-122. 1996.
- Boeker KH, Haberkorn CI, Michels D, et al. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. *Clin Chim Acta* 316(1-2):71-81. 2002.
- Bogart LM, Kelly JA, Catz SL, et al. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. *J Acquir Immune Defic Syndr* 23(5):396-404. 2000.
- Boker KH, Dalley G, Bahr MJ, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. *Hepatology* 25(1):203-10. 1997.
- Bolumar F, Hernandez-Aguado I, Ferrer L, et al. Prevalence of antibodies to hepatitis C in a population of intravenous drug users in Valencia, Spain, 1990–1992. *Int J Epidemiol* 25(1):204-09. 1996.
- Boehringer Ingelheim. Dear Health Care Professional Letter. February 2004a. <http://www.viramune.com/> (accessed on 23 May 2004).
- Boehringer Ingelheim. Viramune® (nevirapine tablets). Package insert. 2004b. <http://www.viramune.com/> (accessed on 23 May 2004).
- Bonancini M, Govindarajan S, Blatt LM. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. *J Viral Hepat* 6(3): 203-08. 1999.



- Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection. *Arch Intern Med* 160:3365-73. 2000.
- Bonacini M, Groshen S, Yu MC, et al. Chronic hepatitis C in minority patients evaluated in Los Angeles County. *Am J Gastroenterol* 96(8):2438-41. 2001.
- Bonfanti P, Landonio S, Ricci E, et al. (letter) Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 27(3):316-18. 2001.
- Bonis PA, Tong MJ, Blatt LM, et al. A predictive model for the development of hepatocellular carcinoma, liver failure or liver transplantation for patients presenting to clinic with chronic hepatitis C. *Am J Gastroenterol* 94(6):1605-12. 1999.
- Bonnet F, Lawson-Ayayi S, Thiébaud R, et al. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. *Clin Infect Dis* 35:1231-37. 2002.
- Bonnet F, Bonarek M, Abridj A, et al. [Severe lactic acidosis in HIV-infected patients treated with nucleoside reverse transcriptase analogs: a report of 9 cases]. *Rev Med Interne* 24(1):11-16. 2003.
- Bortolotti F, Giacchino R, Vajro P, et al. Recombinant interferon-alfa therapy in children with chronic hepatitis C. *Hepatology* 22(6):1623-27. 1995.
- Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. *Clin Infect Dis* 33(11):1931-37. 2001.
- Bouscarat F, Samuel D, Simon F, et al. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. *Clin Infect Dis* 19(5):854-59. 1994.
- Bovier PA, Bock J, Loutan L, et al. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. *J Med Virol* 68(4):489-93. 2002.
- Boyd AE, Taylor C, Norris S, et al. (abstract 578) Liver Transplantation and HIV—a series of 7 patients. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois. 2001.
- Braü N, Rodriguez-Torres M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b + full-course vs. 16-week delayed ribavirin. *Hepatology* 39(4):989-98. 2004a.
- Braü N, Rodriguez-Torres M, Salvatore M, et al. (abstract 91) Control of HIV viral load through highly active antiretroviral therapy (HAART) slows down liver fibrosis progression in HIV/HCV-coinfection and makes it the same as in HCV-monoinfection. The Puerto Rico-New York Hepatitis C Study Group. 39th Meeting of the European Association for the Study of the Liver. Berlin, Germany. 2004b.
- Bressler BL, Guindi M, Tomlinson G, et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. *Hepatology* 38(3):639-44. 2003.

Brettler DB, Mannucci PM, Gringeri A, et al. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophiliac males: an International multi-center study. *Blood* 80(2):540-43. 1992.

Brienza RS, Stein MD, Chen M, et al. Depression among needle exchange program and methadone maintenance clients. *J Subst Abuse Treat* 18(4):331-37. 2000.

Briggs M, Baker C, Hall R, et al. Prevalence and risk factors for hepatitis C virus infection at an urban veterans administration medical center. *Hepatology* 34(6):1200-05. 2001.

Brinkman K. Editorial response: Hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. *Clin Infect Dis* 31:169-69. 2000.

Bristol Myers Squibb. Reyataz™ (atazanivir sulfate). Package insert. 2003.  
[www.fda.gov/cder/foi/label/2003/21567\\_reyataz\\_lbl.pdf](http://www.fda.gov/cder/foi/label/2003/21567_reyataz_lbl.pdf) (accessed on 22 May 2004).

Bristol Myers Squibb. Sustiva™ (efavirenz capsules). Package insert. 2002.  
[www.fda.gov/cder/foi/label/2002/21360lbl.pdf](http://www.fda.gov/cder/foi/label/2002/21360lbl.pdf) (accessed on 22 May 2004).

Bristol Myers Squibb. Videx, (didanosine). Package insert. 2001.  
[www.fda.gov/cder/foi/label/2001/videx\\_lbl.pdf](http://www.fda.gov/cder/foi/label/2001/videx_lbl.pdf) (accessed on 22 May 2004).

Bristol Myers Squibb. Zerit, (stavudine). Package insert. 2002.  
[www.fda.gov/cder/foi/label/2002/20412S017.pdf](http://www.fda.gov/cder/foi/label/2002/20412S017.pdf) (accessed on 22 May 2004).

British HIV Association Guidelines: HIV and chronic hepatitis. 2003.  
<http://www.bhiva.org/guidelines/2003/HCV/index.html> (accessed on 22 May 2004).

Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. *Arch Intern Med* 154(10):1121-27. 1994.

Broner RK, King VL, Kidorf M, et al. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. *Arch Gen Psychiatry*; 54(1):71-80. 1997.

Broussolle C, Steineur MP, Bailly F, et al. Hepatitis C virus infection and thyroid diseases. *Rev Med Interne* 20(9):766-73. 1999.

Bruchfeld A, Stahle L, Andersson J, et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection—a pilot study. *J Viral Hepatol* 8(4):287-92. 2001.

Bruchfeld A, Lindahl K, Schvarcz R et al. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. *Ther Drug Monit*; 24 (6): 701-8. 2002.

Bruguera M, Cremades M, Salinas R, et al. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. *J Clin Gastroenterol* 14(1):27-30. 1992.

Bruno R, Debiaggi M, Ciappina V, et al. (abstract 102172) Hepatitis C virus dynamics during therapy with peginterferon alfa-2a (PEGASYS®) compared to peginterferon alfa-2b (PEGINTRON®) in naïve patients with chronic hepatitis C. American Association for the Study of Liver Disease. Boston, Massachusetts. 2002.

Buchbinder SP, Katz MH, Hessel NA, et al. Hepatitis C virus in sexually active homosexual men. *Journal of Infection* 29:263-69. 1994.

Buggisch P, Wursthorn K, Ullman R, et al. (abstract 670) Impact of methadone therapy on the outcome of combination therapy for hepatitis C. 37th Meeting of the European Association for the Study of the Liver. Madrid, Spain. 2002.

Burris S, Lurie P, Abrahamson D, et al. Physician prescribing of sterile injection equipment to prevent HIV infection: time for action. *Ann Intern Med* 133(3): 218-26. 2000.

Busch MP, Laycock ME, Mohr B, et al. (abstract 235) Failure of serologic assays for diagnosis of hepatitis B and C virus infections in patients with advanced HIV. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, 2001.

Butt A, Fultz SL, Justice AC. (abstract 836) Hepatitis C increases the risk of DM in HIV infected veterans in care. 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2003.

Buzzelli G, Moscarella S, Giusti A et al. A pilot study on the liver protective effect of silybin-phosphatidylcholine (IdB1016) in chronic active hepatitis. *Int J Clin Pharmacol Ther Toxicol* 31(9):456-60. 1993.

Cabassi J, Puplick C.. C Change: Report of the enquiry into hepatitis C related discrimination. New South Wales Anti-Discrimination Board. 2001. <http://adb.nsf/pages/hepcenquiry> (accessed on 18 April 2004; not available as of June 4 2004).

Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). *Hepatology* 32(3): 477-81. 2000.

Caldwell SH, Sue M, Bowden JH, et al. Hepatitis C virus in body fluids after liver transplantation. *Liver Transpl Surg* 2(2):124-29. 1996.

Callaly T, Trauer T, Munro L, et al. Prevalence of psychiatric disorder in a methadone maintenance population. *Aust N Z J Psychiatry* 35(5):601-5. 2001.

Cameron CE, Castro C. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent polymerase. *Curr Opin Infect Dis* 14(6):757-64. 2001.

Cammà C, DiBona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. *Hepatology* 39(2):333-42. 2004.

Campistol JM, Esforzado N, Martínez J, et al. Efficacy and tolerance of interferon- $\alpha$ -2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre-and post-renal transplantation assessment. *Nephrol Dial Transplant* 14:2704-9. 1999.

Carlsson T, Weiland O, Reichard O. Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin. *Scand J Gastroenterol* 37(10):1228-34. 2002.

Carr DJ, Serou M. Exogenous and endogenous opioids as biological response modifiers. *Immunopharmacology* 31:59-71. 1995.

Carreno V, Parra A, Navas S, et al. Granulocyte-macrophage colony-stimulating factor as an adjuvant therapy for interferon alpha treatment of chronic hepatitis C. *Cytokine* 8(4):318-22. 1996.

Carreno V, Martin J, Pardo M, et al. Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis C. *Cytokine* 12(2):165-70. 2000.

Carrieri MP, Chesney MA, Spire B, et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. *Int J Behav Med* 20(1):1-14. 2003.

Casiraghi MA, De Paschale M, Romanò L, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. *Hepatology* 39 (1):90-96. 2004.

Cassidy W, Jeffers LS, Howell C, et al. (abstract 307) Peginterferon alfa-2a (40KD) (Pegasys®) in combination with ribavirin in African American and Caucasian patients with chronic hepatitis C genotype 1 infection: assessment of histologic response. American Association for the Study of Liver Disease. Boston, Massachusetts. 2003.

Castéra L, Zigante F, Bastie A, et al. (letter) Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. *Hepatology* 35(4):978-79. 2002.

Castéra L, Hezode C, Roudot-Thoraval F. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. *Gut* 52(2):288-92. 2003.

Castéra L, Hezode C, Roudot-Thoraval F, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. *Gut* 53(3):420-4. 2004.

Castro FJ, Esteban JI, Juarez A, et al. Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. *J Viral Hepat* 9(3):202-7. 2002.

Center for Biologics Evaluation and Research. Guidance For Industry: Use of nucleic acid tests on pooled and individual samples from donors of whole blood and blood components for transfusion to adequately and appropriately reduce the risk of transmission of HIV-1 and HCV (draft guidance). March 2002.

Center for Drug Evaluation and Research Antiviral Drugs Advisory Committee. 2002.  
<http://www.fda.gov/ohrms/dockets/ac/02/transcripts/3909T1.htm> (accessed on 22 May 2004).

Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Recommendations and Reports 42 (No. RR-4). 1993.  
<http://www.cdc.gov/mmwr/preview/mmwrhtml/00023141.htm>, (accessed on 10 December 2004; site now discontinued).

Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 47 (No. RR-19). 1998.  
<http://www.cdc.gov/mmwr/preview/mmwrhtml/00055154.htm> (accessed on 22 May 2004).

Centers for Disease Control and Prevention. Alter MJ, Lyerla RL, Tokars JI, et al. Recommendations for preventing transmission among chronic hemodialysis patients. MMWR Recommendations and Reports 50(RR05):1-43. April 27, 2001.  
<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5005a1.htm> (accessed on 22 May 2004).

Centers for Disease Control and Prevention. Guidelines for Viral Hepatitis Surveillance and Case Management. Atlanta, GA. June, 2002a.

Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV- infected persons—2002. MMWR Recommendations and Reports 51(RR-8). 2002b.

Centers for Disease Control and Prevention. Diagnosis and reporting of HIV and AIDS in states with HIV/AIDS surveillance—United States, 1994–2000. MMWR Weekly 51(27):595-8. 2002c.

Centers for Disease Control and Prevention. Disease Burden from Hepatitis A, B, and C in the United States. [http://www.cdc.gov/ncidod/diseases/hepatitis/resource/dz\\_burden02.htm](http://www.cdc.gov/ncidod/diseases/hepatitis/resource/dz_burden02.htm) (accessed on 5 May 2004). 2002d.

Centers for Disease Control and Prevention. Drug-associated HIV transmission continues in the United States. <http://www.cdc.gov/hiv/pubs/facts/idu.htm> (accessed on 22 May 2004). 2002e.

Centers for Disease Control and Prevention. Hepatitis C Virus and HIV Coinfection. September 2002f.

Centers for Disease Control and Prevention. Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings. MMWR Recommendations and Reports 52 (RR01):1-33. January 24, 2003.  
<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5201a1.htm> (accessed on 22 May 2004).

- Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. *Hepatology* 30(3):595-601. 1999.
- Chamberlain RW, Adams N, Saeed AA, et al. Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. *J Gen Virol* 78(Pt 6):1341-47. 1997a.
- Chamberlain RW, Adams NJ, Taylor LA, et al. The complete coding sequence of hepatitis C virus genotype 5a, the predominant genotype in South Africa. *Biochem Biophys Res Commun* 236(1):44-49. 1997b.
- Chang CH, Chen KY, Lai MY, et al. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. *Aliment Pharmacol Ther* 16(9):1623-32. 2002.
- Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. *Hepatology* 28(3):823-30. 1998.
- Charuvastra A, Stein J, Schwartzapfel B, et al. Hepatitis B vaccination practices in state and federal prisons. *Public Health Rep* 116(3):203-9. 2001.
- Cheng SJ, Bonis PA, Lau J, et al. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. *Hepatology* 33(1):231-40. 2001.
- Chesney MA. Factors affecting adherence to antiretroviral therapy. *Clin Infect Dis* 30 (Suppl 2):S171-76. 2000.
- Cheung RC, Hanson AK, Maganti K, et al. Viral hepatitis and other diseases in a homeless population. *J Clin Gastroenterol* 34(4):476-80. 2002.
- Chiaromonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. *Cancer* 85(10):2132-37. 1999.
- Cholet F, Nousbaum JB, Richecoeur M, et al. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. *Gastroenterol Clin Biol* 28(3):272-8. 2004.
- Choo Q-L, Kuo G, Weiner A, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 244:359-62. 1989.
- Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B. *Gut* 45:613-17. 1999.
- Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. *AIDS* 16(14):1915-23. 2002a.

Chung RT, Anderson J, Alston B, et al. (abstract LB15) A randomized, controlled trial of pegylated interferon alpha-2a with ribavirin vs. interferon alpha-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG 5071. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2002b.

Chung RT, Evans S, Yang Y, et al (abstract 637-M) Successful immune recovery is associated with persistent increases in HCV RNA, infrequent ALT flares, and appears unimpaired by HCV in co-infected subjects. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2002c.

Chung RT, Anderson J, Volberding P, et al. (abstract 110) A randomized, controlled trial of PEG interferon- $\alpha$ -2a plus ribavirin vs interferon- $\alpha$ -2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons: follow-up results of ACTG A5071. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2004.

Civeira MP, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. *J Hepatol* 31(Suppl 1):237-43. 1999.

Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. *J Hepatol* 39(2):239-44. 2003.

Cribier B, Rey D, Schmitt C, et al. High hepatitis C viraemia and impaired antibody response in patients co-infected with HIV. *AIDS* 9(10):1131-36. 1995.

Clarke S, Keenan E, Ryan M, et al. Directly observed antiretroviral therapy for injection drug users with HIV infection. *AIDS Read* 12(7):305-07, 312-16. 2002.

Collier J, Heathcote J. Hepatitis C infection in the immunosuppressed patient. *Hepatology* 27(1):2-6. 1998.

Collier J, Sherman M. Screening for hepatocellular carcinoma. *Hepatology* 27(1):273- 78. 1998.

Colombo M, De Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. *N Engl J Med* 325(10):675-680. 1991.

Conjeevaram HS, Kleiner DE, Everhart J, et al (abstract 388) Race, insulin resistance, visceral adiposity and hepatic steatosis in genotype 1 patients with chronic hepatitis C. 54th Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.

Conry-Cantilena C, VanRaden M, Gible J, et al. Routes of infection, viremia and liver disease in blood donors found to have hepatitis C virus infection. *N Engl J Med* 334: 1691-96. 1996.

Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection in a cohort of 15,250 pregnant women. *Hepatology* 31(3):751-55. 2000.

Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfecting with hepatitis C virus and human immunodeficiency virus. *Clin Infect Dis* 34(9):1259-62. 2002.

Craib KJP, Sherlock CH, Hogg RS, et al. (abstract 561) Evidence of sexual transmission of hepatitis C virus in a cohort of homosexual men. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois. 2001.

Crane H, Van Rompaey S, Kitatata M. (abstract 878) History of acute pancreatitis and hepatitis C virus infection increases the risk of new-onset diabetes among HIV-infected patients. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA. 2004.

Crespo J, Lozano JL, Carte B, et al. Viral replication in patients with concomitant hepatitis B and C virus infections. *Eur J Clin Microbiol Infect Dis* 16(6):445-51. 1997a.

Crespo J, Carte B, Lozano JL, et al. Hepatitis C virus recurrence after liver transplantation: relationship to anti-HCV core IgM, genotype, and level of viremia. *Am J Gastroenterol* 92(9):1458-62. 1997b.

Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. *Liver Transpl* 8(4):350-55. 2002.

Cromie SL, Jenkins PJ, Bowden DS, et al. Chronic hepatitis C: effect of alcohol on hepatic activity and viral titre. *J Hepatol* 25(6):821-26. 1996.

Cropley I, Main J. Hepatitis C virus infection: co-infection with HIV and HBV. *Bailliers Best Pract Res Clin Gastroenterol* 14(2):265-75. 2000.

Crotty S, Andino R. Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. *Microbes Infect* 4(13):1301-7. 2002.

Cucchiariini M, Kammer AR, Grabscheid B, et al. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. *Cell Immunol* 203(2): 111-23. 2000.

Cummings KJ, Lee SL, West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon. *JAMA* 285(2):193-99. 2001.

Dalgard O, Bjoro K, Hellum K. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. *Eur Addict Res* 8(1):45-49. 2002.

Dal Molin G, D'Agaro P, Ansaldi F, et al. Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of IgM anti-HCV as risk factors. *J Med Virol* 67(2):137-42. 2002.



Danta M, Brown D, Jacobs M, et al. (abstract 561) Epidemiology of acute HCV infection in a London cohort of HIV positive homosexual males. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.

Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. *N Engl J Med* 321(22):1501-06. 1989.

Davis GL. Hepatitis C virus genotypes and quasispecies. *Am J Med* 107(6B):21S-26S. 1999.

Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. *Liver Transplantation* 9(4):331-8. 2003a.

Davis GL, Wong JB, McHutchison J, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology* 38(3):645-52. 2003b.

De Bona A, Uberti-Foppa R, Finazzi M, et al. (abstract B10544) Interferon alfa-2b and ribavirin for hepatitis C compensated cirrhosis in HIV positive patients treated with antiretroviral therapy. XIV International AIDS Conference. Barcelona, Spain. 2002.

De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. *Hepatology* 31(4):997-1004. 2000.

Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon  $\alpha$  in haemodialysis patients with HCV infection: a multicentre, prospective study. *Nephrol Dial Transplant* 16(5):1017-23. 2001.

Delamare C, Carbonne B, Heim N, et al. Detection of hepatitis C virus RNA (HCV RNA) in amniotic fluid: a prospective study. *J Hepatol* 31(3):416-20. 1999.

De Maria N, Coltoni A, Idilman R, et al. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. *Hepatogastroenterology* 49(45):788-92. 2002.

de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. *JAMA* 284(2):190-7. 2000.

den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. *AIDS* 14(18):2895-2902. 2000.

Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 23 March 2004. <http://www.aidsinfo.nih.gov/guidelines> (accessed on 24 March 2004).

Department of Health and Human Services. 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with HIV - November 28, 2001.  
[http://aidsinfo.nih.gov/guidelines/default\\_db2.asp?id=69](http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=69) (accessed on 24 May 2004).

Department of Veteran's Affairs, Treatment Recommendations for Patients with Chronic Hepatitis C. September 2003. Version 5.0. Table 10.  
<http://www.hepatitis.va.gov/vahep?page=tp03-01-04-34#S4B3X> (accessed on 21 March 2004).

Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology* 19(6):1513-20. 1994.

De Socio GV, Francisci D, Mecozzi F, et al. Hepatitis C virus genotypes in the liver and serum of patients with chronic hepatitis C. *Clin Microbiol Infect* 2(1):20-24. 1996.

de Torres M, Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. *Ann Hepatol* 2(1):5-11. 2003.

Dev AT, McCaw R, Sundararajan V, et al. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. *Hepatology* 36(5):1259-65. 2002.

De Vera ME, Smallwood GA, Rosado K, et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. *Transplantation* 71(5):678-86. 2001.

Diallo DA, Baby M, Dembele M, et al. [In process citation]. *Bull Soc Pathol Exot* 96(2): 123-7. 2003.

Diamond C. (letter) Ribavirin-associated hemoglobinuria with treatment of hepatitis C virus infection. *Clin Infect Dis* 38:1042. 2004.

Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind placebo-controlled trial. *N Engl J Med* 321(22):1506-10. 1989.

Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 123 (12):897-903. 1995.

Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. *Hepatology* 26(3 Suppl 1):34S-38S. 1997.

Di Bisceglie AM. (seminar) Hepatitis C. *Lancet* 351:351-55. 1998.

Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. *Hepatology* 31(4):1014-18. 2000.

Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. *Hepatology* 36(5 Suppl 1):S121-S127. 2002.

Dieterich DT, Wasserman R, Braü N, et al. (abstract) Once-weekly recombinant human erythropoetin (Epotin alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C virus (HCV)-infected patients receiving interferon  $\alpha$ -2b (IFN)/RBV combination therapy. *Gastroenterology* 120:A64. 2001.

Dieterich DT, Pokros P, Schiff ER, et al. (abstract 100186) Epoetin alfa (Procrit®) once weekly maintains ribavirin dose in hepatitis C virus (HCV)-infected patients treated with combination therapy: interim results of a randomized, double-blind, placebo-controlled study. American Association for the Study of Liver Disease. Boston, Massachusetts. 2002a.

Dieterich DT. Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. *J Infect Dis* 185(Suppl 2):S128-37. 2002b.

Di Martino V, Ruffat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. *Hepatology* 34(6):1193-99. 2001.

Di Martino V, Thevenot T, Boyer N, et al. HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C. *AIDS* 16(3):441-45. 2002.

Donahue JG, Nelson KE, Muñoz A, et al. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men and intravenous drug users in Baltimore, Maryland. *Am J of Epidemiology* 134(10):1206-11. 1991.

Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. *N Engl J Med* 327(6):369-73. 1992.

Dore GJ, Freeman AJ, Law M, et al. Is severe liver disease a common outcome for people with chronic hepatitis C? *J Gastroenterol Hepatol* 17(4):423-30. 2002.

Dore GJ, Freeman AJ, Law M, et al. Natural history models for hepatitis C-related liver disease: different disease progression parameters for different settings. *Antiviral Therapy* 8:365-72. 2003.

Dorrucci M, Pezzotti P, Phillips AN, et al. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. *J Infect Dis* 172:1503-08.1995.

Dragovic G, Jevtovic D. Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients. *Antivir Chem Chemother* 14(5):281-4. 2003.

Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon  $\alpha$ -2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. *J Infect Dis* 189:964-70. 2004.

Dube MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. *Clin Infect Dis* 31(6):1467-75. 2000.

Dufour DR, Lott JA, Nolte FS, et al. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. *Clinical Chemistry* 46(12):2027-49. 2000.

Dummer JS, Erb S, Breinig MK, et al. Infection with human immunodeficiency virus in the Pittsburgh transplant population. A study of 583 donors and 1043 recipients, 1981–1986. *Transplantation* 47(1):134-40. 1989.

Dumortier J, Scoazec J-Y, Chevalier P, et al. (abstract 775) Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. American Association for the Study of Liver Disease. Boston, Massachusetts. 2003.

Dumoulin FL, Leifeld L, Sauerbruch T, et al. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. *Biomed Pharmacother* 53(5-6):242-54. 1999.

Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients. *J Acquir Immune Defic Syndr* 27(3):245-50. 2001.

Duran F, Danic B, Tardivel R, et al. Discovery of a chronic HCV infection without seroconversion in a blood donor in France during 28 months. *Transfus Clin Biol* 7(3):242-50. 2000.

Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. *J Hepatol* 25(5):591-98. 1996.

Dwight MM, Kowdley KV, Russo JE, et al. Depression, fatigue, and functional disability in patients with chronic hepatitis C. *J Psychosom Res* 49(5):311-17. 2000.

Edlin B. Prevention and treatment of hepatitis C in injection drug users. *Hepatology* 36(5, Suppl 1):S210-19. 2002.

Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet* 360:119-29. 2002.

El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. *N Engl J Med* 340(10):745-50. 1999.

El-Serag HB, Kunik M, Ricahrdson P, et al. Psychiatric disorders among veterans with hepatitis C. *Gastroenterology* 123(2):476-82. 2002.

Erice A, Rhame FS, Heussner RC, et al. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. *Rev Infect Dis* 13(4):537-47. 1991.

Escaffre N, Morin M, Bouhnik AD, et al. Injecting drug users' adherence to HIV antiretroviral treatments: physicians' beliefs. *AIDS Care* 12(6):723-30. 2000.

Esmat GH, Abouzied A, Abdel-Hamid M, et al. (abstract 324) Results of a randomized clinical trial of genotype-4 infected subjects when treated with standard or pegylated interferon alfa-2b in combination with ribavirin. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.

Everson GT, Trouillot T, Trotter T, et al. (abstract 308A) Treatment of decompensated cirrhotics with a slow-accelerating dose regimen. *Hepatology*: 32. 2000.

Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. *Liver Transpl* 8(10 Suppl 1):S19-27. 2002.

Eyster ME, Alter HJ, Aledort LM, et al. Heterosexual transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). *Ann Intern Med* 115(10):764-68. 1991.

Eyster ME, Diamondstone LS, Lien JM, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. *J Acquired Immune Deficiency Syndromes* 6(6):602-10. 1993.

Eyster EM, Fried MF, Di Bisceglie AM, et al. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. *Blood* 84(4):1020-23. 1994.

Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. *Hepatology* 36(1):3-10. 2002.

Farci P, Alter HJ, Shimoda A, et al. Hepatitis C virus-associated fulminant hepatic failure. *N Engl J Med* 335(9):631-34. 1996.

Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of viral quasispecies. *Science* 288:339- 44. 2000.

Farel C, Kottlilil M, Mc Laughlin M, et al. (abstract 844) Serious ophthalmologic pathology with visual compromise in HIV/HCV co-infected patients treated with pegylated interferon alpha-2b and ribavirin. 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2003.

Farinpour R, Miller EN, Satz P, et al. Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS). *J Clin Exp Neuropsychol* 25(5):654-70. 2003.

Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. *J Hepatol* 25(1):38-47. 1996.

Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. *Gastroenterology* 112 (2):651-5. 1997.

- Feray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. *Gastroenterology* 108(4): 1314-17. 1995.
- Feray C, Gigou M, Samuel D, et al. The course of hepatitis C virus infection after liver transplantation. *Hepatology* 20(5):1137-43. 1994.
- Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. *J Hepatol* 9(1):105-13. 1989.
- Ferenci P, Jessner W, Hackl F, et al. (abstract 102745) Prediction of early virologic response to treatment with 40KD pegylated (PEG)-interferon (IFN) alfa 2a/ribavirin in patients with chronic hepatitis C. 53rd American Association for the Study of Liver Disease. Boston, Massachusetts. 2002.
- Fhima A, Henrion R, Lowenstein W, et al. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)]. *Ann Med Interne* 152(Suppl 3):IS 26-36. 2001.
- Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. *Liver Transpl* 8(11):1000-6. 2002.
- Fischl MA, Richman DD, Saag M, et al. Safety and antiviral activity of combination therapy with zidovudine, zalcitabine and two doses of interferon- $\alpha$ -2a in patients with HIV. AIDS Clinical Trials Group Study 197. *J Acquir Immune Defic Syndr Hum Retrovirol* 16(4):247-53. 1997.
- Flamm SL, Eshelman A, Lyons M, et al. (abstract 102845) Improved medication adherence with cognitive behavioral therapy in patients receiving pegylated interferon alpha 2b (1.5 mcg/kg wk) + ribavirin (800–1400 mg/d): results of a prospective, randomized, controlled, multi-center trial. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.
- Fleischer R, Boxwell D, Sherman KE. (abstract 763). Evidence suggesting mitochondrial toxicity in HIV/HCV co-infected patients receiving ribavirin and didanosine. 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2003.
- Fleming CA, Craven DE, Thornton D, et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. *Clin Infect Dis* 36:97-100. 2003.
- Fleming MF, Manwell LB, Kraus M, et al. Who teaches residents about the prevention and treatment of substance use disorders? A national survey. *J Family Practice* 48(9): 725-9. 1999.
- Flora K, Hahn M, Rosen H, et al. Milk thistle (silymarin marianum) for the therapy of liver disease. *Am J Gastroenterol* 93(2):139-43. 1998.
- Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. *Gastroenterology* 122(4):889-96. 2002.

Formann E, Jessner W, Hartmann M, et al. (abstract 502) Twice weekly administration of peginteron improves viral kinetics in patients with chronic hepatitis C genotype 1. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.

Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. *Hepatology* 36(4 Pt 1):986-92. 2002.

Fortgang IS, Belitsos PC, Chaisson RE, et al. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. *Am J Gastroenterol* 90(9):1433-36. 1995.

Forton DM, Allsop JM, Main J, et al. (letter) Evidence for a cerebral effect of the hepatitis C virus. *Lancet* 358(9275):38- 40. 2001.

Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. *Hepatology* 35(2):433-9. 2002.

Foster GR, Fried MW, Hadziyannis SJ, et al. (abstract 189) Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin (Copegus®): patient age has a marked influence on the individual estimated probability of achieving a sustained virological response. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.

Franchini M, Tagliaferri A, Rossetti G, et al. Interferon and ribavirin in HIV-negative haemophiliacs with chronic hepatitis C who were nonresponders to a previous interferon treatment. *Haemophilia* 8(6):794-7. 2002.

Frassetto LA, Baloum M, Roland ME, et al. (abstract/poster 540) Two-year evaluation of the interactions between antiretroviral medication and cyclosporine in HIV+ liver and kidney transplant recipients. 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2003.

Freedman DS, Gates L, Flanders WD, et al. Black/white differences in leukocyte subpopulations in men. *Int J Epidemiology* 23(4):757-64. 1997.

Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. *Hepatology* 34(4):809-16. 2001.

French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly-active antiretroviral therapy. *HIV Med* 1(2): 107-15. 2000.

Fried MW, Shiffman ML, Reddy RK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 347(13):975-82. 2002a.

Fried MW. Side effects of hepatitis C and their management. *Hepatology* 36(5, Suppl 1): S237-S244. 2002b.

- Fried MW, Peter J, Hoots K, et al. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. *Hepatology* 36(4):967-72. 2002c.
- Fukunishi K, Tanaka H, Maruyama J, et al. Burns in a suicide attempt related to psychiatric side effects of interferon. *Burns* 24(6):581-83. 1998.
- Fultz SL, Chang CH, Butt AA, et al. (abstract 836) Impact of hepatitis C, HIV, or both on survival in veterans in care before and after the introduction of HAART (1996). 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2003a.
- Fultz SL, Justice AC, Butt AA, et al. Testing, referral and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus. *Clin Infect Dis* 36:1039-46. 2003b.
- Furusyo N, Hayashi J, Kanamoto-Tanaka Y, et al. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. *Digestive Diseases and Sciences* 45(11):2221-28. 2000.
- Gameiro R, Venneno T, Prieto E, et al. Vaginal shedding of hepatitis C virus. *In J STD AIDS* 12(11):717-21. 2001.
- Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. *N Engl J Med* 334(13):815- 20. 1996.
- Gane EJ, Holland J, Duxfield J, et al. (abstract 102245) Viral kinetics of combination pegylated interferon  $\alpha$ -2a plus ribavirin in patients with hepatitis C cirrhosis. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.
- Ganne-Carrie N, Medini A, Coderc E, et al. Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study. *J Autoimmun* 14(2):189-93. 2000.
- Garcia MA, Guda NM, Shughoury AB, et al. (abstract 107754) HCV and HIV coinfection: impediments for therapy. Abstracts of Digestive Disease Week. New Orleans, Louisiana. 2004.
- Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C viral kinetics during and immediately after liver transplantation. *Hepatology* 35(3):680-87. 2002a.
- Garcia-Retortillo M, Forns X, Canalejo J, et al. (abstract 44) Efficacy and safety of combined interferon and ribavirin therapy in cirrhotic patients infected with hepatitis C virus (HCV) awaiting liver transplantation. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.
- García-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. *Am J Gastroenterol* 92 (7):1130-34. 1997.



Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. *Am J of Public Health* 86(5):655-61. 1996.

Gavazzi G, Bouchard O, LeClerq P, et al. Change in transaminases in hepatitis C virus-and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders? *AIDS Res Hum Retroviruses* 16(11):1021-23. 2000.

Gebo KA, Keruly JC, Moore RD. (abstract 477) Is illicit drug use a risk factor for non-adherence to antiretroviral therapy? 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois. 2001.

Gebo KA, Fleishman JA, Moore RD. (abstract 827) Recent trends in HIV-related hospitalizations by selected diagnoses: a 12-state study. 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2003.

George J, Murray M, Byth K et al. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. *Hepatology* 21(1):120-28. 1995.

George SL, Gebhardt J, Klinzman D, et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. *J Acquir Immune Defic Syndro* 31(2):154- 62. 2002.

Gergely AE, Lafarge P, Fouchard-Hubert, et al. (letter) Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. *Hepatology* 35(5):1281-82. 2002.

Gerlach JT, Diepolder HM, Jung M-C, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. *Gastroenterology* 117(4):933-41. 1999.

Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterology* 125(80):80-88 2003.

Germer JJ, Zein NN. Advances in the molecular diagnosis of hepatitis C and their clinical implications. *Mayo Clin Proc* 76:911-20. 2001.

Gervais A, Bacq Y, Bernuau J, et al. Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. *J Hepatol* 32(2):293-99. 2000.

GESDIA/PNS. Coinfection by HIV and hepatitis A, B and C virus in adult patients. Review and GESIDA/PNS Recommendations. 2003.

[http://www.hivandhepatitis.com/hep\\_c/hepc\\_news\\_treatmentguidelines.html](http://www.hivandhepatitis.com/hep_c/hepc_news_treatmentguidelines.html) (accessed on 16 March 2004).

Ghalib RH et al. (oral abstract 51) Retreatment of recurrent hepatitis C after liver transplantation with pegylated interferon alfa-2b plus ribavirin. Abstracts of Digestive Disease Week. Orlando, Florida. 2003a.

Ghalib RH, Levine CD, Hollinger B, et al. (abstract 762) Safety and efficacy of peg ifn alfa-2b plus ribavirin for recurrent hepatitis C after liver transplantation: a preliminary analysis. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003b.

Ghany MG, Lessinger C, Lagier R, et al. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. *Dig Dis and Sciences* 41(6):1265-72. 1996.

Giannini E, Borro P, Botta F, et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. *J Hepatol* 37(5):572-77. 2002.

Gibb DM, Goodall RL, Dunn DT, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. *Lancet* 356(9233):904-7. 2000.

Giese LA. Milk thistle and the treatment of hepatitis. *Gastroenterol Nurs* 24(2):95-7. 2001.

Gilead Sciences. Viread™ (tenofovir disoproxil fumarate). Package insert. 2004.  
[www.fda.gov/cder/foi/label/2001/21356lbl.pdf](http://www.fda.gov/cder/foi/label/2001/21356lbl.pdf) (accessed on 24 May 2004).

Gilead Sciences. Emtriva™ (emtricitabine). Package insert. 2003.  
[www.fda.gov/cder/foi/label/2003/21500\\_emtriva\\_lbl.pdf](http://www.fda.gov/cder/foi/label/2003/21500_emtriva_lbl.pdf) (accessed on 24 May 2004).

Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. *J Infect Dis* 179(4):859-70. 1999.

Gilmore IT, Burroughs A, Murray-Lkyon IM, et al. Indications, methods and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. *Gut* 3(3):437-41. 1995.

Glaxo Smith Klein. Epivir® Tablets (lamivudine tablets). Package insert. 2002.  
[www.fda.gov/cder/foi/label/2002/20564s14,20596s15lbl.pdf](http://www.fda.gov/cder/foi/label/2002/20564s14,20596s15lbl.pdf) (accessed 22 May 2004).

Glaxo Smith Klein; Vertex Pharmaceuticals. Agenerase® (amprenavir) capsules. Package insert. 2002. [www.fda.gov/cder/foi/label/2002/21007s11,21039s10lbl.pdf](http://www.fda.gov/cder/foi/label/2002/21007s11,21039s10lbl.pdf) (accessed 22 May 2004).

Glaxo Smith Klein; Vertex Pharmaceuticals. Lexiva™ (fosamprenavir calcium) tablets. Package insert. 2003. [www.vrtx.com/pdfs/Lexiva102003\\_label.pdf](http://www.vrtx.com/pdfs/Lexiva102003_label.pdf) (accessed on 22 May 2004).

Glaxo Wellcome. Retrovir® (zidovudine) tablets. Package insert. 2001.  
[www.fda.gov/cder/foi/label/2001/20518S4lbl.pdf](http://www.fda.gov/cder/foi/label/2001/20518S4lbl.pdf) (accessed on 22 May 2004).

Glaxo Wellcome. Ziagen® (abacavir sulfate) tablets. Package insert. 2000.  
[www.fda.gov/cder/foi/label/2000/20978s2lbl.pdf](http://www.fda.gov/cder/foi/label/2000/20978s2lbl.pdf) (accessed 22 May 2004).

Gleason OC, Yates WR, Isbell MD, et al. An open-label trial of citalopram for major depression in patients with hepatitis C. *J Clin Psychiatry* 63(3):194-98. 2002.

Glue P, Rouzier-Panis C, Sabo R, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. *Hepatology* 32(3):647-53. 2000.

Glynn MK, Gerstle J, Lee LM. (abstract 849) Race, ethnicity, and sex disparities: rates of injection drug use-associated HIV diagnoses, 29 U.S. States, 1999-2002. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA. 2004.

Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. *Retrovirus Epidemiology Donor Study (REDS)*. *JAMA* 284:229-35. 2000.

Gochee PA, Jonsson JR, Clouston AD, et al. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. *J Gastroenterol Hepatol* 18(4):386-92. 2003.

Godkin AJ, Thomas HC, Openshaw PJ. Evolution of epitope-specific memory CD4+ T cells after clearance of hepatitis C virus. *J Immunol* 169:2210-14. 2002.

Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. *Blood* 100(5):1584-89. 2002.

Goh J, Coughlan B, Quinn J, et al. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. *Eur J Gastroenterol Hepatol* 11(8):833-38. 1999.

Goldsmith RJ, Mendenhall C, Harrer J, et al. (abstract 101182) Co-morbid behavioral emotional disturbances (BED) associated with hepatitis C virus (HCV): prevalence, compliance and treatment responses using a multidisciplinary approach. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.

Goldstein A. Maryland prison infection rate high. *Washington Post*. May 7th, 2003.

Golie P, et al. (abstract 1207) A preliminary study of growth factors versus dose reduction for peg interferon alfa-2b and ribavirin associated neutropenia and anemia in HIV-HCV coinfecting patients. *Abstracts of Digestive Disease Week*. Orlando, Florida. 2003.

Golub ET, Latka M, Hagan H, et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. *J Urban Health* 81(2):278-90. 2004.

- Goncales F, Bernstein DE, Berg C, et al. (abstract 794) Peginterferon alfa-2a (40 KD) (Pegasys®) plus ribavirin in chronic hepatitis C: retreatment of patients who relapsed virologically after 24 weeks of therapy. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.
- Gonzalez de Requena D, Núñez M, Jimenez-Nacher I, et al. Liver toxicity caused by nevirapine. *AIDS* 16(2): 290-91. 2002.
- Gordon A, MacLean CA, Pedersen JS, et al. (abstract 233) Steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Gordon FD, Poterucha JJ, Germer J, et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. *Transplantation* 63(10):1419-23. 1997.
- Gordon SC, Bayati N, Sliverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. *Hepatology* 28(2):562-67. 1998.
- Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. *N Engl J Med* 345(21):1522-8. 2001.
- Graci JD, Cameron CE. Quasispecies, error catastrophe, and the antiviral activity of ribavirin. *Virology* 298(2):175-80. 2002.
- Graham CS, Koziel MJ. (comment) Why should hepatitis C affect immune reconstitution in HIV-1 infected patients? *Lancet* 357(9245):1865-66. 2000.
- Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C: a meta-analysis. *Clin Infect Dis* 33:562-69. 2001.
- Graham CS, Koziel MJ. First things first: balancing hepatitis C and human immunodeficiency virus. *Clin Infect Dis* 36:368-69. 2003.
- Granovsky MO, Minkoff HL, Tess BL, et al. Hepatitis C virus infection in the mothers and infants cohort study. *Pediatrics* 102:355-59. 1998.
- Gretch DR, Bacchi CE, Corey L, et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. *Hepatology* 22(1):1-9. 1995.
- Gretch DR. Diagnostic tests for hepatitis C. *Hepatology* 26(3)Suppl 1:43S- 47S. 1997.
- Greub G, Ledergerber M, Battegay P, et al. Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV cohort study. *Lancet* 356(9244):1800-05. 2000.

Gross R, Bilker WB, Friedman HM, et al. Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. *AIDS* 16(13):1835-37. 2002.

Grossman Z, Meier-Schellersheim M, Sousa AE, et al. CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? *Nat Med* 8(4):319-23. 2002.

Grüner NH, Gerlach TJ, Jung M-C, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. *J Infect Dis* 181:1528-36. 2000.

Guido M, Rugge M, Jara P, et al. Chronic hepatitis C in children: the pathological and clinical spectrum. *Gastroenterology* 115(6):1525-29. 1998.

Guido M, Bortolotti F, Leandro G, et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? *Am J Gastroenterol* 98(3):660-3. 2003.

Gustavson A. Class action lawsuit by inmates demands treatment for hepatitis C. Associated Press. May 5th, 2003.

Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. *Lancet* 339(8789):321-23. 1992.

Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. *J Viral Hepat* 4(1): 9-28. 1997.

Hadziyannis SJ, et al. (abstract 536) Peginterferon alfa-2a (40KD) (PEGASYS®) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. 37th Meeting of the European Association for the Study of the Liver. Madrid, Spain. 2002.

Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon- $\alpha$  2a and ribavirin combination therapy in chronic hepatitis C. *An Intern Med* 140(5):346-55. 2004.

Hagan H, Thiede H, Weiss N, et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. *Am J Public Health* 91(1):42- 46. 2001.

Hagan H, Snyder N, Hough E, et al. Case-reporting of acute hepatitis B and C among injection drug users. *J Urban Health* 79(4):579-85. 2002.

Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities. *Am J Public Health* 92(11):1789-94. 2002.

Hanabusa H. Efficacy of induction therapy with high-dose interferon for patients with hemophilia and human immunodeficiency virus-hepatitis C virus coinfection. *Clin Infect Dis* 35:1527-33. 2002.

- Hanley JP, Jarvis LM, Andrew J, et al. Interferon treatment for chronic hepatitis C infection in hemophiliacs—influence of virus load, genotype, and liver pathology on response. *Blood* 87(5):1704-9. 1996.
- Hardy H, Esch LD, Morse GD. Glucose disorders associated with HIV and its drug therapy. *Ann Pharmacothera* 35(3):343-51. 2001.
- Hare CB, Peters MJ, Watson JJ, et al. (abstract 662-M) Viral hepatitis, liver damage, and antiretroviral prescribing patterns in an HIV community network. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2002.
- Harris H, Ramsay ME, Andrews N, et al. Clinical course of hepatitis C virus during the first decade of infection: cohort study. *BMJ* 324:1-6. 2002.
- Hasan F, Asker H, Al-Khaldi J, et al. (abstract 982) Pegylated interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C genotype 4. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. *AIDS* 13(9):1099-1107. 1999.
- Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. *Int J STD AIDS* 15(1):7-16. 2004.
- Hayasaka S, Nagaki Y, Matsumoto M, et al. Interferon associated retinopathy. *Br J Ophthalmol* 82:323-25. 1998.
- Hayashi J, Furusyo N, Ariyama I, et al. A relationship between the evolution of hepatitis C virus variants, liver damage and hepatocellular carcinoma in patients with hepatitis C viremia. *J Infect Dis* 181:1523- 27. 2000.
- Hayashi K, Fukuda Y, Nakano I, et al. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs. *Haemophilia* 6(6):677-81. 2000.
- Haynes RB, McDonald H, Garg AX, et al. Interventions for helping patients to follow prescriptions for medications. *Cochrane Database Syst Rev* (2):CD000011. 2002.
- Heathcote JE, Shiffman ML, Cooksley G, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. *N Eng J Med* 343(23):1673-80. 2000.
- Heller J, Musiolik J, Homrighausen A, et al. Occurrence and significance of autoantibodies in the course of interferon therapy of chronic hepatitis C. *Dtsch Med Wochenschr* 121(39):1179-83. 1996.

Hepatitis C Support Project. Viral Load Fact Sheet. 2003.

<http://www.hcvadvocate.org/hepatitis/factsheets.asp> (accessed on 14 May 2004).

Hermans P, Rozenbaum W, Jou A, et al. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 Study Group. *AIDS* 10(14):1627-33. 1996.

Hernández-Quero J, Granados R, Pérez-Guzmán, et al. (abstract 987) Peg-interferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) in patients with HIV/HCV coinfection: interim results of a randomized, multicenter study from Spain. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.

Herrmann E, Neumann AU, Schmidt JM, et al. Hepatitis C viral kinetics. *Antivir Ther* 5(2):85- 90. 2000.

Herve S, Savoye G, Riachi G, et al. Chronic hepatitis C with normal or abnormal alanine aminotransferase levels: is it the same entity? *Eur J Gastroenterol Hepatol* 13(5):495-500. 2001.

Hess G, Clemens R, Bienzle U, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. *J Med Virol* 46(1):40-2. 1995.

Hezode C, Roudot-Thoraval F, Zafrani E-S, et al. (abstract 419) Hepatitis C virus genotype 3, but not genotype 1, is cytopathic, steatogenic. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003a.

Hezode C, Lonjon I, Roudot-Thoraval F, et al. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. *Aliment Pharmacol Ther* 17(8):1031-7. 2003b.

Hisada M, O'Brien TR, Rosenberg PS, et al. (concise communication) Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. *J Infect Dis* 181(4):1475-78. 2000.

Hofer H, Bankl HC, Wrba F et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. *Am J Gastroenterol* 97(11):2880-85. 2002.

Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. *Hepatology* 37(1):60-4. 2003.

Hoffman-Terry M, Khalili M, Bernstein D, et al. (abstract H-1725) Safety and efficacy of peginterferon alfa-2a (40KD) (Pegasys®) with or without ribavirin in the treatment of patients coinfecting with HIV and HCV: preliminary results from a randomized, multicenter trial. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California. 2002.

- Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. *CMAJ* 160(5):659-65. 1999.
- Hoggard PG, Lloyd J, Khoo SH, et al. Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretrovirals. *Antimicrob Agents Chemother* 45(3):976-80. 2001.
- Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. *Hepatology* 26(3 Suppl 1):15S-20S. 1997.
- Hoofnagle JH. (editorial) Therapy for acute hepatitis C. *N Engl J Med* 345(20):1495- 97. 2001.
- Holodniy M, Babik J. (abstract WePeB6039) Evolution of HCV quasi-species after initiation of HAART in HIV-1 co-infected patients. XIV International AIDS Conference. Barcelona, Spain. 2002.
- Hopkins S, Lyons F, Brannigan E, et al. (abstract ThPeC7531) Tolerability of pegylated interferon and ribavirin in the HIV/HCV co-infected population. XIV International AIDS Conference. Barcelona, Spain. 2002.
- Hosoda S, Takimura H, Shibayama M, et al. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. *Psychiatry Clin Neurosci* 54(5):565-72. 2000.
- Hourigan LF, MacDonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. *Hepatology* 29(4):1215-19. 1999.
- Hu K-Q, Cheung RC, Currie S, et al. (abstract 589) Hepatic steatosis in patients with chronic hepatitis C: a multicenter study of US veterans. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Huang MJ, Tsai SL, Huang BY, et al. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. *Clin Endocrinol (Oxf)* 50(4):503- 9. 1999.
- Huang SJ, Lee SD, Chan CY, et al. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. *J Hepatol* 21(5):831-6. 1994.
- Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. *Gastroenterology* 125(6):1695-1704. 2003.
- Hunt PW, Martin JM, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. *J Infect Dis* 187:1534-43. 2003.



- Huraib S, Iqbal A, Tanimu D, et al. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic hepatitis C. *Am J Nephrol* 21(6):435-40. 2001.
- Hutin YJF, Hauri AM, Armstrong GL. Use of injections in health care settings worldwide, 2000: literature review and regional estimates. *BMJ* 327(7423):1075-79. 2003.
- Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. *J Gastroenterol Hepatol* 16(2):190-95. 2001.
- Hyams KC, Riddle J, Rubertone M, et al. Prevalence and incidence of hepatitis C virus infection in the U.S. military: a seroepidemiologic survey of 21,000 troops. *Amer J Epidemiology* 153(8):764- 770. 2001
- Idilman R, De MN, Colantoni A, et al. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. *Am J Gastroenterol* 97(2):435-9. 2002.
- Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. *Hepatology* 18(1):47-53. 1993.
- Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. *J Hepatol* 28(6):930-38. 1998.
- Imazeki F, Yokosuka O, Fukai K, et al. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. *Hepatology* 38(2):493-502. 2003.
- Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with chronic hepatitis C virus infection: a prospective study. *Lancet* 357:1069-75. 2001.
- Imperiale TF, Said AT, Cummings OW, et al. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. *Amer J Gastroenterol* 95(9):2328-32. 2000.
- Imperiale SM, Lanes SF, Stern JO, et al. (abstract 89) TARGET: Incidence of elevated ALT/AST with HAART in a large observational cohort. 4th International Workshop on Adverse Events and Lipodystrophy in HIV. San Diego, California. 2002.
- International Interferon- $\alpha$  Hepatocellular Carcinoma Study Group: Brunetto MR, Oliveri F, Koehler M, et al. Effect of interferon- $\alpha$  on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. *Lancet* 351:1535-39. 1998.
- Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. *J Hepatol* 22(6):696-9. 1995.

Izopet J, Rostaing L, Mousson F, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. *J Infect Dis* 176(6):1614-17. 1997.

Jacobson I, Brown RS, Afdhal N, et al. (abstract 100415) Characteristics of HCV infection in African-Americans: findings from the WIN-R trial. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.

Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med* 354(20):1452-57. 2001.

Jain AB, Eghtesad B, Venkataramanan R, et al. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. *Liver Transpl* 8(11):1007-13. 2002a.

Jain AK, Venkataramanan R, Shapiro R, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. *Liver Transpl* 8(9):841-45. 2002b.

Jain AK, Venkataramanan R, Fridell JA, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. *Liver Transpl* 8(9):838-40. 2002c.

Jain AK, Venkataramanan R, Eghtesad B. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. *Liver Transpl* 9(9):954-60. 2003.

Jamal MM, Soni A, Quinn PG, et al. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. *Hepatology* 30(5):1307-11. 1999.

Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. *Ann Intern Med* 118(2):96-8. 1993.

Janssen HL, Brouwer JT, van der Mast RC, et al. Suicide associated with alfa-interferon therapy for chronic hepatitis. *J Hepatol* 21(2):241-43. 1994.

Jara P, Resti M, Hierro L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. *Clin Infect Dis* 36:275-80. 2003.

Jarrousse B, Bentata M, Honoré P, et al. (abstract WePeB6042) Feasibility of interferon alpha-2b and ribavirin combination therapy for chronic hepatitis C in HIV and HCV coinfecting patients in a real life clinical setting. XIV International AIDS Conference. Barcelona, Spain. 2002.

Jarvis LM, Watson HG, McOmish F, et al. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. *J Infect Dis* 170:1018-22. 1994.

Jeantils V, Wade A, Touitou H, et al. (abstract H-1995) Therapeutic drug monitoring of efavirenz (EFV) in HIV-1 infected patients treated with efavirenz containing regimen. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. 2003.

Jeffers LJ, Cassidy W, Howell C, et al. (abstract 784) Peginterferon alfa-2a (40KD) (Pegasys®) in combination with ribavirin in African American and Caucasian patients with HCV genotype 1: a preliminary report of a comparative, multicenter, efficacy and safety study. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.

Jeffers LJ, Cassidy W, Howell C, et al. (abstract 71) Peginterferon alfa-2a (40KD) (PEGASYS®) in combination with ribavirin in African American and Caucasian patients with chronic hepatitis C virus genotype 1: results of a multicenter study. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.

Jessner W, Gschwantler M, Steindl-Munda P, et al. (research letter) Primary interferon resistance and treatment response in chronic hepatitis C: a pilot study. *Lancet* 358:1241-42. 2001.

John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? *AIDS* 12(7):2289-93. 1998.

John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. *AIDS* 15(6):717-23. 2001.

Johnson JG, Rabkin JG, Lipsitz JD, et al. Recurrent major depressive disorder among human immunodeficiency virus (HIV)-positive and HIV-negative intravenous drug users: findings of a 3-year longitudinal study. *Compr Psychiatry* 40(1):31-4. 1999.

Johnson ME, Fisher DG, Fenaughty A, et al. Hepatitis C virus and depression in drug users. *Am J Gastroenterol* 93(5):785-9. 1998.

Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. *N Engl J Med* 328(7):465-70. 1993.

Jonas MM, Ott MJ, Nelson SP, et al. Interferon-alpha treatment of chronic hepatitis C virus infection in children. *Pediatr Infect Dis* 17(3):241-46. 1998.

Jonas MM. Children with hepatitis C. *Hepatology* 36(5, Suppl 1):S173-78. 2002.

Justice AC, Wagner JH, Fusco GP, et al. (abstract MoOrB1058) Liver function tests independently predict HIV survival. XIV International AIDS Conference. Barcelona, Spain. 2002.

Kadayifcilar S, Boyacioglu S, Kart H, et al. Ocular complications with high-dose interferon alpha in chronic active hepatitis. *Eye* 13(Pt 2):241-46. 1999.

Kage M, Fujisawa T, Shiraki K, et al. Pathology of chronic hepatitis C in children. Child liver study group of Japan. *Hepatology* 26(3):771-75. 1997.

Kearney BP, Benhamou Y, Flaherty J, et al. (abstract 600) Tenofovir pharmacokinetics in hepatic impairment and drug interaction potential with agents used to treat viral hepatitis. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2004.

Khan KN, Yatsunami H. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients. *Alcohol Alcohol* 35(3):286-95. 2000.

Kakimoto K, Takahara S, Kokado Y, et al. [A case of allograft rejection induced by the interferon-alpha therapy to hepatitis type C after renal transplantation]. *Hinyokika Kyo* 40(6):529-32. 1994.

Kamal SM, Fehr J, Roesler B, et al. Peginterferon alone or with ribavirin enhances HCV-specific CD4+ T-helper 1 responses in patients with chronic hepatitis C. *Gastroenterology* 123(4):1070-83. 2002.

Kamath PS, Kim WR. Is the change in MELD score a better indicator of mortality than baseline MELD score? *Liver Transpl* 9(1):12-18. 2003.

Kane A, Lloyd J, Zaffran M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. *Bull World Health Organ* 77(10):801-07. 1999.

Kanno A, Yamada M, Abe M, et al. A case of interferon alpha-induced manic psychosis in chronic hepatitis C. *Tohoku J Exp Med* 187(1):79-82. 1999.

Kayali Z, Buckwold VE, Zimmerman B, et al. Hepatitis C, cryoglobulinemia and cirrhosis: a meta-analysis. *Hepatology* 26(4):978-85. 2002.

Keefe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. *Hepatology* 27(3):881-86. 1998.

Kelly DA, Bunn SK, Apelian D, et al. (abstract 680) Safety, efficacy and pharmacokinetics of interferon alfa-2b plus ribavirin in children with chronic hepatitis C. *Hepatology* 34:2342A. 2001.

Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. *N Engl J Med* 340(16):1228-33. 1999.

Kim WR, Brown RS Jr, Terrault NA, et al. Burden of liver disease in the United States: summary of a workshop. *Hepatology* 36(1):227-42. 2002a.

Kim WR. The burden of hepatitis C in the United States. *Hepatology* 36(5, Suppl 1): S30-S34. 2002b.

- Kinzie JL, Naylor PH, Nathani MG, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. *J Viral Hepat* 8(4):264-69. 2001.
- Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. *Hepatology* 12(4 Pt 1):671-75. 1990.
- Klein RS, Strasfield L, Lo Y, et al. The association of hepatitis C virus prevalence, activity and genotype with HIV infection in a cohort of New York City drug users. 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2003.
- Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology* 1(5):431-35. 1981.
- Knoll GA, Tankersley MR, Lee JY, et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. *Am J Kidney Dis* 29(4):608-14. 1997.
- Kobayashi M, Tanaka E, Sodeyama T, et al. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. *Hepatology* 23(4):695- 99. 1996.
- Koff RS. Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. *J Clin Gastroenterol* 33(1):20-26. 2001.
- Koretz RL, Brezina M, Polito AJ, et al. Non-A, non-B posttransfusion hepatitis: comparing C and non-C hepatitis. *Hepatology* 17(3):361-65. 1992.
- Koretz RL, Abbey H, Coleman E, et al. Non-A, non-B post-transfusion hepatitis. *Ann Intern Med* 119:110-15. 1993.
- Kornberg A, Hommann M, Tannapfel A, et al. Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients. *Am J Transplant* 1(4):350-55. 2001.
- Koskinas J, Merkouraki P, Manesis E, et al. Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. *Dig Dis* 20(3-4):284-88. 2002.
- Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. *Aliment Pharmacol Ther* 16(6):1091-99. 2002.
- Kraus MR, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. *J Clin Psychiatry* 64(6):708-14. 2003.
- Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. *Hepatology* 36(5):1266-72. 2002.

Kumar RM, Shahul S. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. *J Hepatol* 29(2):191-97. 1998.

Kuo G, Choo Q-L, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. *Science* 244:362-64. 1989.

Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. *AIDS* 12(1):65-74. 1998.

Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. *Clin Infect Dis* 30(2):256-60. 2000.

Lafeuillade A, Hittinger G, Chadapaud S. (research letter) Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. *Lancet* 357(9252):280-81. 2001.

Lampertico P, Rumi M, Romeo R, et al. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. *Hepatology* 19(1):19-22. 1994.

Lana R, Núñez M, Mendoza JL, et al. Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy. *Med Clin (Barc)* 117(16):607-10. 2001.

Landau A, Batisse D, Piketty C, et al. Long-term efficacy of combination therapy with interferon- $\alpha$ -2a and ribavirin for severe chronic hepatitis in HIV-infected patients. *AIDS* 15(16):2149-55. 2001.

Lange C, Lederman M. Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. *J Antimicrob Chemother* 51(1):1-4. 2002.

Lanphear BP, Linnemann CC Jr, Cannon CG, et al. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. *Infect Control Hosp Epidemiol* 15(12):745-50. 1994.

Larcos G, Sorokopud H, Berry G, et al. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. *Am J Roentgenology* 171:433-35. 1998.

Larghi A, Zuin M, Crosignani A, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. *Hepatology* 36(4):993-1000. 2002.

Laskus T, Radkowski M, Bednarska A, et al. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. *J Virol* 76(19):10064-68. 2002a.

Laskus T, Radkowski M, Wilkinson J, et al. (abstract 649- M) Hepatitis C virus replication in the central nervous system. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2002b.

Lau DT, Kleiner DE, Ghany MG et al. 10-year follow-up after interferon- $\alpha$  therapy for chronic hepatitis C. *Hepatology* 28(4):1121-27. 1998.

Lau JY, Davis GL, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. *Lancet* 341:1501-4. 1993.

Lauer GM, Walker BD. Hepatitis C virus infection. *N Engl J Med* 345(1):41-52. 2001.

Lavezzo B, Franchello A, Smedile A, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. *J Hepatol* 37(2):247-52. 2002.

Lavezzo B, et al. (abstract 4157.00) Preliminary results of naïve combination therapy with 12KDA PEG-IFN  $\alpha$ -2B and ribavirin in recurrent hepatitis C after liver transplantation (LT). 38th Annual Meeting of the European Association of the Study of the Liver (EASL). Geneva, Switzerland. 2003.

Law PW, Duncombe C, Dore GJ, et al. (abstract 661-M) Hepatitis viruses: influence on morbidity, mortality and response to antiretroviral therapy. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2002.

Law PW, Dore GJ, Duncombe C, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001. *AIDS* 17(15):2191-99. 2003.

Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. *AIDS* 18(8):1169-1177. 2004

Layden JE, Layden TJ, Reddy KR, et al. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. *J Viral Hepat* 9(5): 340-45. 2002a.

Layden JE, Layden TJ. (editorial) Viral kinetics of hepatitis C: new insights and remaining limitations. *Hepatology* 35(4):967-70. 2002b.

Leckie G, Schneider G, Abravaya K, et al. Performance attributes of the LCx HCV RNA quantitative assay. *J Virol Methods* 115(2):207-15. 2004.

Lecube A, Hernandez C, Genesca J, et al. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. *Diabetes Care* 27(5):1171-75. 2004.

Lee S, Heathcote E, Reddy K, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). *J Hepatol* 37(4):500-6. 2002.

Lee WM. Hepatitis B virus infection. *N Engl J Med* 337(24):1733-45. 1997.

- Lehman CL, Cheung RC. Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. *Am J Gastroenterol* 97(10):2640-46. 2002.
- Leroy V, Bourliere M, Durand M, et al. The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study. *Eur J Gastroenterol Hepatol* 14(5):485-89. 2002.
- Leroy V, Monier F, Bottari S, et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. *Am J Gastroenterol* 99(2):271-9. 2004.
- Leruez-Ville M, Kunstmann JM, De Almeida M, et al. Detection of hepatitis C virus in the semen of infected men. *Lancet* 356(9240):42-3. 2000.
- Lesens O, Deschênes M, Steben M, et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. *J Infect Dis* 179:1254-58. 1999.
- Leveque L, de Boulard A, Bielefeld P, et al. Sarcoidosis during the treatment of hepatitis C by interferon-alpha and ribavirin: 2 cases. *Rev Med Interne* 22(12):1248-52. 2001.
- Levine AM, Berhane K, Masri-Lavine L, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. *J Acquir Immune Defic Syndr* 26(1): 28-35. 2001.
- Li XW. A report on therapy of interferon- $\alpha$ -2b in patients with acute hepatitis C. *Zhonghua Nei Ke Za Zhi* 32(6):409-11. 1993.
- Liang TJ (moderator), Rehermann B, Seeff LB, Hoofnagle JH. NIH Conference: pathogenesis, natural history, treatment and prevention of hepatitis C. *Ann Intern Med* 132:296-305. 2000.
- Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B superinfection on chronic hepatitis C virus infection. *Am J Gastroenterol* 95(10):2978- 80. 2000.
- Lin HH, Chiou HM, Lee SJ, et al. (abstract WePeB5978) Use of Cobas Amplicator HCV test for the detection of HCV RNA in HIV-1 infected patients. XIV International AIDS Conference. Barcelona, Spain. 2002.
- Lin J, Fazollah M. Prisoner unlocks hepatitis C epidemic. *Philadelphia Inquirer*. July 22, 2002.
- Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. *Hepatology* 34(2):395-403. 2001.



- Liu Z, Cumberland WG, Hultin LE, et al. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. *J Acquir Immune Defic Syndr Hum Retrovirol* 18(4):332-40. 1998.
- Loguercio C, Di Pierro M, Di Marino M, et al. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. *Alcohol Alcohol* 35(3):296-301. 2000.
- Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. *Gastroenterology* 126(2):586-97. 2004.
- Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. *Clin Infect Dis* 31:162-66. 2000.
- Lorenzini S, Biselli M, Gramenzi A, et al. (abstract 489) Pegylated interferon plus ribavirin for the treatment of recurrent HCV infection after liver transplantation. 39th Annual Meeting of the European Association of the Study of the Liver (EASL). Berlin, Germany. 2004.
- Louache F, Vainchenker W. Thrombocytopenia in HIV infection. *Curr Opin Hematol* 1(5):369-72. 1994.
- Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. *J Acquir Immune Defic Syndr* 27(3):251-59. 2001.
- Luper S. A review of plants used in the treatment of liver disease: part 1. *Altern Med Rev* 3(6):410-21. 1998.
- MacDonald M, Crofts N, Kaldor J. Transmission of hepatitis C virus: rates, routes and cofactors. *Epidemiol Rev* 18(2):137-48. 1996.
- Macías J, Pineda JA, Leal M, et al. Influence of hepatitis C virus infection on the mortality of antiretroviral-treated patients with HIV disease. *Eur J Clin Microbiol Infect Dis* 17:167-70. 1998.
- Macías Rodríguez MA, Rendon Unceta P, Tejada Cabrera M, et al. Risk Factors for hepatocellular carcinoma in patients with liver cirrhosis. *Rev Esp Enferm Dig* 92(7):458- 69. 2000.
- Maisels L, Steinberg J, Tobias C. An investigation of why eligible patients do not receive HAART. *AIDS Patient Care STDS* 15(4):185-91. 2001.
- Mallat D, Young L, Milikowski C, et al. The histopathological impact of race in veterans with HCV infection. *Hepatology* 32(Suppl 2):A281. 2000.
- Manavi M, Baghestanian M, Watkins-Riedel T, et al. Detection of hepatitis C virus (HCV) RNA in normal cervical smears of HCV-seropositive patients. *Clin Infect Dis* 35: 966-73. 2002.

Mangia A, Minerva N, Ricci GL, et al. (abstract 93) HCV Genotype 2 and 3 can be cured by PEG-IFN-alfa-2B and RBV for 12 wks: A randomized controlled study. 39th Annual Meeting of the European Association of the Study of the Liver (EASL). Berlin, Germany. 2004.

Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C: a randomized trial. *Lancet* 358(9286):958-65. 2001.

Manolio TA, Burke GL, Savage PJ, et al. Sex-and race-related differences in liver-associated serum chemistry tests in young adults in the CARDIA study. *Clin Chem* 38 (9):1853-59.1992.

Marceau G, Sapin V, Jacomet C, et al. Frequency, risk factors, and outcome of hyperlactatemia in HIV-positive patients: implications for the management of treated patients. *Clin Chem* 49(7): 1154-62. 2003.

Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon- $\alpha$  therapy. *Ann Intern Med* 127(10):875-81. 1997.

Marcellin P. Hepatitis C: the clinical spectrum of disease. *J Hepatol* 31(Suppl 1):9 -16. 1999.

Marcellin P et al. (abstract 4510.00) Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) is an efficacious and safe treatment for chronic hepatitis C (CHC) in patients with compensated cirrhosis. 38th Annual Meeting of the European Association of the Study of the Liver (EASL). Geneva, Switzerland. 2003.

Marcellini M, Kondili LA, Comparcola D, et al. High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease. *Pediatr Infect Dis* 16(11):1049-53. 1997.

Marco M, Schouten J. The Hepatitis Report: a critical review of the research and treatment of hepatitis C virus (HCV) and hepatitis & HIV coinfection. Treatment Action Group. New York City. 2000.

Marsh BJ, Rosenberg SD, Butterfield MI, et al. (abstract B10540) Comorbidity of human immunodeficiency virus, hepatitis B virus and hepatitis C virus in people with severe mental illness. XIV International AIDS Conference. Barcelona, Spain. 2002.

Martín J, López M, Arranz M, et al. (abstract 572) Impact of hepatitis C in HIV-infected individuals in an urban center in Madrid, Spain. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois. 2001.

Martin P, Di Bisceglie A, Kassianides C, et al. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus. *Gastroenterology* 97:1559-61. 1989.

Martín-Carbonero L, Soriano V, Valencia E, et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. *AIDS Res and Human Retroviruses* 17(16):1467-71. 2001.

Martín-Carbonero L, Núñez M, Ríos P, et al. (letter) Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. *AIDS* 16(10):1423-25. 2002.

Martín-Carbonero L, Soriano V, Benhamou Y, et al. (abstract 830) Histological damage in liver biopsy samples from 492 HIV-HCV co-infected patients: a European collaborative study. 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2003.

Martín-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. *Clin Infect Dis* 38:128-33. 2004.

Martínez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. *AIDS* 15(10):1261-68. 2001.

Martinot-Peignoux M, Boyer N, Hatem-Cazals D, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. *Hepatology* 34(5):1000-05. 2001.

Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. *Hepatology* 29(2):328-33. 1999.

Massoud OI, Yousef WI, Mullen KD. Hemoglobinuria with ribavirin treatment. *J Clin Gastroenterol* 36(4):367-8. 2003.

Mathurin P, Moquet C, Poynard T, et al. Impact of hepatitis B and C on kidney transplantation outcome. *Hepatology* 29(1):257-63. 1999.

Matsiota-Bernard P, Vrioni G, Onody C, et al. Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients. *Int J Antimicrob Agents* 17(2):155-57. 2001.

Matthews J, Kadish W, Barrett SV, et al. The impact of a brief interclerkship about substance abuse on medical students' skills. *Acad Med* 77(5):419-26. 2002.

Mauss S, Klinker H, Ulmer A, et al. Response to treatment of chronic hepatitis C with interferon  $\alpha$  in patients infected with HIV-1 is associated with higher CD4+ cell count. *Infection* 26(1):16-19. 1998.

Mauss S et al. (abstract 4124.00) Is treatment of chronic hepatitis C in patients under methadone maintenance feasible? A prospective, controlled study. 38th Meeting of the European Association of the Study of the Liver. Geneva, Switzerland. 2003a.

Mauss S, Berger F, Schmutz G, et al. (abstract 1218) A prospective, controlled study assessing the treatment of chronic hepatitis C in patients on methadone maintenance. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003b.

Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. *Transplant Proc* 33:1355-57. 2001.

McCance-Katz EF, Gourevitch MN, Arnsten J, et al. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. *Am J Addict* 11(4):271-78. 2002.

McCormick SE, Goodman ZD, Maydonovitch CL, et al. Evaluation of liver histology, ALT elevation and HCV RNA titer in patients with chronic hepatitis C. *Amer J Gastroenterol* 9(8):1516-22. 1996.

McDonald J, Jayasuriya J, Bindley P, et al. Fatigue and psychological disorders in chronic hepatitis C. *J Gastroenterol Hepatol* 17(2): 171-76. 2002.

McFarland W, Chen S, Hsu L, et al. Low socioeconomic status is associated with a higher rate of death in the era of highly active antiretroviral therapy, San Francisco. *J Acquir Immune Defic Syndr* 33(1):96-103. 2003.

McGill DB, Rakela J, Zinsmeister AR, et al. A 21-year experience with major hemorrhage after percutaneous liver biopsy. *Gastroenterology* 99(5):1396-00. 1990.

McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *N Engl J Med* 339:1485-92. 1998.

McHutchison JG, Poynard T, Piako S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. *Gastroenterology* 119(5):1317-23. 2000.

McHutchison JG, Shad JA, Gordon SC, et al. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. *J Viral Hepat* 8(6):414-20. 2001.

McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. *Gastroenterology* 123:1061-69. 2002.

McKee J. Prisoners with hepatitis, other ailments sue the state. *Independent Record*. July 21, 2002.

Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. *Ann Intern Med* 133: 592-99. 2000.

Mehta SH, Cox A, Hoover DH, et al. Protection against persistence of hepatitis C. *Lancet* 359(9316):1478-83. 2002.

Mehta SH, Brancati FL, Strathdee S, et al. Hepatitis C virus infection and incident type 2 diabetes. *Hepatology* 38(1):50-56. 2003a.

Mehta SH, Moore RD, Thomas DL, et al. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. *J Acquir Immune Defic Syndr* 33(5):577-84. 2003b.

Mehta SH, Bhaskar K, Sulkowski M, et al. (abstract 809) Serum Markers of Liver Fibrosis in HIV/HCV-infected Adults. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA. 2004.

Meisel H, Reip A, Faltus B, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. *Lancet* 345 (8959):1209-11. 1995.

Melbye M, Biggar RJ, Wantzin P, et al. Sexual transmission of hepatitis C virus: cohort study (1981-9) among European homosexual men. *Br Med J* 301:210-12. 1990.

Mendel I, Clotteau L, Lambert S, et al. Hepatitis C virus infection in an HIV-positive population in Normandy: antibodies, HCV RNA and genotype prevalence. *J Med Virol* 47(3):231-36. 1995.

Mendes-Corrêa MC, Martins-Filho LG, Guastini C, et al. (abstract 13.2/11) Liver biopsy in HIV and hepatitis C virus co-infected patients. 9th European AIDS Conference. Warsaw, Poland. 2003.

Merchante M, Macías J, Palacios RB, et al. (abstract 13.2/19) Prevalence of non-advanced liver fibrosis among HIV/HCV-coinfected patients. 9th European AIDS Conference. Warsaw, Poland. 2003.

Merck. Crixivan® (indinavir sulfate). Package insert. 2003.  
[http://www.crixivan.com/indinavir\\_sulfate/crixivan/consumer/product\\_information/pi/index.jsp](http://www.crixivan.com/indinavir_sulfate/crixivan/consumer/product_information/pi/index.jsp) (accessed on 26 May 2004).

Meyer D, Neff G, Montalbano M, et al. (abstract S1165) Comparison of MELD scores in hepatitis C patients prior to and after adaptation of the MELD scoring system. Abstracts of Digestive Disease Week. Orlando, Florida. 2003.

Meyer JM. Prevalence of hepatitis A, hepatitis B and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State Hospital. *J Clin Psychiatry* 64(5):540-45. 2003.

Michielsen PP, Hauben EI, Ramon AM, et al. Serum aminotransferase levels and histological disease in chronic hepatitis C. *Acta Gastro-Enterologica Belgica* LX:11- 14. 1997.

Miles SA. Hematopoietic growth factors as adjuncts to antiretroviral therapy. *AIDS Res Hum Retroviruses* 8(6):1073-80. 1992.

Miller KD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. *Ann Intern Med* 133(3):192-96. 2000.

- Miller LG, Liu H, Hays RD. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? *J Gen Intern Med* 17(1):1-11. 2002.
- Miller NS, Sheppard LM, Colenda CC, et al. Why physicians are unprepared to treat patients who have alcohol-and drug-related disorders. *Acad Med* 76(5):410-18. 2001.
- Mitsuyasu R. Prevention of bacterial infections in patients with advanced HIV infection. *AIDS* 13(Suppl 2):S19-23. 1999.
- Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA Study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. *J Acquir Immune Defic Syndr* 22(4):369-78. 1999a.
- Mocroft A, Kirk O, Barton SE et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA Study Group. *AIDS* 13(8):943-50. 1999b.
- Mohsen AH, Taylor C, Portmann B, et al. (abstract MoOrB1057) Progression rate of liver fibrosis in human immunodeficiency virus and hepatitis C virus coinfecting patients, UK experience. XIV International AIDS Conference. Barcelona, Spain, 2002.
- Mokrzycki MH, Harris C, May H, et al. Lactic acidosis associated with stavudine administration: a report of five cases. *Clin Infect Dis* 30(1):198-200. 2000.
- Mondelli MU, Silini E. Clinical significance of hepatitis C virus genotypes. *J Hepatol* 31 (Suppl 1):65-70. 1999.
- Monga HK, Rodriguez- Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. *Clin Infect Dis* 33:240-47. 2001.
- Monto A. Hepatitis C and steatosis. *Semin Gastrointest Dis* 13(1):40-46. 2002a.
- Monto A, Alonzop J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus and alcohol. *Hepatology* 36(3):726-36. 2002b.
- Monto A, Patel K, Bostrom A, et al. Risks of a range of alcohol intake on hepatitis C fibrosis. *Hepatology* 39(3):826-34. 2004.
- Moore RD, Jeruly JC, Chaisson RE. Anemia and survival in HIV infection. *J Acquir Immune Defic Syndr Hum Retrovirol* 19(1):29-33. 1998.
- Moore RD. Human immunodeficiency virus, anemia and survival. *Clin Infect Dis* 29:44-49. 1999.
- Moore RD. Anemia and human immunodeficiency virus disease in the era of highly active antiretroviral therapy. *Semin Hematol* 37(4 Suppl 6):18-23. 2000.

Moreno L, Quereda C, Moreno A, et al. Pegylated interferon  $\alpha$ -2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. *AIDS* 18(1):67-73. 2004.

Moses A, Nelson J, Bagby GC Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. *Blood* 91(5):1479-95. 1998.

Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. *J Clin Gastroenterol* 34(3):268-71. 2002.

Mukherjee S, Gilroy RK, Rogge J, et al. (abstract 148) Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis for recurrent hepatitis C in liver transplantation—a single center experience. 54th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts. 2003.

Murphy DA, Roberts KJ, Hoffman D, et al. Barriers and successful strategies to antiretroviral adherence among HIV-infected monolingual Spanish-speaking patients. *AIDS Care* 15(2):217-30. 2003.

Murphy EL, Bryzman SM, Glynn SA, et al. Risk factors for hepatitis C virus infection in United States blood donors. *Hepatology* 31(3):756-62. 2000.

Murri R, Fantoni M, Del Borgo C, et al. Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. *J Acquir Immune Defic Syndr* 22(5):461-66. 1999.

Myers RP, Messous D, Thabut D, et al. (abstract 752; *Hepatology* 36:351 A. 2002) Serum biochemical markers for the prediction of fibrosis in patients with chronic hepatitis C: prospective validation study. 53rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts. 2002.

Myers RP, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. *AIDS* 17(5):721-25. 2003.

Myers RP, Benhamou Y, Bouchet M, et al. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus co-infected non-responders and relapsers to interferon-based therapy. *AIDS* 18(1):75-79. 2004.

Nakashima E, Fujisawa T, Kimura A, et al. Efficacy of interferon-alpha treatment in Japanese children with chronic hepatitis C. *J Gastroenterol Hepatol* 18(4):411-14. 2003.

Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. *Liver Transpl* 8(7):623-29. 2002.

Nasiff VM, Beltran R, Gil N. (abstract WePeB6024) The role of hepatitis infection and nevirapine on liver abnormalities among HIV patients. XVI International AIDS Conference. Barcelona, Spain 2002.

Nasti G, Di Gennaro GD, Tavio M, et al. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin. *AIDS* 15(14): 1783-87. 2001.

National ADAP Monitoring Project. Annual Report. Kaiser Family Foundation. May 2004. <http://www.kff.org/hiv/aids/ADAP.cfm> (accessed on 26 May 2004).

National Household Survey on Drug Abuse, 2000 and 2001. Substance Abuse and Mental Health Service Administration, Office of Applied Statistics. <http://oas.samhsa.gov/p0000016.htm#Standard> (accessed on 26 May 2004).

National Institutes of Health Consensus Statement. Effective medical treatment of opiate addiction. Volume 15, Number 6. 1997. [http://odp.od.nih.gov/consensus/cons/108/108\\_intro.htm](http://odp.od.nih.gov/consensus/cons/108/108_intro.htm) (accessed on 26 May 2004).

National Institutes of Health Consensus Development Conference Statement. Management of Hepatitis C: 2002. Final statement September 12th, 2002. [http://consensus.nih.gov/cons/116/091202116cdc\\_statement.htm#2](http://consensus.nih.gov/cons/116/091202116cdc_statement.htm#2) (accessed on 24 May 2004)

Nawras A, Alsolaiman MM, Mehboob S, et al. Systemic sarcoidosis presenting as a granulomatous tattoo reaction secondary to interferon-alpha treatment for chronic hepatitis C and review of the literature. *Dig Dis Sci* 47(7):1627-31. 2002.

Neau D, Trimoulet P, Winnock M, et al. Comparison of 2 regimens that include interferon- $\alpha$ -2a plus ribavirin for the treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. *Clin Infect Dis* 36:1564-71. 2003.

Neff GW et al. (abstract 4447.00) Preliminary treatment results of pegylated interferon alpha 2B and ribavirin in liver transplant recipients with recurrent HCV nonresponsive to interferon alpha 2B and ribavirin. 38th Annual Meeting of the European Association of the Study of the Liver (EASL). Geneva, Switzerland. 2003a.

Neff GW et al. (abstract 4449.00) Treatment of naïve hepatitis C recurrence (HCV-R) in liver transplant recipients with pegylated interferon alpha-2B and ribavirin. 38th Annual Meeting of the European Association of the Study of the Liver (EASL). Geneva, Switzerland. 2003b.

Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. *Liver Transpl* 9(3):239-47. 2003c.

Neglia V, Sookoian S, Herrera M, et al. Development of cutaneous sarcoidosis in a patient with chronic hepatitis C treated with interferon alpha 2a. *J Cutan Med Surg* 5(5): 406-8. 2001.



- Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and-uninfected homosexual men. *J Infect Dis* 176(4):1064-67. 1997.
- Nelson M, Browne R, Asboe D, et al. (abstract F12/3) Increasing incidence of acute hepatitis C in HIV positive men secondary to sexual transmission, epidemiology and treatment. 9th European AIDS Conference. Warsaw, Poland. 2003.
- Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. *Science* 282:103-7. 1998.
- Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. *J Infect Dis* 182(1):28-35. 2000.
- Neumann AU, Hagai E, Schalm SW, et al. (abstract 192) Early viral kinetics prediction of sustained virological response after 1 or 4 weeks of peg-interferon-alfa-2a and ribavirin therapy (DITTO-HCV Project). 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Neumann UP, Langrehr JM, Berg T, et al. (abstract 768) Treatment of recurrent hepatitis C after liver transplantation with peginterferon alfa-2b and ribavirin. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Nguyen HA, Miller AI, Dieperink E, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. *Am J Gastroenterol* 97(7):1813-20. 2002.
- Nguyen MH, Trinh HN, Garcia RT, et al. (abstract 1014) Evaluation and outcomes of combination therapy with interferon or peginterferon plus ribavirin in 67 Southeast Asian patients with hepatitis C genotypes 6, 7, 8, and 9. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Nicklin DE, Schultz C, Brensinger CM, et al. Current care of hepatitis C-positive patients by primary care physicians in an integrated delivery system. *J Am Board Fam Pract* 12(6):427-35. 1999.
- Norcia F, Di Maria A, Prandini F, et al. Natural interferon therapy: optic nerve ischemic damage? *Ophthalmologica* 213(5):339-40. 1999.
- Nousbaum JB. Genomic subtypes of hepatitis C virus: epidemiology, diagnosis and clinical consequences. *Bul Soc Pathol Extol* 91(1):29-33. 1998.
- Nowak P, Schvartz R, Ericzon BG, et al. Follow-up of antiretroviral treatment in liver transplant recipients with primary and chronic HIV type 1 infection. *AIDS Res Hum Retroviruses* 19(1): 13-19. 2003.

Nowicki M, Laskus T, Radkowski M, et al. (abstract 648-M) Presence of HCV RNA in cervico-vaginal lavages obtained from HIV-1/HCV co-infected women. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2002.

Nunez G, Urzua J. [Opioids and the immune system]. *Rev Med Chil* 127(3):341-48. 1999.

Núñez M, Lana R, Mendoza JL et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. *J Acquir Immune Defic Syndr*; 27 (5):426-31. 2001.

Núñez M, Ríos P, Martín-Carbonero L, et al. Brief report: role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 30(1):65-68. 2002.

Nyamathi A, Robbins WA, Fahey JL, et al. Presence and predictors of hepatitis C virus RNA in the semen of homeless men. *Biol Res Nurs* 4(1):22-30. 2002.

Obhrai J, Hall Y, Anand BS. Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. *J Clin Gastroenterol* 32(5):413-17. 2001.

Ockenga J, Stoll, M, Tillmann HL, et al. [Coinfection of hepatitis B and C in HIV- infected patients]. *Wien Med Wochenschr* 147(19-20):439-42. 1997.

O'Connor PG, Molde S, Henry S, et al. Human immunodeficiency virus infection in intravenous drug users: a model for primary care. *Am J Med* 93(4):382-86. 1992.

Office of National Drug Control Policy. Methadone (fact sheet). 2000.  
<http://www.whitehousedrugpolicy.gov>.

Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. *Am J Gastroenterol* 91(7):1374-79. 1996.

Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. *N Engl J Med* 330(11):744-50. 1994.

Okamoto H, Kurai K, Okada S. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. *Virology* 188(1): 331-41. 1992.

Okamoto M, Nagata I, Murakami J, et al. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. *J Infect Dis* 182:1511-14. 2000.

Okazaki T, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. *Scand J Gastroenterol* 29(11): 1039-43. 1994.

Olano JP, Borucki MJ, Wen JW, et al. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. *Clin Infect Dis* 21(4):973-76. 1995.

Orenstein R, Tsongas N. Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection. *Pharmacotherapy* 22(11):1468-78. 2002.

Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients. Annual report. 2002. <http://www.optn.org/data/annualReport.asp> (accessed on 5 April 2004).

Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C RNA levels among alcoholic patients with chronic hepatitis C. *Hepatology* 20(5):1115-20. 1994.

Paccagnini S, Principi N, Massironi E, et al. Perinatal transmission and manifestation of hepatitis C virus infection in a high-risk population. *Pediatr Infect Dis J* 14(3):195-99. 1995.

Pageaux GP, Ducos J, Mondain AM, et al. Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection. *Liver Transpl Surg* 3(5):501-5. 1997.

Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *N Eng J Med* 338(13):853-60. 1998.

Papo T. Interferon-alpha and auto-immunity. *Rev Med Interne* 23(Suppl 4):501s-510s. 2002.

Park GJ-H, Lin BPC, Ngu, MC, et al. Chronic viral hepatitis and liver cirrhosis. *J Gastroenterol and Hepatol* 15:386-90. 2000.

Pasquier C, Bujan L, Daudin M et al. Intermittent detection of hepatitis C virus (HCV) in semen from men with human immunodeficiency virus type 1 (HIV-1) and HCV. *J Med Virol* 69(3):344-9. 2003.

Patel K, Muir AJ, McHutchison JG. Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients. *Hepatology* 37(5):1222. 2003.

Paternoster DM, Santarossa C, Grella P et al. Viral load in HCV RNA-positive women. *Am J Gastroenterol*; 96 (9): 2751- 54. 2001.

Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med* 133(1):21-30. 2000.

Patroni A, Torit C, Tomasoni L, et al. Effect of highly active antiretroviral therapy (HAART) and hepatitis C co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. *HIV Clin Trials* 3(6):451-61. 2002.

Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. *J Hepatol* 40(3):484-90. 2004.

Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. *Hepatology* 19(4):841-48. 1994.

Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. *J Infect Dis* 171:1607-10. 1995.

Pawlotsky JM, Roudot-Thoraval F, Bastie A, et al. Factors affecting treatment responses to interferon-alpha in chronic hepatitis C. *J Infect Dis* 174(1):1-7. 1996.

Pawlotsky JM, Hezode C, Pellegrin B, et al. (abstract 102579) Early HCV genotype 4 replication kinetics during treatment with peginterferon alfa-2a (Pegasys)-ribavirin combination. A comparison with HCV genotypes 1 and 3 kinetics. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.

Peck-Radosavljevic M, Wichlas M, Homoncik-Kramil M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon- $\alpha$ . *Gastroenterology* 123:141-51. 2002.

Pérez-Olmeda M, Asensi V, Romero M, et al. (abstract 653-M) Treatment of chronic hepatitis C: SHIRT (Spanish HIV Interferon Ribavirin Trial). 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2002.

Pérez-Olmeda M, Martín-Carbonero L, Riquez PR, et al. (abstract 842) Predictive value of early virological response (12 weeks) to pegylated interferon plus ribavirin in HIV-HCV co-infected patients. 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2003a.

Pérez-Olmeda M, Núñez M, Romero M, et al. Pegylated IFN- $\alpha$ -2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. *AIDS* 17(7):1024-28. 2003b.

Perrault J, McGill DB, Ott BJ, et al. Liver biopsy: complications in 1000 inpatients and outpatients. *Gastroenterology* 74(1):103-06. 1978.

Perronne C, Carrat F, Bani Sadr F, et al. (abstract LBO16) RIBAVIC trial (ANRS HC02): a controlled randomized trial of pegylated interferon alfa-2b plus ribavirin vs. interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients: preliminary results. XVI International AIDS Conference. Barcelona, Spain. 2002.

Perronne C, Carrat F, Bani Sadr F, et al. (abstract 117LB) Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated interferon- $\alpha$ -2b plus ribavirin vs interferon- $\alpha$ -2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2004.

- Perry CM, Jarvis B. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C. *BioDrugs* 16(3):213-17. 2002.
- Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. *Gastroenterology* 118:760-64. 2001.
- Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C RNA and histological lesions in chronic hepatitis C. *Hepatology* 27 (6):1717-22. 1998.
- Peters MG, Terrault NA. Alcohol use and hepatitis C. *Hepatology* 36(5, Suppl 1):S220-25. 2002.
- Peterson PK, Molitor TW, Chao CC. The opioid-cytokine connection. *J Neuroimmunol* 83(1-2): 63-69. 1998.
- Pham TN, MacParland SA, Mulrooney PM, et al. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. *J Virol* 78(11):5867-74. 2004.
- Pialoux G, Gouezel P, Delarocque-Astagneau E, et al. (abstract ThPeC7518) Epidemiology of patients with HIV and HCV co-infection. XIV International AIDS Conference. Barcelona, Spain. 2002.
- Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68, 276 biopsies. *J Hepatol* 2(2):165-73. 1986.
- Piccolo P, Borg L, Lin A, et al. Hepatitis C virus and human immunodeficiency virus-1 coinfection in former heroin addicts in methadone maintenance treatment. *J Addict Dis* 21(4):55-66. 2002.
- Piliero PJ, Faragon JJ. Case report. Hepatitis B virus and HIV coinfection. *AIDS Read* 12(10):443- 4, 448- 51. 2002.
- Pineda JA, Macias J, Lozano F ,et al. (abstract ThPeA7158) Impaired CD4+ cell counts, recovery and immune deactivation following highly active antiretroviral therapy (HAART) among drug-naïve HIV/HCV-coinfected patients. XIV International AIDS Conference. Barcelona, Spain. 2002.
- Piroth L, Duong M, Quantin C, et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? *AIDS* 12(4):381-88. 1998.
- Pockros PJ, Carithers R, Desmond P, et al. (abstract H-457) Evaluation of two doses of peginterferon alfa-2a for the treatment of chronic hepatitis C (CHC). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. 2001.
- Pockros PJ, Duchini A, McMillian R, et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. *Am J Gastroenterol* 97(8):2040-45. 2002.
- Pokorny CS, Waterland M. Short-stay, out-of-hospital radiologically guided liver biopsy. *Med J Australia* 176:67-69. 2002.

- Pol S, Thiers V, Nousbaum JB, et al. The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients. *Gastroenterology* 109(5):581-83. 1995.
- Pol S. Treatment of hepatitis C virus infection in dialysis patients. *Nephrol Dial Transplant* 15(Suppl 8):46-48. 2000.
- Pol S, Vallet-Pichard A, Fontaine H, et al. HCV infection and hemodialysis. *Semin Nephrol* 22(4):331-39. 2002.
- Pol S et al. (abstract 3530.00) High risk of mitochondrial toxicity in HIV/HCV coinfecting patients under concomitant ddI/d4T and interferon (standard or pegylated IFN)/ribavirin treatments. 38th Annual Meeting of the European Association of the Study of the Liver (EASL). Geneva, Switzerland. 2003.
- Pomova NI, Ivanikov IO, Siutkin VE. [Use of peg-intron in combined treatment of chronic liver disease caused by HIV infection]. *Eksp Klin Gastroenterol* (1):42-45, 182. 2003.
- Pontisso P, Gerotto M, Ruvoletto MG, et al. Hepatitis C genotypes in patients with dual hepatitis B and C virus infection. *J Med Virol* 248(2):157-60. 1996.
- Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. *AIDS* 15: 1115-23. 2001.
- Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. *Lancet* 349(9055):825-32. 1997.
- Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon  $\alpha$ -2b plus ribavirin for 48 weeks or for 24 weeks versus interferon  $\alpha$ -2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet* 352(9138):1426-32. 1998.
- Poynard T, McHutchison J, Goodman Z et al. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. *Hepatology* 31(1):211-18. 2000.
- Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. *J Hepatol* 34(5):730-9. 2001.
- Poynard T, Cacoub P, Ratziu V, et al. Fatigue in patients with chronic hepatitis C. *J Viral Hepat* 9(4):295-303. 2002a.
- Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. *Gastroenterology* 122(5): 1303-13. 2002b.

Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology* 38(1):75-85. 2003.

Pradat P, Alberti A, Poynard T, et al. (abstract 562) Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. *Hepatology* 36(4):973- 77. 2002.

Pradat P, Tillmann HL, Braconier J-H, et al. Long-term follow-up of chronic hepatitis C patients—response to therapy and incidence of liver-related complications. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.

Pramoolsinsap C, Poovorawan Y, Hirsch P, et al. Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. *Ann Trop Med Parasitol* 93(7):745-51. 1999.

Proctor VE, Tesfa A, Tompkins DC. Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. *AIDS Patient Care STDS* 13(9):535-44. 1999.

Proust B, Dubois F, Bacq Y, et al. Two successive hepatitis C virus infections in an intravenous drug user. *J Clin Microbiol* 38(8):325-27. 2000.

Pugh RNM, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 60:646-49. 1973.

Puoti C, Magrini A, Stati T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. *Hepatology* 26(6): 1393-98. 1997.

Puoti M, Bonancini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfecting with hepatitis C virus and human immunodeficiency virus. *J Infect Dis* 183:134-37. 2001.

Puoti M, Airoidi M, Bruno R. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. *AIDS Rev* 4(1):27-35. 2002.

Puoti M, Torti C, Ripamonti D, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology and outcome. *J Acquir Immune Defic Syndr* 32(3):259-67. 2003.

Qadri A, Barnes D, Carey W, et al. (abstract 107211) Hepatic steatosis in patients with chronic hepatitis C is associated with HCV genotype and BMI but is not associated with advanced hepatic fibrosis or response to therapy. Abstracts of Digestive Disease Week. New Orleans, Louisiana. 2004.

Quintana M, Barrasa A, Del Amo J, et al. (abstract ThPeC7511) Morbidity and mortality by hepatitis C virus (HCV) infection and HCV genotype in a cohort of HIV positive hemophiliacs in Madrid: 1979 to 2000. XIV International AIDS Conference. Barcelona, Spain. 2002.

Qurishi N, Kreuzberg C, Hess L et al. (abstract ThPeC7490) Effect of antiretroviral therapy on liver-related mortality in HIV/HCV coinfecting patients. XIV International AIDS Conference. Barcelona, Spain. 2002a.

Qurishi N, Kreuzberg C, Voigt E, et al. (abstract 95) Effect of anti-retroviral therapy on liver-related mortality in HIV/HCV coinfecting patients. 37th Annual Meeting of the European Association of the Study of the Liver (EASL). Madrid, Spain. 2002b.

Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. *Lancet* 362 (9397):1708-13. 2003.

Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. *J Infect Dis* 183:1112-15. 2001.

Ragni M, Belle S, Im K, et al. (abstract 155) Survival in HIV-infected liver transplant recipients. 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2003.

Rajan S, Liebman HA. Treatment of hepatitis C related thrombocytopenia with interferon alpha. *Am J Hematol* 68(3):202-9. 2001.

Rakela J, Radkowski M, Laskus T, et al. (abstract 60) HCV presence in genital secretions in HIV/HCV coinfecting women. 54th Annual Meeting of the Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.

Ramos-Casals M, Garcia-Carrasco M, Lopez-Medrano F, et al. Severe autoimmune cytopenias in treatment-naïve hepatitis C virus infection: clinical description of 35 cases. *Medicine (Baltimore)* 82(2):87-96. 2003.

Rancinan C, Neau D, Savès M, et al. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? *AIDS* 16:1357-62. 2002.

Ratziu V, Munteanu M, Charlotte F, et al. Fibrogenic impact of high serum glucose in chronic hepatitis C. *J Hepatol* 39(6):1049-55. 2003.

Ratziu V, Trabut JB, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C. *Curr Gastroenterol Rep* 6(1):22-9. 2004.

Reddy RK, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. *Hepatology* 30(3):787-93. 1999.

Reddy RK, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon  $\alpha$ -2a in noncirrhotic patients with chronic hepatitis C. *Hepatology* 33(2):433-38. 2001.

Reed WW, Diehl LF. Leukopenia, neutropenia and reduced hemoglobin levels in healthy American blacks. *Arch Intern Med* 151(3):501-05. 1991.



Regazzi MB, Villani P, Zucchi P, et al. (abstract 14:P 3.5) Clinical pharmacokinetics of nelfinavir and its metabolite M8 in HIV/HCV coinfecting patients with and without cirrhosis. 4th International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, France. 2003.

Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol* 97(10):2614-8. 2002.

Reid AE, Koziel MJ, Aiza I, et al. Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States. *Am J Gastroenterol* 94(6):1619-26. 1999.

Reindollar RW. Hepatitis C and the correctional population. *Am J Med* 107(6B):100S-103S. 1999.

Reisler RB, Han C, Burman W, et al. (abstract 657-M) Risk of Grade IV events and death in HIV patients co-infected with hepatitis B and/or hepatitis C receiving HAART. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2002.

Reisler RB, Han C, Burman W, et al. Grade 4 events are as important as AIDS events in the era of HAART. *J Acquir Immune Defic Syndr* 34(4):397-86. 2003.

Reliquet V, Mussini JM, Chenebault JM, et al. Peripheral neuropathy during stavudine-didanosine antiretroviral therapy. *HIV Med* 2(2):92-6. 2001.

Resti M, Azzari C, Lega L, et al. Mother-to-infant transmission of hepatitis C virus. *Acta Paediatr* 84(3):251-55. 1995.

Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. *BMJ* 317:437-41. 1998.

Resti M, Azzari C, Galli L, et al. Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. *J Infect Dis* 185:567-72. 2002.

Restrepo A et al. (abstract/poster M1625) The rate of hepatitis C in patients co-infected with HIV in an urban medical center. Abstracts of Digestive Disease Week. Orlando, Florida. 2003.

Revicki DA, Brown RE, Henry DH, et al. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia. *J Acquir Immune Defic Syndr* 7(5):474-84. 1994.

Rich JD, Whitlock TL, Towe CW, et al. Prescribing syringes to prevent HIV: a survey of infectious disease and addiction medicine physicians in Rhode Island. *Subst Use Misuse* 36(5):535-50. 2001.

Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. *N Engl J Med* 336(13):919-22. 1997.

- Rifflet H, Vuillemin E, Oberti F, et al. Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha. *Gastroenterol Clin Bio* 22(3):353-57. 1998.
- Rimland D, Guest JL. (abstract 873) Mortality in the HIV Atlanta VA Cohort Study (HAVACS): a 22 year analysis. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2004.
- Rivera-Coll A, Fuentes-Arderiu X, Diez-Noguera A. Circadian rhythms of serum concentrations of 12 enzymes of clinical interest. *Chronobiol Int* 10(3):190-200. 1993.
- Rizzardi PG, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporine A coupled with highly active antiretroviral therapy. *J Clin Invest* 109(5):681-88. 2002.
- Robaeys G, Mathei C, Buntinx F, et al. Management of hepatitis C virus infections in intravenous users. *Acta Gastroenterol* 65(2):99-100. 2002.
- Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. *Hepatology* 36(5, Suppl 1):S106-13. 2002.
- Roca B, Gomex CJ, Arnedo A. Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. *J Infect* 39 (2):141-45. 1999.
- Rocco A, Gargano S, Provenzano A, et al. Incidence of autoimmune thyroiditis in interferon-alpha treated and untreated patients with chronic hepatitis C virus infection. *Neuroendocrinol Lett* 22(1):39-44. 2001.
- Roche Pharmaceuticals. Copegus™ (ribavirin, USP). Package insert. 2002. [www.rocheusa.com/products/copegus/pi.pdf](http://www.rocheusa.com/products/copegus/pi.pdf) (accessed 22 May 2004).
- Roche Pharmaceuticals. Fortovase® (saquinavir). Package insert. 2003. [www.rocheusa.com/products/fortovase/pi.htm](http://www.rocheusa.com/products/fortovase/pi.htm) (accessed 22 May 2004).
- Roche Pharmaceuticals. Fuzeon® (enfuvirtide). Package insert. 2003. [www.fda.gov/cder/foi/label/2003/021481lbl.pdf](http://www.fda.gov/cder/foi/label/2003/021481lbl.pdf) (accessed 22 May 2004).
- Roche Pharmaceuticals. Hivid® (zalcitabine). Complete Product Information. 2001. [www.rocheusa.com/products/hivid/pi.pdf](http://www.rocheusa.com/products/hivid/pi.pdf) (accessed 22 May 2004).
- Roche Pharmaceuticals. Pegasys® (peg-interferon alfa-2a). Package insert. 2002. [www.rocheusa.com/product/s/pegasys/pi.pdf](http://www.rocheusa.com/product/s/pegasys/pi.pdf) (accessed 22 May 2004).
- Rockstroh JK, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfecting with HIV. *Am J Gastroenterol* 91(12):2563-68. 1996.

Rockstroh JK, Schulz C, Mauss S, et al. (abstract WePeB6025) Pegylated interferon-alpha and ribavirin therapy for hepatitis C in HIV-coinfected patients: 24-weeks results. XIV International AIDS Conference. Barcelona, Spain. 2002.

Rockstroh JK, Konopnicki D, Soriano V, et al. (abstract 799) Hepatitis B (HBV) and hepatitis C (HCV) in the EuroSIDA Cohort: prevalence and impact on mortality, AIDS progression and response to HAART. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2004.

Rodriguez-Guardado A, Maradona JA, Asensi V, et al. (letter) Hepatitis C virus in patients with HIV infection and lipodystrophy. *J Acquir Immune Defic Syndr* 32(3):348-49. 2003.

Rodriguez-Torres M, Rodriguez-Orengo J. (abstract 343) Efficacy of peg-interferon alfa-2a (PEGASYS) and RBV for HIV/HCV coinfecting patients that are nonresponders to previous therapy. 54th Annual Meeting of the Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.

Rodriguez-Torres M, Torriani FJ, Lissen E, et al. (abstract 507) Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with HIV/HCV coinfection: results from the AIDS Pegylated Ribavirin International Coinfection Trial. 39th Meeting of the European Association for the Study of the Liver. Berlin, Germany. 2004.

Rohrig S, Grob PJ. [Infection with hepatitis viruses HAV, HBV and HCV as well as with AIDS virus HIV in drug addicts of the Zurich street scene—a prevalence study]. *Schweiz Med Wochenschr* 120(17):621-29. 1990.

Roland ME, Stock P, Carlson L, et al. (abstract 655-M) Liver and kidney transplantation in HIV-infected patients: a preliminary multi-site experience. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2002.

Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. *Transplantation* 75(4):425-29. 2003.

Roland M, Carlson L, Terrault N, et al. (abstract 826) Patient and graft outcomes following solid organ transplantation. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2004.

Romero-Gomez M, Castellano-Megias VM, Grande L, et al. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. *Am J Gastroenterol* 98(5):952-2. 2003.

Roselle GA, Danko LH, Kralovic SM, et al. National hepatitis C surveillance day in the Veterans Health Administration of the Department of Veterans Affairs. *Mil Med* 167(9):756-59. 2002.

- Rosen HR, Chou S, Sasaki AW, et al. Molecular epidemiology of hepatitis C infection in US veteran liver transplant recipients: evidence for decreasing relative prevalence of genotype 1b. *Am J Gastroenterol* 94(10):3015-19. 1999.
- Rosen HR, Ribeiro RR, Weinberger L, et al. Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. *J Hepatol* 37(1):124-30. 2002.
- Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, hepatitis B and hepatitis C in people with severe mental illness. *Am J Public Health* 91(1):31-37. 2001.
- Rosenthal E, Poirée M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). *AIDS* 17(2):1803-09. 2003.
- Ross A, Chung RT. (abstract 105779) Natural history of acute hepatitis C in a U.S. cohort. Abstracts of Digestive Disease Week. New Orleans, Louisiana. 2004.
- Rostaing L, Modeato A, Baron E, et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. *Nephron* 74(3):512-16. 1996.
- Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alpha IFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. *J Am Soc Nephrol* 9(12):2344-48. 1998.
- Rostaing L. Treatment of hepatitis C virus infection after renal transplantation: new insights. *Nephrol Dial Transplant* 15(Suppl 8):74-76. 2000.
- Rouveix B. Opiates and immune function. Consequences on infectious diseases with special reference to AIDS. *Therapie* 47(6):503-12. 1992.
- Roy S, Loh HH. Effects of opioids on the immune system. *Neurochem Res* 21(11):1375- 86. 1996.
- Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. *Gut* 53(3):406-12. 2004.
- Rufi G, Barcena R, Vargas V, et al. (abstract 827) Orthotopic liver transplantation (OLT) in 21 HIV-1-infected recipients: evaluation of Spanish experience in the highly active antiretroviral (HAART) era. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2004.
- Ruiz JD, Molitor F, Sun RK, et al. Prevalence and correlates of hepatitis C infection among inmates entering the California correctional system. *Western J of Medicine* 170 (3):156-60. 1999.
- Rumi MG, Santagostino E, Morfini M, et al. A multicenter controlled, randomized, open trial of interferon  $\alpha$ -2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. *Blood* 89(10):3529-33.1997.

- Rutschman OT, Negro F, Hirschel B, et al. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfecting with HIV. *J Infect Dis* 177(3):783- 85. 1998.
- Ryder SD, Irving WL, Jones DA, et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. *Gut* 53(3):318-21. 2004.
- Sabatino G, Ramenghi LA, diMarzio, et al. Vertical transmission of hepatitis C: an epidemiological study on 2,980 pregnant women in Italy. *Eur J Epidemiol* 12(5):443-47. 1996.
- Sachithanandan S, Fielding JF. Low rate of HCV transmission from women infected with contaminated anti-D immunoglobulin to their family contacts. *Ital J Gastroenterol Hepatol* 29(1):47-50. 1997.
- Saitz R, Friedmann PD, Sullivan LM, et al. Professional satisfaction experienced when caring for substance-abusing patients. *J Gen Intern Med* 17(5):373-76. 2002.
- Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. *Scand J Gastroenterol* 17(4): 517-21. 1982.
- Salmon-Céron D, Chauvelot-Moachon L, Abad S, et al. (correspondance) Mitochondrial toxic effects and ribavirin. *Lancet* 357(9270):1803-4. 2001.
- Salomon J, Weinstein MC, Hammitt J ,et al. Empirically calibrated model of hepatitis C virus infection in the United States. *Am J Epidemiol* 156(8):761-73. 2002.
- Samet JH, Friedman P, Saitz R. Benefits of linking primary medical care and substance abuse services. *Arch Intern Med* 161(1):85-91. 2001.
- Samet JH, Larson MJ, Horton NJ. Linking alcohol-and drug-dependent adults to primary medical care: a randomized controlled trial of a multi-disciplinary health intervention in a detoxification unit. *Addiction* 98(4):509-16. 2003.
- Samuel D, Vittecoq D, Duclos-Vallee JC, et al. (abstract 259). Liver transplantation for HCV cirrhosis in HIV-HCV coinfecting patients. Evaluation of antiretroviral therapy and of HCV recurrence. American Association for the Study of Liver Disease. Boston, Massachusetts. 2002.
- Samuel D, Bizollon T, Feray C, et al. Interferon-alfa-2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. *Gastroenterology* 124 (3):642-50. 2003a.
- Samuel D. (abstract 767) Treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon and ribavirin. 54th Annual Meeting of the Association for the Study of Liver Diseases. Boston, Massachusetts. 2003b.

Sanchez JF, Pascua J, Sanchez F, et al. [Treatment of chronic hepatitis C virus infection with interferon in patients infected with the human immunodeficiency virus]. *An Med Interna* 11(12):575-79. 1994.

Sanchez N, Lambiase L, Li J, et al. (abstract 100804) Severe depression induced by HCV therapy results in decreased compliance to treatment and viral response. American Association for the Study of Liver Disease. Boston, Massachusetts. 2002.

Sanchez Montero F. (abstract WePeB6018) Efficacy and safety of therapy with interferon and ribavirin in HIV infected patients with chronic hepatitis C. XIV International AIDS Conference. Barcelona, Spain. 2002.

Sánchez-Quijano A, Andreu J, Gavilán F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. *Eur J Clin Infect Dis* 14(11):949-53. 1995.

Sanchez-Tapias JM, Diago M, Escartin P, et al. (abstract 509) Sustained virological response after prolonged treatment with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) in treatment-naïve patients with chronic hepatitis C and detectable HCV RNA after week 4 of therapy: TERAVID-4 STUDY. 39th Meeting of the European Association for the Study of the Liver. Berlin, Germany. 2004.

Santos L, Barrasa J, Sanz N, et al. (abstract ThPeC7492) Sustained response to combination therapy with interferon  $\alpha$ -2b (IFN) and ribavirin (RBV) for chronic hepatitis C in HIV-infected patients. XIV International AIDS Conference. Barcelona, Spain. 2002.

Sauleda S, Esteban JI, Altisent C et al. Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C. *Thromb Haemost* 83(6):807-10. 2000.

Salueda S, Juárez A, Esteban JL, et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. *Hepatology* 34(5):1035-40. 2001.

Savès M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort France 1996-1998. *AIDS* 12(17):F115-21. 1999.

Sawada M, Takada A, Takase S, et al. Effects of alcohol on the replication of hepatitis C virus. *Alcohol Alcohol Suppl* 1B:85-90. 1993.

Sawada A, Tajiri H, Kozaiwa K, et al. Favorable response to lymphoblastoid interferon-alpha in children with chronic hepatitis C. *J Hepatol* 28(2):184-88. 1998.

Scalori A, Apale P, Panizzuti F, et al. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. *Eur J Gastroenterol Hepatol* 12(5):505-9. 2000.

Scaradavou A. HIV-related thrombocytopenia. *Blood Rev* 16(1):73-76. 2002.

Schafer M, Boetsch T, Laakmann G, et al. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. *Addiction* 95(7):1101-4. 2000.

Schafer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. *Hepatology* 37(2):443-51. 2003a.

Schafer M, Schwaiger M, Berg T, et al. (abstract 333) Citalopram for prevention of interferon-alpha associated depression in psychiatric risk factors. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003b.

Schering Corporation. Peg Intron™ (Peginterferon alfa-2b). Package insert. 2001.  
<http://www.fda.gov/cder/biologics/products/pegsche080701.htm> (accessed on 22 May 2004).

Scheuer P. Liver biopsy size matters in chronic hepatitis: bigger is better. *Hepatology* 38(6):1356-58. 2003.

Schiff ER. Hepatitis C and alcohol. *Hepatology* 26(3 Suppl 1):39S-42S. 1997.

Schijman A, Colina R, Mukomolov S, et al. Comparison of hepatitis C viral loads in patients with or without coinfection with different genotypes. *Clin Diagn Lab Immunol* 11(2):433-5. 2004.

Schlanger K, Trei J, Factor S. (abstract 797) The role of hepatitis C in mortality among people living with AIDS in New York City. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2004.

Schmitt C, Bertel J, Jacob C. [Incidence of serological markers of hepatitis B and C viruses and HIV in a population of drug abusers hospitalized from 1990 to 1992]. *Ann Med Interne* 145(1):7-12. 1994.

Schramm TM, Lawford BR, Macdonald GA, et al. Sertraline treatment of interferon-alfa-induced depressive disorder. *Med J Aust* 173(7):359-61. 2000.

Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. *N Engl J Med* 344:1686-90. 1996.

Schvarcz R, Glaumann H, Reichard O, et al. Histological and virological long-term outcome in patients treated with interferon-alpha-2b and ribavirin for chronic hepatitis C. *J Viral Hepat* 6(3):237-42. 1999.

- Schvarcz R, Rudbeck G, Soderdahl G, et al. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfecting with HIV and hepatitis C virus. *Transplantation* 69(10):2194-95. 2000.
- Schwartzapfel B, Taylor LE, MacLeod ER, et al. (abstract ThPeC7512) A pilot program for treating hepatitis C in HIV/hepatitis C virus coinfecting individuals with comorbid psychiatric illness and/or addiction. XIV International AIDS Conference. Barcelona, Spain. 2002.
- Schwarz A, Offermann G, Keller F, et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation—data on four cases and review of the literature. *Transplantation* 55(3):95-103. 1993.
- Schwarz KB, et al. (abstract 215) The safety, efficacy and pharmacokinetics of peginterferon alfa-2a (40KD) in children with chronic hepatitis C. Abstracts of Digestive Disease Week. Orlando, Florida. 2003.
- Scientific Registry of Transplant Recipients. About Transplants: Fast Facts. <http://www.ustransplant.org/facts.html> (accessed on 18th April 2004).
- Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. *N Engl J Med* 27:1906-11. 1992.
- Seeff LB. Natural history of hepatitis C. *Hepatology* 26(3 Suppl 1):21S-28S. 1997.
- Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. *Ann Intern Med* 132:105-11. 2000.
- Seeff LB, Lindsay KL, Bacon BR, et al. Complementary and alternative medicine in chronic liver disease. *Hepatology* 34(3):595-603. 2001.
- Semba RD, Shah N, Klein RS, et al. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. *Clin Infect Dis* 34:260-66. 2002.
- Sendi PP, Bucher HC, Craig BA, et al. Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr Hum Retrovirol* 20(4):376-81. 1999.
- Senkbeil LE, Moss JG, Gaglio PJ, et al. (abstract 1213) Erythropoietin maintains ribavirin dose and sustained virologic response during HCV treatment. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Servin L, Molina E, Baracco G, et al. (abstract 260) Predictors of HAART induced hepatotoxicity in patients with HIV and hepatitis C. American Association for the Study of Liver Disease. Boston, Massachusetts. 2002.



Shakil AO, Di Bisceglie AM, Hoofnagle JH. Seizures during alpha interferon therapy. *J Hepatol* 24(1):48-51. 1996.

Sharma P, Balan V, Hernandez J, et al. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? *Dig Dis Sci* 49(1):25-9. 2004.

Shehab TH, Sonnand SS, Jeffries M, et al. Current practice patterns of primary care physicians in the management of patients with hepatitis C. *Hepatology* 30(3):794-800. 1999.

Shehab TH, Sonnand SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. *J Viral Hepat* 8(5):377-83. 2001.

Shehab TM, Orrego M, Chunduri R et al. Identification and management of hepatitis C patients in primary care clinics. *Am J Gastroenterol* 98(3):639-44. 2003.

Skeikh AM, Wolf DC, Lebovics E, et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. *Transplantation* 68(2):307-9. 1999.

Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. *Hepatology* 28(3):831-38. 1998.

Sherlock S. Landmarks in viral hepatitis. *JAMA* 252(3):402-06. 1984.

Sherman KE, O'Brien J, Gutierrez AG ,et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. *J Clin Microbiol* 31(10): 2679- 82. 1993.

Sherman KE, Creager RL, O'Brien J et al. The use of oral fluid for hepatitis C antibody screening. *Am J Gastroenterol*; 89 (11): 2025- 27. 1994.

Sherman KE, Rouster SD, Mendenhall C, et al. Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. *Hepatology* 30(1):265-70. 1999.

Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials group. *Clin Infect Dis* 34:831-37. 2002a.

Sherman KE, Horn P, Rouster S, et al. (abstract 122) HCV RNA kinetic response to PEG-interferon and ribavirin in co-infected patients, 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2002b.

Sherman KE, Rouster SD, Horn PS. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfecting with human immunodeficiency virus. *Clin Infect Dis* 35(4):482-87. 2002c.

Shields PL, Mutimer DJ, Muir D. Combined alpha interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders. *Br J Haematol* 108(2):254-58. 2000.

Shiffman ML, Hoffman CM, Thompson EB, et al. Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C. *Hepatology* 26(3):780-85. 1997.

Shiffman ML, Hoffman CM, Luketic VA, et al. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. *J Hepatol* 28(3):382-89. 1998.

Shiffman ML. Retreatment of patients with chronic hepatitis C. *Hepatology* 36(5, Suppl. 1): S128-34. 2002a.

Shiffman ML. HALT-C Trial Investigators. (abstract 101756) Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. American Association for the Study of Liver Disease. Boston, Massachusetts. 2002b.

Shiffman ML, DiBisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. *Gastroenterology* 126(4):1015-23. 2004.

Shindo M, Hamada K, Oda Y, et al. Long-term follow-up study of sustained biochemical responders with interferon therapy. *Hepatology* 33(5):1299-02. 2001.

Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. *Ann Intern Med* 132 (7):517-24. 2000.

Shuhart, MC, Bronner MP, Gretch DR, et al. Histological and clinical outcome after liver transplantation for hepatitis C. *Hepatology* 26(6):1646-52. 1997.

Silvestri F, Barillari G, Fanin R, et al. Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin's lymphomas. *Haematologica* 82(3):314-17. 1997.

Singh N, Gayowski T, Wannstedt CF, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. *Transplantation* 15(65):82-86. 1998.

Siren S, Nurhan O, Munire T, et al. Renal transplantation offers better survival in HCV-infected end-stage renal disease patients. *Tissue Antigens* 60(6):559. 2002.

Slim J, John G, Smith S, et al. (abstract 977) Neutropenia as an adverse drug reaction in patients co-infected with HIV/HCV receiving interferon and ribavirin therapy. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France. 2003.

Smith CM, Davies DB, McBride MA, et al. Liver transplantation in the United States: a report from the Organ Procurement and Transplantation Network. *Clin Transpl*: 19-30. 2000.

Smith DM, Puoti M, Sulkowski M, et al. (abstract MoOrb1059) Symptomatic hyperlactatemia during a large hepatitis C treatment trial in HIV/HCV co-infected participants on stable antiretroviral therapy. XIV International AIDS Conference. Barcelona, Spain. 2002.

Solmi L, Primerano AM, Gandolini L. Ultrasound follow-up of patients at risk for hepatocellular carcinoma: results of a prospective study on 360 cases. *Am J Gastroenterol* 91(6):1189-94. 1996.

Soriano V, Garcia-Samaniego J, Bravo R, et al. Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. HIV-Hepatitis Spanish Study Group. *J Infect* 31(1): 9-13. 1995.

Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. *Clin Infect Dis* 23(3):585-91. 1996.

Soriano V, Kirk O, Atunes F, et al. (abstract ThOrB655) The influence of hepatitis C virus on the prognosis of HIV-infected persons: the EuroSIDA study. XIII International AIDS Conference. Durban, South Africa. 2000.

Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV international panel. *AIDS* 16 (6):813-828. 2002.

Soriano V, Pérez-Olmeda M, Ríos P, et al. (letter) Is treatment failure for hepatitis C virus infection in HIV-positive drug users associated with a shift in HCV genotypes? *J Acquir Immune Defic Syndro* 34(4):465-66. 2003.

Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. *AIDS* 18(1):1-12. 2004.

Soto B, Sánchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. *J Hepatol* 26(1):1-5. 1997.

Soto TA, Sadowski LS. (abstract ThPeC7516) The prevalence of hepatitis C among HIV patients with psychiatric and substance abuse diagnoses. XIV International AIDS Conference. Barcelona, Spain. 2002.

Soyer P, Debroucker F, Lacheheb D, et al. [Ultrasound-guided biopsy in focal lesions of the liver. Report on an automated biopsy system]. *J Radio* 74(4):215-19. 1993.

Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. *Hepatology* 36(5):1273-79. 2002.

Spaulding A, Greene C, Davidson K, et al. Hepatitis C in state correctional facilities. *Prev Med* 28(1):92-100. 1999.

Spencer JD, Latt N, Beeby PJ, et al. Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission. *J Viral Hepat* 4(6):395-409. 1997.

Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The view of U.S. transplant centers. *Transplantation* 65(9):1187-91. 1998.

Staples CT, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans affairs medical center) cohort study (HAVACS): the effect of co-infection on survival. *Clin Infect Dis* 29(1):150-54. 1999.

Stapleton JT, Polgreen PM, Fultz S, et al. (abstract ThPeC7519) HCV Infection is associated with lower levels of serum LDL cholesterol and total cholesterol in HIV-positive individuals. XIV International AIDS Conference. Barcelona, Spain. 2002.

Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. *Drug Alcohol Depend* 61(3):211-15. 2001.

Sterling RK, Contos MJ, Sanyal AJ, et al. The clinical spectrum of hepatitis C virus in HIV coinfection. *J Acquir Immune Defic Syndro* 29(3):315-17. 2002.

Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. *Clin Infect Dis* 33:865-72. 2001.

Strader DB, Bacon BR, Lindsay KL, et al. Use of complementary and alternative medicine in patients with liver disease. *Am J Gastroenterol* 97(9):2391-97. 2002.

Strader DB, Wright T, Thomas DL, Seeff LB. AASLD Practice Guideline: Diagnosis, Management and Treatment of Hepatitis C. *Hepatology* 39 (4):1147-71. 2004.

Sud A, Hui JJ, Farrell GC, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. *Hepatology* 39(5):1239-47. 2004.

Sugimoto K, Stadanlick J, Ikeda F, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. *Hepatology* 32(1):30-37. 2003.

Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. *JAMA* 283(1):74-80. 2000.

Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. *Hepatology* 35(1):182-89. 2002a.

Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of HIV disease. *JAMA* 288(2):199-06. 2002b.

Sulkowski MS, et al. (abstract 231) Pharmacokinetics, pharmacodynamics and antiviral response in patients with chronic hepatitis C infection on methadone maintenance therapy receiving peginterferon (40KD) alfa-2a (Pegasys®). Abstracts of Digestive Disease Week. Orlando, Florida. 2003a.

Sulkowski MS, Felizarta F, Slim J, et al. (abstract 841) Final results of daily vs. 3-times weekly interferon alpha 2-b plus ribavirin for the treatment of hepatitis C infection in HIV-infected persons. A multi-center, randomized, open-label study. 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2003b.

Sulkowski MS, Thomas DL, Mehta SH, et al. (abstract 1125) Hepatotoxicity associated with the antiretroviral therapy (ART) containing protease inhibitors (PI) with or without pharmacokinetic boosting by low-dose ritonavir (RTV). 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003c.

Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. *Ann Intern Med.* 138(3): 197-207. 2003d.

Sullivan P. Associations of anemia, treatments for anemia, and survival in patients with human immunodeficiency virus infection. *J Infect Dis* 185(Suppl 2):S138-42. 2002.

Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project. *Blood* 91(1):301-08. 1998.

Süoglu D ÖD, Elkabes B, Sokucu S, et al. Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C? *J Pediatr Gastroenterol Nutr* 34(2):199-06. 2002.

Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. *Drug Alcohol Depend* 67(2):117-23. 2002a.

Sylvestre DL. Treatment of HCV in the methadone patient. *Medical Writer's Circle.* 2002b.

Tada H, Saitoh S, Nakagawa Y et al. Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C. *J Gastroenterol* 31(4):582-84. 1996.

Tajiri H, Miyoshi Y, Funada S, et al. Prospective study of mother-to-infant transmission of hepatitis C virus. *Pediatr Infect Dis J* 20(1):10-14. 2001.

Takada N, Takase S, Takada A, et al. Differences in the hepatitis C virus genotypes in different countries. *J Hepatol* 17(3):277-83. 1993.

Takahashi M, Yamada G, Miyamoto R, et al. Natural course of hepatitis C. *Am J Gastroenterol* 88(2):240-43. 1993.

Tang Z, Yang D, Hao L, et al. [Detection and significance of HCV RNA in saliva, seminal fluid and vaginal discharge in patients with hepatitis C]. *J Tongji Med Univer* 16 (1):11-13, 24. 1996.

Tate D, Paul RH, Flanigan TP, et al. The impact of apathy and depression on quality of life in patients infected with HIV. *AIDS Patient Care STDS* 17(3):115-20. 2003.

Taylor C, Burns DA, Wiselka MJ. Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C. *Postgrad Med J* 76(896):365-67. 2000.

Taylor LE, Tashima KT, Alt E, et al. (abstract ThPeC7513) Addiction and mental illness are barriers to hepatitis C treatment among HIV/Hepatitis C virus coinfecting individuals. XIV International AIDS Conference. Barcelona, Spain. 2002.

Teldali EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. *Clin Infect Dis*; 36:363-67. 2003a.

Tedali EM, Huppler Hullsiek K, Malvestutto CD, et al. Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Bein Community Programs for Clinical Research on AIDS. *Clin Infect Dis* 36: 1313-28. 2003b.

Tedali EM, Baker RK, Moorman AC, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. *Clin Infect Dis* 38:1483-89. 2004.

Telfer P, Sabin C, Devereux H, et al. The progression of HCV-associated liver disease in a cohort of haemophiliac patients. *Br J Haematol* 87:555-61. 1994.

Terrault NA, Wright TL, Pereira BJ. Hepatitis C infection in the transplant recipient. *Infect Dis Clin North Am* 9(4):943-64. 1995.

Terrault NA, Khalili M, Straley S, et al. (abstract 7) Efficacy and tolerability of preemptive interferon (IFN) versus IFN plus ribavirin (RBV) treatment in hepatitis C virus (HCV) infected liver transplant recipients. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.

Teshale EH, Kellerman SE, Adams MR, et al. (abstract 665-M) Adherence to guidelines among HIV/HCV coinfecting persons and providers. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2002.

Testa G, Crippin JS, Netto GJ, et al. Liver transplantation for hepatitis C: recurrence and disease progression. *Liver Transpl* 6(5):553-61. 2000.

Thaca I. One junky's odyssey. *Harm Reduction Communication*. Fall 1997.  
<http://www.harmreduction.org/newsletter.html> (accessed on 30 May 2004).

The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. *Hepatology* 20(1):15-20. 1994.

Theodore D, Shiffman ML, Sterling RK, et al. Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. *Dig Dis Sci* 48(1):140-45. 2003.

Thio CL, Nolt KR, Astemborski J, et al. Screening for hepatitis C in human immunodeficiency virus-infected individuals. *J Clin Microbiol* 38(2):575-77. 2000.

Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injecting drug users. *Medicine (Baltimore)* 74(4):212- 20. 1995a.

Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore - an analysis of 309 sex partnerships. *J Infect Dis* 171:768- 75.1995b.

Thomas DL, Gruninger SE, Siew C, et al. Occupational risk of hepatitis C infections among general dentists and oral surgeons in North America. *Am J Med* 100(1):41-45. 1996.

Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C from human immunodeficiency virus type-1 infected mothers. *J Infect Dis* 177:1480-88. 1998.

Thomas DL. Mother-infant hepatitis C transmission: second generation research. *Hepatology* 29(3):992-93. 1999.

Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C infection: host, viral, and environmental factors. *JAMA* 284(4):450-56. 2000a.

Thomas DL, Astemborski J, Vlahov D, et al. Determinants of the quantity of hepatitis C virus RNA. *J Infect Dis* 18:844-51. 2000b.

Thomas DL. (commentary) Hepatitis C epidemiology: injecting new tools into the field. *Hepatology* 31(3):790- 91. 2000c.

Thomas DL, Rich JD, Schuman P, et al. Multicenter evaluation of hepatitis C RNA levels among female injection drug users. *J Infect Dis* 183:973-76. 2001.

Thomas DL. Hepatitis C and human immunodeficiency virus infection. *Hepatology* 36 (5, Suppl 1):S201-S209. 2002.

- Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. *Am J Epidemiol* 155(7):645-53. 2002.
- Thuret I, Lacaille F, Canioni D, et al. (letter) Histopathology of the liver in adolescents co-infected with HIV and hepatitis C virus. *AIDS* 17(15):2265-67. 2003.
- Tokars JL, Frank M, Alter MJ, et al. National surveillance of dialysis-associated diseases in the United States, 2000. *Semin Dial* 15(3):162-71. 2002.
- Tokita H, Okamoto H, Tsuda T, et al. Hepatitis C variants from Vietnam are classifiable into the seventh, eighth and ninth major groups. *Proc Natl Acad U S A* 91(23):11022-26.. 1994.
- Tong MJ, Neveen S, El-Farra BS, et al. Clinical outcomes after transfusion associated hepatitis C. *N Engl J Med* 22:1463-66. 1995.
- Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. *J Gastroenterol and Hepatol* 16: 553-59. 2001.
- Torre D, Tambini R, Cadario F, et al. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. *Clin Infect Dis* 33:1579-85. 2001.
- Torriani FJ, Byrnes C, Asensi V, et al. (abstract 575) A comparison of hepatotoxicity and response to potent antiretroviral therapy (ARV) in HIV/HCV-infected and matched HIV-infected patients. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois. 2001.
- Torriani FJ, Ribeiro RM, Gilbert TL, et al. (abstract 121) Early HCV viral dynamics in HIV/HCV infected patients on HCV treatment. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2002a.
- Torriani FJ, Asensi V, Byrnes C, et al. (abstract WePeB6035) Hepatitis C RNA levels are unchanged after one year of effective antiretroviral therapy. XIV International AIDS Conference. Barcelona, Spain. 2002b.
- Torriani FJ, Rockstroh J, Rodriguez-Torres M, et al. (abstract 112) Final results of APRICOT: a randomized, partially blinded, international trial evaluating peginterferon- $\alpha$ -2a + ribavirin vs. interferon- $\alpha$ -2a + ribavirin in the treatment of HCV in HIV/HCV co-infection. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2004.
- Torti C, Patroni A, Tinelli C, et al. (letter) Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy. *J Acquir Immune Defic Syndro* 29(3):315-17. 2002.
- Tortu S, Neaigus A, McMahon J, et al. Hepatitis C among noninjecting drug users: a report. *Subst Use Misuse* 36(4):523-34. 2001.



Totos G, Gizaris V, Papaevangelou G. Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination. *Vaccine* 15(11):1252-53. 1997.

Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. *Hepatology* 18(2):253-57. 1993.

Tsai JF, Jeng JE, Ho MS, et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. *Br J Cancer* 76(7):968-74. 1997.

Tsogas N, Orenstein R. (abstract 664-M) HIV-HCV co-infection in women. An urban HIV clinic experience. IX Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2002.

Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. *N Engl J Med* 328(25):1797-1801. 1993.

Tucker JS, Burman MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. *Am J Med* 114(7):573-80. 2003.

Tuldra A, Wu AW. Interventions to improve adherence to antiretroviral therapy. *J Acquir Immune Defic Syndr* 31(Suppl 3):S154-S157. 2002.

Turner BJ, Laine C, Cosler L, et al. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. *J Gen Intern Med* 18 (4):248-57. 2003.

Tuveri R, Rothschild C, Pol S, et al. Hepatitis C virus genotypes in French haemophiliacs: kinetics and reappraisal of mixed infections. *J Med Virol* 5:36-41. 1997.

Tzakis AG, Cooper MH, Dummer JS, et al. Transplantation in HIV+ patients. *Transplantation* 49(2):354-58. 1990.

Uberti-Foppa C, De Bona A, Morsica G, et al. Pretreatment of chronic hepatitis C in patients coinfecting with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. *J Acquir Immune Defic Syndr* 33(2):146-52. 2003.

Uberti-Foppa C, De Bona A, Galli L, et al. (abstract 814) Fibrosis damage in liver biopsy specimens from 354 HIV-HCV co-infected patients: role of persistently normal alanine aminotransferase. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2004.

United Network for Organ Sharing. UNOS Policies 4.0: Acquired Immune Deficiency System (AIDS) and Human Pituitary Derived Growth Hormone. <http://www.unos.org/policiesandbylaws/policies.asp?whatWeDo=true> (assessed on 20 April 2004).

- Vadan R, Gheorghe L, Becheanu G, et al. Predictive factors for the severity of liver fibrosis in patients with chronic hepatitis C and moderate alcohol consumption. *Rom J Gastroenterol* 12(3):183-7. 2003.
- Valdez H, Anthony D, Farukhi F, et al. Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfecting patients. *AIDS* 14 (15):2239-46. 2000.
- Valente SM. Depression and HIV disease. *J Assoc Nurses AIDS Care* 14(2):41-51. 2003.
- Van den Hoek JA, van Haastrecht HJ, Goudsmit J, et al. Prevalence, incidence and risk factors of hepatitis C virus infection among drug users in Amsterdam. *J Infect Dis* 162: 823-26. 1990.
- Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. *J Med Virol* 63(1):1-7. 2001.
- Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug use abuse. *Am J Gastroenterol* 98(10):2281-88. 2003.
- Velázquez RF, Rodríguez M, Navascués C, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. *Hepatology* 37(3):520-27. 2003.
- Veldt BJ, Saracco G, Hansen BE, et al. (abstract 971) Long term follow up of sustained virologic responders to interferon alpha in chronic hepatitis C: a meta-analysis assessing true clinical end-points. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Vento S, Garfano F, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. *N Engl J Med* 338(5):286-90. 1998.
- Vento, S. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. *J Viral Hepatol* 7(Suppl 1):7-8. 2000.
- Veronese L, Rautureau J, Sadler BM, et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired liver function. *Antimicrobial Agents and Chemotherapy* 44(4):821-26. 2000.
- Verucchi G, Calza L, Biagetti C, et al. (letter) Ultrastructural liver mitochondrial abnormalities in HIV/HCV coinfecting patients receiving antiretroviral therapy. *J Acquir Immune Defic Syndr* 35 (3):326-28. 2004.
- Vidal-Trecan GM, Varescon-Pousson I, Gagniere B, et al. Association between first injection risk behaviors and hepatitis C seropositivity among injecting drug users. *Ann Med Interne (Paris)* 153(4):219-25. 2002.

Viksna L, Mocroft A, Knysz B, et al. (abstract 18.2/3) Regional differences in characteristics of HIV patients from across Europe. The EuroSIDA Study. 9th European AIDS Conference. Warsaw, Poland. 2003.

Viladomiu L, Genesca J, Esteban JI, et al. Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial. *Hepatology* 15(5):767-69. 1992.

Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. *Hepatology* 29(3):908-14. 1999.

Vogel W, Graziadei I, Umlauft F, et al. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study. *Dig Dis Sci* 41(12 Suppl):81S-85S. 1996.

Vogt M, Lang T, Frösner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. *N Engl J Med* 341(12):866-70. 1999.

Voigt E, Schultz C, Mauss S, et al. (abstract 976) Factors related to outcome of treatment with pegylated interferon alpha 2b (PEG-IFN) plus ribavirin (RBV) in HIV/HCV co-infected patients. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France. 2003.

Voirin N, Trépo C, Mialhes P, et al. (abstract 956) Survival of patients infected with HIV and HCV in the era of highly active antiretroviral therapy. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France. 2003.

Volberding PA, Levine AM, Dieterich D, et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. *Clin Infect Dis* 38:1459-67. 2004.

Von Wichmann MA, Rodriguez Arrondo F, Arrizabalaga J, et al. (abstract V-776) HIV-HCV coinfecting patients. A study of eligibility for therapy in a short-term. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. 2003a.

Von Wichmann MA, Arevalo S, Zapata E, et al. (abstract V-782) Survival in HIV+ patients with viral hepatitis after ascites has developed. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. 2003b.

Vrieling H, Reesink HW, van den Burg PJ, et al. Performance of three generations of anti-hepatitis C enzyme-linked immunosorbent assays in donors and patients. *Transfusion* 37(8):845-49. 1997.

Wai C-T, Greenson JK, Fontana R, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 38(2):518-26. 2003.

Walker UA, Bäuerle J, Laguno M, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine or zalcitabine. *Hepatology* 39(2):311-17. 2004.

- Waller L. Living with hepatitis C: from self-loathing to advocacy. *MJA* 180: 293-94. 2004.
- Walsh MJ, Vanags DM, Clouston AD, et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. *Hepatology* 39 (5):1230-38. 2004.
- Wanke CA, Silva M, Knox TA, et al. (brief report) Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. *Clin Infect Dis* 31:803-5. 2000.
- Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. *Semin Liver Dis* 20(1):1-16. 2000.
- Wasserman R, Brau N, Hassanein T, et al. (abstract) Once-weekly epoetin alfa increases hemoglobin and decreases ribavirin dose reductions among HCV-infected patients who develop anemia on ribavirin/interferon alfa-2b therapy. *Hepatology* 32:368A. 2000.
- Wattanagoon Y, Bangchang KN, Hoggard PJ, et al. Pharmacokinetics of zidovudine phosphorylation in Human Immunodeficiency Virus-positive Thai patients and healthy volunteers. *Antimicrob Agents Chemother* 44(7):1986-9. 2000.
- Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. *BioDrugs* 15(7):465-89. 2001.
- Weigand J, Boecher W, Buggisch P, et al. (abstract 250) 24 weeks of monotherapy with pegylated interferon alfa-2b in patients with acute hepatitis C. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Weissman S, Feucht C, Moore BA. (abstract 830) Response to hepatitis A vaccine in HIV positive patients. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2004.
- Weisz K, Kreiswirth S, McMeeking M, et al (abstract 501) Erythropoietin use for ribavirin/interferon induced anemia in patients with hepatitis C. American Association for the Study of Liver Disease. Chicago, Illinois. 1998.
- Weisz K, Goldman D, Talal A, et al. (abstract 283) Interferon (IFN) and ribavirin (RBV) therapy for hepatitis C (HCV) in HIV coinfecting patients. 12-month follow-up. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2000.
- Westin J, Nordlinder H, Lagging M, et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. *J Hepatol* 37(6):837-42. 2002.
- Wheeler DA, Gilbert CL, Launer CA, et al. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Bein Community Programs for Clinical Research on AIDS. *J Acquir Immune Defic Syndr Hum Retrovirol* 18(1):80-85. 1998.

- Wheeler DA. Weight loss and disease progression in HIV infection. *AIDS Read* 9(5):347-53. 1999.
- WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board. Global surveillance and control of hepatitis C. *J Viral Hepatitis* 6:35-47. 1999.
- Wiedman M, Liebert UG, Oesen U, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. *Hepatology* 31(1):230-34. 2000.
- Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. *Hepatology* 32(1):92-96. 2000.
- Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. *Hepatology* 28(3):805-9. 1998.
- Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. *Am J Gastroenterol*; 97 (3):520-2. 2002.
- Williams B, Waters B, Parker K. Evaluation and treatment of weight loss in adults with HIV disease. *Am Fam Physician* 60(3):843-54, 857-60. 1999.
- Wirth S, Lang T, Gehring S, et al. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. *Hepatology* 36(5):1280-84. 2002.
- Wirth S, Klinkum H, Kullmer U, et al. (abstract 1201) Peg-interferon alpha-2b and ribavirin treatment in children and adolescents with chronic hepatitis C. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Wit FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. *J Infect Dis* 186(1):23-31. 2002.
- Wolfer LU, Goerdts S, Schroder K, et al. [Interferon-alpha-induced psoriasis vulgaris]. *Hautarzt* 47(2):124-28. 1996.
- Wong S, Kaita K, Gauthier T, et al. A comparative trial of recombinant interferon alpha 2a versus alpha 2 beta on myelosuppression in healthy adult volunteers. *Hepatogastroenterology* 43(7):301-5. 1996.
- Wood E, Montaner JS, Chan K, et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. *AIDS* 16(15):2065-72, 2002.
- Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. *Gastroenterology* 103(1):317-22. 1992.
- Wright TL, Hollander H, Pu X, et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. *Hepatology* 20(5):1152-55. 1994.

- Wünschmann S, Stapleton JT. (abstract WePeB6041) Hepatitis C virus envelope protein E2 enhances human lipoprotein binding to cells. XIV International AIDS Conference. Barcelona, Spain. 2002.
- Yabuuchi I, Imai Y, Kawata S, et al. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma. *Liver* 20:290-95. 2000.
- Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. *Hepatology* 23(6):1334-40. 1996.
- Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. *Hepatology* 34(2):223-27. 2001.
- Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. *Gastroenterology* 123(2):483-91. 2002.
- Yotsuyanagi H, Koike K, Yasuda K, et al. Hepatitis C virus genotypes and development of hepatocellular carcinoma. *Cancer* 76(8):1352-55. 1995.
- Yovtcheva SP, Rifai MA, Moles JK, et al. Psychiatric comorbidity among hepatitis C-positive patients. *Psychosomatics* 42(5):411-15. 2001.
- Yuce A, Kocak N, Gurakan F, et al. Interferon-alpha treatment for chronic hepatitis C in children. *Turk J Pediatr* 42(1):34-38. 2000.
- Zacks SL, Friend MW. Hepatitis B and C and renal failure. *Infect Dis Clin North Am* 15(3):877-99. 2001.
- Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. *J Hepatol* 28(1):27-33. 1998.
- Zein NN, Persing DH. Hepatitis C genotypes: current trends and future implications. *Mayo Clinic Proc* 71(5):458-62. 1996a.
- Zein NN, Rakela J, Krawutt El, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity and response to interferon therapy. Collaborative study group. *Ann Intern Med* 125(8):634- 39. 1996b.
- Zein NN, Poterucha JJ, Gross JB Jr, et al. Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b. *Am J Gastroenterol* 91(12):2560-62. 1996c.
- Zein NN. Clinical significance of hepatitis C genotypes. *Clin Microbiol Reviews* 13(2):223-35. 2000.

- Zekry A, Whiting P, Crawford DH, et al. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. *Liver Transplantation* 9(4):339-47. 2003.
- Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med* 23(343):1666-72. 2000.
- Zeuzem S, Herrmann E, Lee J-H, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon  $\alpha$ -2a. *Gastroenterology* 120(6):1438-47. 2001.
- Zeuzem S, Hultcrantz R, Bourliere M, et al. (abstract 347A) Peg-interferon alfa-2b 1.5  $\mu$ g/kg plus ribavirin 800–1400 mg/day for 24 weeks in patients with HCV 2 or 3. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Zeulka AV, Gill JS, Beevers DG. 'Neutropenia' in black west Indians. *Postgrad Med J* 63(738):257-61. 1987.
- Zhou S, Terrault N, Ferrell L, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. *Hepatology* 24(5):1041-46. 1996.
- Zuckerman E, Zuckerman T. Hepatitis C and B-cell lymphoma: the hemato-hepatologist linkage. *Blood Rev* 16(2):119-25. 2002.
- Zuffa E, Vianelli N, Martinelli G, et al. Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia. *Haematologica* 81(6):533-35. 1996.
- Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. *Clin Infect Dis* 23:1117-25. 1996.
- Zylberberg H, Pialoux G, Carnot F, et al. Rapidly evolving hepatitis C-virus related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. *Clin Infect Dis* 27:1255-58. 1998a.
- Zylberberg H, Chaix ML, Rabian C, et al. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfecting subjects. *Clin Infect Dis* 26(5):1104-6. 1998b.
- Zylberberg H, Thiers V, Lagoree D, et al. Epidemiological and virological analysis of couples infected with hepatitis C virus. *Gut* 45(1):7-8. 1999.
- Zylberberg H, Nalpas B, Pol S, et al. (letter) Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipodystrophy? *AIDS* 14(13):2065. 2000.
- Zylberberg H, Barennes C, Carnot F, et al. (abstract 831) Progression of liver histological status in HIV hepatitis C virus coinfecting patients started on HAART: a prospective study. 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2003.

## Endnotes: Volume II

Abbate I, Romano M, Longo R, et al. Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients. *J Med Virol* 70(4):581-87. 2003.

Abbate I, Cappiello G, Rosati S, et al. Intra-hepatic messenger RNA levels for interferons and related genes in hepatitis C virus/HIV co-infected patients. *AIDS* 18(4):691-692. 2004.

Abrignani S, Rosa D. Perspectives for a hepatitis C virus vaccine. *Clin Diagn Virol* 10(2-3):181-85. 1998.

Accapezzato D, Francavilla V, Rawson P, et al. Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: the role of the virus. *Eur J Immunol* 34(2):438-46. 2004a.

Accapezzato D, Francavilla V, Paroli M, et al. Hepatic expansion of a virus-specific regulatory CD8+ T cell population in chronic hepatitis C virus infection. *J Clin Invest* 113(7):963-72. 2004b.

Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology* 33(6):1358-64. 2001.

Afdahl N, Flamm S, Imperial JC, et al. Analyses of 40 kDa peginterferon alfa-2a (Pegasys) in combination with ribavirin, mycophenylate mofetil, amantadine, or amantidine plus ribavirin in patients that relapsed or did not respond to Rebetron therapy: a report of two randomized, multicenter, efficacy and safety studies. Abstract 277. 52nd Annual Meeting of the American Association for the Study of Liver Diseases. Dallas, Texas. 2001.

Agnello V, Ábel G, Elfahal M, et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. *Proc Natl Acad Sci USA* 96(22):12766-71. 1999.

Agnello V, De Rosa FG. Extrahepatic disease manifestations of HCV infection: some current issues. *J Hepatol* 40(2):341-52. 2004.

Agora S, Lau D, Gish R, et al. Phase I clinical studies of viraclidine – a liver-targeting prodrug of ribavirin. Abstract 773. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.

Agrati C, D'Offizi G, Narciso P, et al.  $\gamma\delta$  T lymphocytes expressing a  $T_H1$  phenotype are the major gammadelta T cell subset infiltrating the liver of HCV-infected persons. *Mol Med* 7(1):11-19. 2001a.

Agrati C, D'Offizi G, Narciso P, et al.  $\gamma\delta$  T cell activation by chronic HIV infection may contribute to intrahepatic  $\gamma\delta$ 1 compartmentalization and hepatitis C virus disease progression independent of highly active antiretroviral therapy. *AIDS Res Hum Retroviruses* 17(14):1357-63. 2001b.



- Agrati C, Nisii C, Oliva A, et al. Lymphocyte distribution and intrahepatic compartmentalization during HCV infection: a main role for MHC-unrestricted T cells. *Arch Immunol Ther Exp (Warsz)* 50(5):307-16. 2002.
- Ahlenstiel G, Woitas RP, Rockstroh J, Spengler U. CC-chemokine receptor 5 (CCR5) in hepatitis C—at the crossroads of the antiviral immune response? *J Antimicrob Chemother* 53(6):895-8. 2004.
- Ahlquist P, Noueir AO, Lee WM, et al. Host factors in positive-strand RNA virus genome replication. *J Virol* 77(15):8181-6. 2003.
- Aizaki H, Saito S, Ogino T, et al. Suppression of interferon-induced antiviral activity in cells expressing hepatitis C virus proteins. *J Interferon Cytokine Res* (12):1111-20. 2000.
- Aizaki H, Harada T, Otsuka M, et al. Expression profiling of liver cell lines expressing entire or parts of hepatitis C virus open reading frame. *Hepatology* 36(6):1431-38. 2002.
- Ajuebor MN, Hogaboam CM, Le T, Swain MG. C-C Chemokine Ligand 2/Monocyte Chemoattractant Protein-1 Directly Inhibits NKT Cell IL-4 Production and Is Hepatoprotective in T Cell-Mediated Hepatitis in the Mouse. *J Immunol* 170(10):5252-59. 2003.
- Al Tawil A, Graham C, Qi He. Intrafamilial transmission of hepatitis C virus in patients with acute hepatitis C: correlation with virological and immunological parameters. Abstract 59. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Alam SS, Nakamura T, Naganuma A, et al. Hepatitis C virus quasispecies in cancerous and noncancerous hepatic lesions: the core protein-encoding region. *Acta Med Okayama* 56(3):141-7. 2002.
- Alatrakchi N, Di Martino V, Thibault V, et al. Strong CD4 T<sub>H</sub>1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. *AIDS* 16(5):713-17. 2002.
- Aldaz-Carroll L, Tallet B, Dausse E, et al. Apical loop-internal loop interactions: a new RNA-RNA recognition motif identified through *in vitro* selection against RNA hairpins of the hepatitis C virus mRNA. *Biochemistry* 41(18):5883-93. 2002.
- Ali N, Siddiqui A. Interaction of polypyrimidine tract-binding protein with the 5' noncoding region of the hepatitis C virus RNA genome and its functional requirement in internal initiation of translation. *J Virol* 69(10):6367-75. 1995.
- Ali N, Siddiqui A. The La antigen binds 5' noncoding region of the hepatitis C virus RNA in the context of the initiator AUG codon and stimulates internal ribosome entry site-mediated translation. *Proc Natl Acad Sci USA* 94(6):2249-54. 1997.

- Ali N, Pruijn GJ, Kenan DJ, et al. Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation. *J Biol Chem* 275(36):27531-40. 2000.
- Ali N, Tardif KD, Siddiqui A. Cell-free replication of the hepatitis C virus subgenomic replicon. *J Virol* 76(23):12001-7. 2002.
- Ali S, Pellerin C, Lamarre D, Kukulj G. Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line. *J Virol* 78(1):491-501. 2004.
- Alisi A, Giambartolomei S, Cupelli F, et al. Physical and functional interaction between HCV core protein and the different p73 isoforms. *Oncogene* 22(17):2573-80. 2003.
- Alter HJ, Holland PV, Purcell RH. The emerging pattern of post-transfusion hepatitis. *Am J Med Sci* 270(2):329-34. 1975.
- Alvarado Esquivel C, Elewaut A, Philippe J, et al. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon- $\alpha$ . *Rev Invest Clin* 54(1):41-50. 2002.
- Amaraa R, Mareckova H, Urbanek P, Fucikova T. T helper, cytotoxic T lymphocyte, NK cell and NK-T cell subpopulations in patients with chronic hepatitis C. *Folia Microbiol (Praha)* 47(6):717-22. 2002.
- Amati L, Caradonna L, Magrone T, et al. Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN- $\alpha$ /ribavirin. *Curr Pharm Des* 8(11):981-93. 2002.
- Ando K, Hiroishi K, Kaneko T, et al. Perforin, Fas/Fas ligand, and TNF- $\alpha$  pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. *J Immunol* 158(11):5283-91. 1997.
- André P, Komurian-Pradel F, Deforges S, et al. Characterization of low- and very-low-density hepatitis C virus RNA- containing particles. *J Virol* 76(14):6919-28. 2002.
- Anthony DD, Post AB, Valdez H, et al. ELISPOT analysis of hepatitis C virus protein-specific IFN- $\gamma$ -producing peripheral blood lymphocytes in infected humans with and without cirrhosis. *Clin Immunol* 99(2):232-40. 2001.
- Anthony DD, Valdez H, Post AB, et al. Comprehensive determinant mapping of the hepatitis C-specific CD8 cell repertoire reveals unpredicted immune hierarchy. *Clin Immunol* 103(3 Pt 1):264-76. 2002.
- Anthony DD, Yonkers NL, Post AB, et al. Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. *J Immunol* 172(8):4907-16. 2004.

- Antonaci S, Piazzolla G, Napoli N, et al. Relationship between T lymphocyte responsiveness and T-helper1/T-helper2 type cytokine release in chronic hepatitis C: a critical reappraisal. *Microbios* 106(415):203-12. 2001.
- Anwar A, Ali N, Tanveer R, et al. Demonstration of functional requirement of polypyrimidine tract-binding protein by SELEX RNA during hepatitis C virus internal ribosome entry site-mediated translation initiation. *J Biol Chem* 275(44):34231-35. 2000.
- Apolinario A, Majano PL, Alvarez-Perez E, et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. *Am J Gastroenterol* 97(11):2861-70. 2002.
- Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. *Nat Med* 8(4):379-85. 2002.
- Arima N, Kao CY, Licht T, et al. Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. *J Biol Chem* 276(16):12675-84. 2001.
- Armendariz-Borunda J, Islas-Carbajal MC, Meza E, et al. A pilot study of a novel anti-inflammatory and anti-fibrotic agent, pirfenidone, in patients with liver cirrhosis. Abstract 314. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Arribillaga L, de Cerio AL, Sarobe P, et al. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. *Vaccine* 21(3-4):202-10. 2002.
- Asselah T, Boyer N, Guimont MC, et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. *Gut* 52(11): 1638-43. 2003.
- Asti M, Martinetti M, Zavaglia C, et al. Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. *Hepatology* 29(4):1272-79. 1999.
- Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. *Blood* 97(10):3171-76. 2001.
- Azzari C, Resti M, Moriondo M, et al. Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection. *Blood* 96(6):2045-48. 2000.
- Babik JM, Holodniy M. Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. *J Virol* 77(3):1940-50. 2003.
- Baginski SG, Pevear DC, Seipel M, et al. Mechanism of action of a pestivirus antiviral compound. *Proc Natl Acad Sci USA* 97(14):7981-6. 2000.

- Bain C, Fatmi A, Zoulim F, et al. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. *Gastroenterology* 120(2):512-24. 2001.
- Balasubramanian A, Ganju RK, Groopman JE. HCV and HIV envelope proteins collaboratively mediate IL-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes. *J Biol Chem* 278(37):35755-66. 2003.
- Balayan MS, Andjaparidze AG, Savinskaya SS, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. *Intervirology* 20(1):23-31. 1983.
- Ballardini G, De Raffe E, Groff P, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. *Liver Transpl* 8(1):10-20. 2002.
- Bantel H, Luger A, Poremba C, et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. *Hepatology* 34(4 Pt 1):758-67. 2001.
- Bantel H, Schulze-Osthoff K. Apoptosis in hepatitis C virus infection. *Cell Death Differ* 10 Suppl 1:S48-58. 2003.
- Baranowski E, Ruiz-Jarabo CM, Domingo E. Evolution of cell recognition by viruses. *Science* 292(5519):1102-05. 2001.
- Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. *Proc Natl Acad Sci USA* 94(4):1200-05. 1997.
- Barbaro G, Barbarini G. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon  $\alpha$ -2b and ribavirin in combination: an Italian pilot study. *Eur J Gastroenterol Hepatol* 14(5):477-83. 2002.
- Barnes E, Harcourt G, Brown D, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. *Hepatology* 36(3):743-54. 2002.
- Baron JL, Gardiner L, Nishimura S, et al. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. *Immunity* 2002 16(4):583-94. 2002.
- Baroni GS, D'Ambrosio L, Curto P, et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. *Hepatology* 23(5):1189-99. 1996.
- Baroni GS, Pastorelli A, Manzin A, et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and T<sub>H</sub>1-like response in chronic hepatitis C. *Liver* 19(3):212-19. 1999.

Bartenschlager R, Ahlborn-Laake L, Mous J, et al. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. *J Virol* 67(7):3835-44. 1993.

Bartenschlager R, Ahlborn-Laake L, Mous J, et al. Kinetic and structural analyses of hepatitis C virus polyprotein processing. *J Virol* 68(8):5045-55. 1994.

Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. *J Viral Hepat* 6(3):165-81. 1999.

Bartenschlager R, Lohmann V. Replication of hepatitis C virus. *J Gen Virol* 81(Pt 7):1631-48. 2000.

Bartenschlager R, Lohmann V. Novel cell culture systems for the hepatitis C virus. *Antiviral Res* 52(1):1-17. 2001.

Bartenschlager R. Hepatitis C virus replicons: potential role for drug development. *Nat Rev Drug Discov* 1(11):911-16. 2002.

Barth H, Schafer C, Adah MI, et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. *J Biol Chem* 278(42):41003-12. 2003.

Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. *J Exp Med* 197(5):633-642. 2003a.

Bartosch B, Vitelli A, Granier C, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. *J Biol Chem* 278(43):41624-30. 2003b.

Bartosch B, Cosset FL, Granier C, et al. Neutralizing antibody to hepatitis C virus: new assays, new opportunities. Abstract 66A. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003c.

Bashirova AA, Geijtenbeek TB, van Duijnhoven GC, et al. A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection. *J Exp Med* 193(6):671-78. 2001.

Bassett SE, Brasky KM, Lanford RE. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. *J Virol* 72(4):2589-99. 1998.

Bassett SE, Thomas DL, Brasky KM, et al. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. *J Virol* 73(2):1118-26. 1999.

- Bassett SE, Guerra B, Brasky K, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. *Hepatology* 33(6):1479-87. 2001.
- Basu A, Meyer K, Ray RB, et al. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. *Virology* 288(2):379-90. 2001.
- Basu A, Beyene A, Meyer K, Ray R. The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system. *J Virol* 78(9):4478-86. 2004.
- Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. *Hepatology* 37(3):493-503. 2003.
- Baumert TF, Wellnitz S, Aono S, et al. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. *Hepatology* 32(3):610-17. 2000.
- Beales LP, Rowlands DJ, Holzenburg A. The internal ribosome entry site (IRES) of hepatitis C virus visualized by electron microscopy. *RNA* 7(5):661-70. 2001.
- Beames B, Chavez D, Guerra B, et al. Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus. *J Virol* 74(24):11764-72. 2000.
- Beames B, Chavez D, Lanford RE. GB virus B as a model for hepatitis C virus. *ILAR J* 42(2):152-60. 2001.
- Beaulieu PL, Bös M, Bousquet Y, et al. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. *Bioorg Med Chem Lett* 14(4):967-71. 2004.
- Beeson PB. Jaundice occurring one to four months after transfusion of blood or plasma. Report of seven cases. *JAMA* 121:1332-34. 1943.
- Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. *EMBO J* 15(1):12-22. 1996.
- Beinker NK, Voigt MD, Arendse M, et al. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. *J Hepatol* 25(5):633-38. 1996.
- Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfecting patients. The Multivirc Group. *Hepatology* 30(4):1054-58. 1999.
- Berg T, Kronenberger B, Hinrichsen H, et al. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. *Hepatology* 37(6):1359-67. 2003.

- Bergamini A, Bolacchi F, Cerasari G, et al. Lack of evidence for the Th2 predominance in patients with chronic hepatitis C. *Clin Exp Immunol* 123(3):451-58. 2001a.
- Bergamini A, Bolacchi F, Cepparulo M, et al. Treatment with ribavirin and interferon- $\alpha$  reduces interferon-gamma expression in patients with chronic hepatitis C. *Clin Exp Immunol* 123(3):459-64. 2001b.
- Bergqvist A, Rice CM. Transcriptional activation of the interleukin-2 promoter by hepatitis C virus core protein. *J Virol* 75(2):772-81. 2001.
- Bergqvist A, Sundström S, Dimberg LY, et al. The hepatitis C virus core protein modulates T cell responses by inducing spontaneous and altering T-cell receptor-triggered  $Ca^{2+}$  oscillations. *J Biol Chem* 278(21):18877-83. 2003.
- Bertoletti A, D'Elios MM, Boni C, et al. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. *Gastroenterology* 112(1):193-99. 1997.
- Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. *Hepatology* 38(1):4-13. 2003.
- Beyene A, Basu A, Meyer K, Ray R. Hepatitis C virus envelope glycoproteins and potential for vaccine development. *Vox Sang* 83 Suppl 1:27-32. 2002.
- Bianchi E, Pessi A. Inhibiting viral proteases: challenges and opportunities. *Biopolymers* 66(2):101-14. 2002.
- Bichr S, Rende-Fournier R, Vona G, et al. Detection of neutralizing antibodies to hepatitis C virus using a biliary cell infection model. *J Gen Virol* 83(Pt 7):1673-8. 2002.
- Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. *J Virol* 75(15):7059-66. 2001.
- Blackard JT, Yang Y, Bordoni P, et al. Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. *J Infect Dis* 189(8):1472-81. 2004.
- Blanchard E, Brand D, Roingard P. Endogenous virus and hepatitis C virus-like particle budding in BHK-21 cells. *J Virol* 77(6):3888-89. 2003a.
- Blanchard E, Hourieux C, Brand D, et al. Hepatitis C virus-like particle budding: role of the core protein and importance of its Asp111. *J Virol* 77(18):10131-8. 2003b.
- Blatt LM, Davis JM, Klein SB, et al. The biologic activity and molecular characterization of a novel synthetic interferon- $\alpha$  species, consensus interferon. *J Interferon Cytokine Res* 16(7):489-99. 1996.
- Blendis L, Lurie Y, Oren R. Occult HBV infection—both hidden and mysterious. *Gastroenterology* 125(6):1903-5. 2003.

- Blight KJ, Rice CM. Secondary structure determination of the conserved 98-base sequence at the 3' terminus of hepatitis C virus genome RNA. *J Virol* 71(10):7345-52. 1997.
- Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. *Science* 290(5498):1972-74. 2000.
- Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. *J Virol* 76(24):13001-14. 2002.
- Blight KJ, McKeating JA, Marcotrigiano J, et al. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. *J Virol* 77(5):3181-90. 2003.
- Blindenbacher A, Duong FH, Hunziker L, et al. Expression of hepatitis C virus proteins inhibits interferon  $\alpha$  signaling in the liver of transgenic mice. *Gastroenterology* 124(5):1465-75. 2003.
- Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. *Oncogene* 22(33):5093-107. 2003.
- Blumberg BS, Gerstley BJ, Hungerford DA, et al. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. *Ann Intern Med* 66(5):924-31. 1967.
- Boaz MJ, Waters A, Murad S, et al. Presence of HIV-1 Gag-specific IFN- $\gamma$ +IL-2<sup>+</sup> and CD28+IL-2<sup>+</sup> CD4 T cell responses is associated with nonprogression in HIV-1 infection. *J Immunol* 169(11):6376-85. 2002.
- Bocharov G, Ludewig B, Bertoletti A, et al. Underwhelming the immune response: effect of slow virus growth on CD8<sup>+</sup>-T-lymphocyte responses. *J Virol* 78(5):2247-54. 2004.
- Bode JG, Ludwig S, Ehrhardt C, et al. IFN- $\alpha$  antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. *FASEB J* 17(3):488-90. 2003.
- Boden D, Pusch O, Lee F, et al. Human immunodeficiency virus type 1 escape from RNA interference. *J Virol* 77(21):11531-5. 2003.
- Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. *Hepatology* 26(2):473-7. 1997.
- Boisvert J, Kunkel EJ, Campbell JJ, et al. Liver-infiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes. *J Hepatol* 38(1):67-75. 2003.
- Bonacchi A, Petrai I, Defranco RM, et al. The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. *Gastroenterology* 125(4):1060-76. 2003.
- Bonacini M, Govindarajan S, Blatt LM, et al. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. *J Viral Hepat* 6(3):203-8. 1999.



- Bonino F, Hoyer B, Shih JW, et al. Delta hepatitis agent: structural and antigenic properties of the delta-associated particle. *Infect Immun* 43(3):1000-05. 1984.
- Booth JC, Kumar U, Webster D, et al. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. *Hepatology* 27(1):223-7. 1998.
- Borman AM, Le Mercier P, Girard M, et al. Comparison of picornaviral IRES-driven internal initiation of translation in cultured cells of different origins. *Nucleic Acids Res* 25(5):925-32. 1997.
- Borowski P, Mueller O, Niebuhr A, et al. ATP-binding domain of NTPase/helicase as a target for hepatitis C antiviral therapy. *Acta Biochim Pol* 47(1):173-80. 2000.
- Borowski P, Lang M, Niebuhr A, et al. Inhibition of the helicase activity of HCV NTPase/helicase by 1- $\beta$ -D-ribofuranosyl-1,2,4-triazole-3-carboxamide-5'-triphosphate (ribavirin-TP). *Acta Biochim Pol* 48(3):739-44. 2001.
- Borowski P, Schalinski S, Schmitz H. Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy. *Antiviral Res* 55(3):397-412. 2002.
- Boulant S, Becchi M, Penin F, Lavergne JP. Unusual multiple recoding events leading to alternative forms of hepatitis C virus core protein from genotype 1b. *J Biol Chem* 278(46):45785-92. 2003.
- Bourgeois C, Veiga-Fernandes H, Joret AM, et al. CD8 lethargy in the absence of CD4 help. *Eur J Immunol* 32(8):2199-207. 2002.
- Braasch DA, Corey DR. Novel antisense and peptide nucleic acid strategies for controlling gene expression. *Biochemistry* 41(14):4503-10. 2002.
- Brady MT, MacDonald AJ, Rowan AG, Mills KH. Hepatitis C virus non-structural protein 4 suppresses T<sub>H</sub>1 responses by stimulating IL-10 production from monocytes. *Eur J Immunol* 33(12):3448-57. 2003.
- Brander C, Walker BD. Gradual adaptation of HIV to human host populations: good or bad news? *Nat Med* 9(11):1359-62. 2003.
- Branza-Nichita N, Durantel D, Carrouée-Durantel S, et al. Antiviral effect of N-butyldeoxyjirimycin against bovine viral diarrhoea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers. *J Virol* 75(8):3527-36. 2001.
- Brass V, Bieck E, Montserret R, et al. An amino-terminal amphipathic  $\alpha$ -helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. *J Biol Chem* 277(10):8130-39. 2002.
- Brehm MA, Pinto AK, Daniels KA, et al. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. *Nat Immunol* 3(7):627-34. 2002.

- Brenchley JM, Hill BJ, Ambrozak DR, et al. T-cell subsets that harbor human immunodeficiency virus (HIV) *in vivo*: implications for HIV pathogenesis. *J Virol* 78(3):1160-8. 2004.
- Bressanelli S, Stiasny K, Allison SL, et al. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. *EMBO J* 23(4):728-38. 2004.
- Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. *Hepatology* 38(3):639-44. 2003.
- Bridge AJ, Pebernard S, Ducraux A, et al. Induction of an interferon response by RNAi vectors in mammalian cells. *Nat Genet* 34(3):263-4. 2003.
- Briggs JA, Wilk T, Welker R, et al. Structural organization of authentic, mature HIV-1 virions and coRes *EMBO J* 22(7):1707-15. 2003.
- Bright H, Carroll AR, Watts PA, Fenton RJ. Development of a GB virus B marmoset model and its validation with a novel series of hepatitis C virus NS3 protease inhibitors. *J Virol* 78(4):2062-71. 2004.
- Brinster C, Muguet S, Lone YC, et al. Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. *Hepatology* 34(6):1206-17. 2001.
- Brinster C, Chen M, Boucreux D, et al. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. *J Gen Virol* 83(Pt 2):369-81. 2002.
- Britten RJ. Divergence between samples of chimpanzee and human DNA sequences is 5%, counting indels. *Proc Natl Acad Sci USA* 99(21):13633-35. 2002.
- Bromham L, Penn D. The modern molecular clock. *Nat Rev Genet* 4(3):216-24. 2003.
- Brown EA, Zhang H, Ping LH, et al. Secondary structure of the 5' nontranslated regions of hepatitis C virus and pestivirus genomic RNAs. *Nucleic Acids Res* 20(19):5041-45. 1992.
- Büchen-Osmond, C (Ed). 00.026.0.03. Hepacivirus. In: ICTVdB - The Universal Virus Database, version 3. ICTVdB Management, The Earth Institute, Biosphere 2 Center, Columbia University, Oracle, AZ, USA. 2003.
- Buckwold VE, Wei J, Wenzel-Mathers M, et al. Synergistic *in vitro* interactions between  $\alpha$  interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. *Antimicrob Agents Chemother* 47(7):2293-98. 2003.

Buckwold VE. Implications of finding synergic *in vitro* drug-drug interactions between interferon-alpha and ribavirin for the treatment of hepatitis C virus. *J Antimicrob Chemother* 53(3):413-4. 2004.

Buerckstuemmer T, Kriegs M, Hildt E. Abstract 27. Identification of c-Raf1 as a novel binding partner of HCV regulatory protein NS5A. 39th Annual Meeting of the European Association for the Study of the Liver. Berlin, Germany. 2004.

Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. *Semin Liver Dis* 15(1):41-63. 1995.

Bukh J, Apgar CL, Yanagi M. Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent. *Virology* 262(2):470-78. 1999.

Bukh J, Forns X, Emerson SU, Purcell RH. Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. *Intervirology* 44(2-3):132-42. 2001a.

Bukh J, Apgar CL, Govindarajan S, et al. Host range studies of GB virus-B hepatitis agent, the closest relative of hepatitis C virus, in New World monkeys and chimpanzees. *J Med Virol* 65(4):694-97. 2001b.

Bukh J, Pietschmann T, Lohmann V, et al. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. *Proc Natl Acad Sci USA* 99(22):14416-21. 2002.

Bureau C, Bernad J, Chaouche N, et al. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. *J Biol Chem* 276(25):23077-83. 2001.

Burgio VL, Ballardini G, Artini M, et al. Expression of co-stimulatory molecules by Kupffer cells in chronic hepatitis of hepatitis C virus etiology. *Hepatology* 27(6):1600-06. 1998.

Burioni R, Plaisant P, Manzin A, et al. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. *Hepatology* 28(3):810-4. 1998.

Burton DR. Antibodies, viruses and vaccines. *Nat Rev Immunol* 2(9):706-13. 2002.

Caamaño J, Hunter CA. NF- $\kappa$ B family of transcription factors: central regulators of innate and adaptive immune functions. *Clin Microbiol Rev* 15(3):414-29. 2002.

Cacciarelli TV, Martinez OM, Gish RG, et al. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. *Hepatology* 24(1):6-9. 1996.

- Calabrese F, Pontisso P, Pettenazzo E, et al. Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. *Hepatology* 31(5):1153-59. 2000.
- Cameron CE, Castro C. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. *Curr Opin Infect Dis* 14(6):757-64. 2001.
- Cantaloube JF, Biagini P, Attoui H, et al. Evolution of hepatitis C virus in blood donors and their respective recipients. *J Gen Virol* 84(Pt 2):441-6. 2003.
- Carrère-Kremer S, Montpellier-Pala C, Cocquerel L, et al. Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. *J Virol* 76(8):3720-30. 2002.
- Carroll SS, Tomassini JE, Bosserman M, et al. Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs. *J Biol Chem* 278(14):11979-84. 2003.
- Casaril M, Stanzial AM, Tognella P, et al. Role of iron load on fibrogenesis in chronic hepatitis C. *Hepatology* 47(31):220-25. 2000.
- Casbarra A, Piazz FD, Ingallinella P, et al. The effect of prime-site occupancy on the hepatitis C virus NS3 protease structure. *Protein Sci* 11(9):2102-12. 2002.
- Castelruiz Y, Larrea E, Boya P, et al. Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls. *Hepatology* 29(6):1900-4. 1999.
- Castéra L, Hézode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. *Gut* 52(2):288-92. 2003.
- Castet V, Moradpour D. A model for the study of hepatitis C virus entry. *Hepatology* 38(3):771-4. 2003.
- Castillo I, Pardo M, Bartolomé J, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. *J Infect Dis* 189(1):7-14. 2004.
- Castro A, Carballo E, Dominguez A, et al. Tolerance and efficacy of subcutaneous interferon-beta administered for treatment of chronic hepatitis C. *J Interferon Cytokine Res* 17(2):65-67. 1997.
- Caussin-Schwemling C, Schmitt C, Stoll-Keller F. Study of the infection of human blood derived monocyte/macrophages with hepatitis C virus *in vitro*. *J Med Virol* 65(1):14-22. 2001.

Centers for Disease Control (CDC). Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. *MMWR Morb Mortal Wkly Rep* 31(24):317-22, 327-8. 1982.

Cerino A, Meola A, Segagni L, et al. Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles. *J Immunol* 167(7):3878-86. 2001.

Cerny A, McHutchison JG, Pasquinelli C, et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. *J Clin Invest* 95(2):521-30. 1995.

Cerny A. Viral crosstalk: who gets to say what first? *Hepatology* 35(6):1540-3. 2002.

Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. *Nature* 410(6824):106-11. 2001.

Chan J, O'Riordan K, Wiley TE. Amantadine's viral kinetics in chronic hepatitis C infection. *Dig Dis Sci* 47(2):438-42. 2002.

Chan L, Reddy TJ, Proulx M, et al. Identification of N,N-disubstituted phenylalanines as a novel class of inhibitors of hepatitis C NS5B polymerase. *J Med Chem* 46(8):1283-5. 2003.

Chang J, Yang SH, Cho YG, et al. Hepatitis C virus core from two different genotypes has an oncogenic potential but is not sufficient for transforming primary rat embryo fibroblasts in cooperation with the H-ras oncogene. *J Virol* 72(4):3060-65. 1998.

Chang KM, Rehermann B, McHutchison JG, et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. *J Clin Invest* 100(9):2376-85. 1997.

Chang KM, Thimme R, Melpolder JJ, et al. Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection. *Hepatology* 33(1):267-76. 2001.

Chang KM. Immunopathogenesis of hepatitis C virus infection. *Clin Liver Dis* 7(1):89-105. 2003.

Chang M, Williams O, Mittler J, et al. Dynamics of hepatitis C virus replication in human liver. *Am J Pathol* 163(2):433-44. 2003.

Chang SC, Yen JH, Kang HY, et al. Nuclear localization signals in the core protein of hepatitis C virus. *Biochem Biophys Res Commun* 205(2):1284-90. 1994.

Chapel HM, Christie JM, Peach V, Chapman RW. Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. *Clin Immunol* 99(3):320-4. 2001.

Charloteaux B, Lins L, Moereels H, et al. Analysis of the C-terminal membrane anchor domains of hepatitis C virus glycoproteins E1 and E2: toward a topological model. *J Virol* 76(4):1944-58. 2002.

- Charlton MR. Mycophenolate and hepatitis C: salve on a wound or gasoline on a fire? *Liver Transpl* 8(1):47-9. 2002.
- Check E. Gene regulation: RNA to the rescue? *Nature* 425(6953):10-2. 2003.
- Chen CM, You LR, Hwang LH, et al. Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor. *J Virol* 71(12):9417-26. 1997.
- Chen M, Sallberg M, Sonnerborg A, et al. Limited humoral immunity in hepatitis C virus infection. *Gastroenterology* 116(1):135-43. 1999.
- Cheney IW, Lai VC, Zhong W, et al. Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by  $\alpha$ , beta, and gamma interferons. *J Virol* 76(21):11148-54. 2002.
- Chiang BL, Yang PM, Hwang LH, et al. Establishment and characterization of NS3 protein-specific T-cell clones from a patient with chronic hepatitis C. *J Biomed Sci* 5(4):290-6. 1998.
- Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. *RNA* 9(9):1034-48. 2003.
- Choi J, Xu Z, Ou JH. Triple decoding of hepatitis C virus RNA by programmed translational frameshifting. *Mol Cell Biol* 23(5):1489-97. 2003.
- Choi J, Lee KJ, Zheng Y, et al. Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. *Hepatology* 39(1):81-89. 2004.
- Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 244:359-62. 1989.
- Choo QL, Richman KH, Han JH, et al. Genetic organization and diversity of the hepatitis C virus. *Proc Natl Acad Sci USA* 88(6):2451-55. 1991.
- Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. *Proc Natl Acad Sci USA* 91(4):1294-98. 1994.
- Choo SH, So HS, Cho JM, Ryu WS. Association of hepatitis C virus particles with immunoglobulin: a mechanism for persistent infection. *J Gen Virol* 76 ( Pt 9):2337-41. 1995.
- Choukhi A, Pillez A, Drobecq H, et al. Characterization of aggregates of hepatitis C virus glycoproteins. *J Gen Virol* 80(Pt 12):3099-107. 1999.
- Christensen JP, Kauffmann SO, Thomsen AR. Deficient CD4+ T cell priming and regression of CD8+ T cell functionality in virus-infected mice lacking a normal B cell compartment. *J Immunol* 171(9):4733-41. 2003.

- Chung YL, Sheu ML, Yen SH. Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. *Int J Cancer* 107(1):65-73. 2003.
- Chung YM, Park KJ, Choi SY, et al. Hepatitis C virus core protein potentiates TNF- $\alpha$ -induced NF- $\kappa$ B activation through TRAF2-IKK $\beta$ -dependent pathway. *Biochem Biophys Res Commun* 284(1):15-19. 2001.
- Ciccaglione AR, Marcantonio C, Costantino A, et al. Expression of HCV E1 protein in baculovirus-infected cells: effects on cell viability and apoptosis induction. *Intervirology* 46(2):121-26. 2003.
- Clayton RF, Owsianka A, Aitken J, et al. Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. *J Virol* 76(15):7672-82. 2002.
- Clouston AD, Jonsson JR, Purdie DM, et al. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. *J Hepatol* 34(2):314-20. 2001.
- Cocquerel L, Meunier JC, Pillez A, et al. A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. *J Virol* 72(3):2183-91. 1998.
- Cocquerel L, Duvet S, Meunier JC, et al. The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. *J Virol* 73(4):2641-49. 1999.
- Cocquerel L, Quinn ER, Flint M, et al. Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. *J Virol* 77(2):1604-9. 2003a.
- Cocquerel L, Kuo CC, Dubuisson J, Levy S. CD81-dependent binding of hepatitis C virus E1E2 heterodimers. *J Virol* 77(19):10677-83. 2003b.
- Coelho-Borges S, Cheinquer H, Cheinquer N, et al. HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload. *Am J Gastroenterol* 97(6):1570-72. 2002.
- Cohen J. The scientific challenge of hepatitis C. *Science* 285(5424):26-30. 1999.
- Coito C, Diamond DL, Neddermann P, et al. High-throughput screening of the yeast kinome: identification of human serine/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein. *J Virol* 78(7):3502-13. 2004.
- Collier AJ, Tang S, Elliott RM. Translation efficiencies of the 5' untranslated region from representatives of the six major genotypes of hepatitis C virus using a novel bicistronic reporter assay system. *J Gen Virol* 79(Pt 10):2359-66. 1998.
- Contreras AM, Hiasa Y, He W, et al. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. *J Virol* 76(17):8505-17. 2002.

- Coon JT, Ernst E. Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review. *J Hepatol* 40(3):491-500. 2004.
- Cooper S, Erickson AL, Adams EJ, et al. Analysis of a successful immune response against hepatitis C virus. *Immunity* 10(4):439-49. 1999.
- Corado J, Toro F, Rivera H, et al. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. *Clin Exp Immunol* 109(3):451-57. 1997.
- Cramp ME, Carucci P, Rossol S, et al. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. *Gut* 44(3):424-29. 1999.
- Cramp ME, Rossol S, Chokshi S, et al. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. *Gastroenterology* 118(2):346-55. 2000.
- Craxi A, Lo Lacono O. Amantadine for chronic hepatitis c: a magic bullet or yet another dead duck? *J Hepatol* 35(4):527-30. 2001.
- Crespo J, Rivero M, Fabrega E, et al. Plasma leptin and TNF- $\alpha$  levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. *Dig Dis Sci* 47(7):1604-10. 2002.
- Crispe IN. Hepatic T cells and liver tolerance. *Nat Rev Immunol* 3(1):51-62. 2003.
- Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. *J Exp Med* 195(1):35-41. 2002.
- Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. *Nat Med* 6(12):1375-79. 2000.
- Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. *Proc Natl Acad Sci USA* 98(12):6895-900. 2001.
- Crotty S, Cameron C, Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis? *J Mol Med* 80(2):86-95. 2002.
- Crotty S, Saleh MC, Gitlin L, et al. The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein. *J Virol* 78(7):3378-86. 2004.
- Cucchiaroni M, Kammer AR, Grabscheid B, et al. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. *Cell Immunol* 203(2):111-23. 2000.
- Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. *Nucleic Acids Res* 31(11):2705-16. 2003.



Dagan S, Ilan E, Aviel S, et al. Abstract 135. In-vitro and in-vivo evaluation of HCV polymerase inhibitors as potential drug candidates for treatment of chronic hepatitis C infection. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.

Daifuku R. Stealth nucleosides: mode of action and potential use in the treatment of viral diseases. *BioDrugs* 17(3):169-77. 2003.

Dandri M, Burda MR, Torok E, et al. Repopulation of mouse liver with human hepatocytes and *in vivo* infection with hepatitis B virus. *Hepatology* 33(4):981-88. 2001.

Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. *Lancet* 1(7649):695-98. 1970.

Das AT, Brummelkamp TR, Westerhout EM, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. *J Virol* 78(5):2601-5. 2004.

Das S, Kenan DJ, Bocskai D, et al. Sequences within a small yeast RNA required for inhibition of internal initiation of translation: interaction with La and other cellular proteins influences its inhibitory activity. *J Virol* 70(3):1624-32. 1996.

Das S, Ott M, Yamane A, Tsai W, et al. A small yeast RNA blocks hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation and inhibits replication of a chimeric poliovirus under translational control of the HCV IRES element. *J Virol* 72(7):5638-47. 1998a.

Das S, Ott M, Yamane A, et al. Inhibition of internal entry site (IRES)-mediated translation by a small yeast RNA: a novel strategy to block hepatitis C virus protein synthesis. *Front Biosci* 3:D1241-52. 1998b.

da Silva LC, Bassit L, Ono-Nita SK, et al. High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to  $\alpha$ -interferon and ribavirin: a pilot study. *J Gastroenterol* 37(9):732-36. 2002.

Date T, Kato T, Miyamoto M, et al. Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. *J Biol Chem* 279(21):22371-6. 2004.

Davidson F, Simmonds P, Ferguson JC, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. *J Gen Virol* 76(Pt 5):1197-204. 1995

Davis G, et al. (poster 490) A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Escalating Doses of a Novel Recombinant Human Albumin-Interferon  $\alpha$  Fusion Protein (Albuferon™) in Subjects with Chronic Hepatitis C. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.

Day CL, Lauer GM, Robbins GK, et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. *J Virol* 76(24):12584-95. 2002.

- Day CL, Seth NP, Lucas M, et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. *J Clin Invest* 112(6):831-42. 2003.
- Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the *CKR5* structural gene. *Science* 273(5283):1856-62. 1996.
- De Francesco R, Urbani A, Nardi MC, et al. A zinc binding site in viral serine proteinases. *Biochemistry* 35(41):13282-7. 1996.
- Deignan T, Curry MP, Doherty DG, et al. Decrease in hepatic CD56<sup>+</sup> T cells and V $\alpha$ 24<sup>+</sup> natural killer T cells in chronic hepatitis C viral infection. *J Hepatol* 37(1):101-8. 2002.
- Deinhardt F, Holmes AW, Capps RB, et al. Studies on the transmission of human viral hepatitis to marmoset monkeys. I. Transmission of disease, serial passages, and description of liver lesions. *J Exp Med* 125(4):673-88. 1967.
- Deleersnyder V, Pillez A, Wychowski C, et al. Formation of native hepatitis C virus glycoprotein complexes. *J Virol* 71(1):697-04. 1997.
- Delhem N, Sabile A, Gajardo R, et al. Activation of the interferon-inducible protein kinase PKR by hepatocellular carcinoma derived-hepatitis C virus core protein. *Oncogene* 20(41):5836-45. 2001.
- De Maria N, Colantoni A, Faggioli S, et al. Association between reactive oxygen species and disease activity in chronic hepatitis C. *Free Radic Biol Med* 21(3):291-95. 1996.
- De Mitri MS, Mele L, Chen CH, et al. Comparison of serum and liver hepatitis C virus quasispecies in HCV-related hepatocellular carcinoma. *J Hepatol* 29(6):887-92. 1998.
- De Mitri MS, Morsica G, Cassini R, et al. Prevalence of wild-type in NS5A-PKR protein kinase binding domain in HCV-related hepatocellular carcinoma. *J Hepatol* 36(1):116-22. 2002.
- De Moliner L, Pontisso P, De Salvo GL, et al. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. *Gut* 42(6):856-60. 1998.
- De Tomassi A, Pizzuti M, Graziani R, et al. Cell clones selected from the Huh7 human hepatoma cell line support efficient replication of a subgenomic GB virus B replicon. *J Virol* 76(15):7736-46. 2002.
- de Veer MJ, Holko M, Frevel M, et al. Functional classification of interferon-stimulated genes identified using microarrays. *J Leukoc Biol* 69(6):912-20. 2001.
- De Vos R, Verslype C, Depla E, et al. Ultrastructural visualization of hepatitis C virus components in human and primate liver biopsies. *J Hepatol* 37(3):370-9. 2002.
- Devroe E, Silver PA. Therapeutic potential of retroviral RNAi vectors. *Expert Opin Biol Ther* 4(3):319-27. 2004.

- Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 123(12):897-903. 1995.
- Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. *Lancet* 346(8981):1006-7. 1995.
- Diepolder HM, Gerlach JT, Zachoval R, et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. *J Virol* 71(8):6011-19. 1997.
- Diepolder HM, Gruener NH, Heeney J. Of chimps and men--finding the path to an HCV vaccine. *Hepatology* 37(6):1472-74. 2003.
- Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. *Hepatology* 34(6):1193-99. 2001.
- Dimitrova M, Imbert I, Kieny MP, et al. Protein-Protein Interactions between Hepatitis C Virus Nonstructural Proteins. *J Virol* 77(9):5401-14. 2003.
- Disson O, Hahne M, Hibner U, et al. Hepatocytes transgenic for the full hepatitis C virus open reading frame are resistant to fas-induced cell death. *Ann N Y Acad Sci* 973:214-17. 2002.
- Disson O, Haouzi D, Desagher S, et al. Impaired clearance of virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus polyprotein. *Gastroenterology* 126(3):859-72. 2004.
- Distante S, Bjoro K, Hellum KB, et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. *Liver* 22(3):269-75. 2002.
- Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. *J Antimicrob Chemother* 48(6):751-5. 2001.
- Doherty DG, Norris S, Madrigal-Estebas L, et al. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and T<sub>H</sub>1, Th2, and T<sub>H</sub>0 cytokine secretion patterns. *J Immunol* 163(4):2314-21. 1999.
- Dolganiuc A, Kodys K, Kopasz A, et al. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. *J Immunol* 170(11):5615-24. 2003.
- Domingo E. Quasispecies and the development of new antiviral strategies. *Prog Drug Res* 60:133-58. 2003.
- Donato MF, Arosio E, Del Ninno E, et al. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. *Hepatology* 34(3):523-28. 2001.

- Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. *Nat Rev Drug Discov* 3(4):318-29. 2004.
- Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. *Nature* 417(6884):95-8. 2002.
- Dove A. Antisense and sensibility. *Nat Biotechnol* 20(2):121-24. 2002.
- Draenert R, Le Gall S, Pfafferott KJ, et al. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. *J Exp Med* 199(7):905-15. 2004.
- Drummer HE, Maerz A, Pountourios P. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. *FEBS Lett* 546(2-3):385-90. 2003.
- Drummer HE, Pountourios P. Hepatitis C virus glycoprotein E2 contains a membrane-proximal heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry. *J Biol Chem* May 10 [Epub ahead of print]. 2004.
- Dubuisson J, Hsu HH, Cheung RC, et al. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. *J Virol* 68(10):6147-60. 1994.
- Dubuisson J, Rice CM. Hepatitis C virus glycoprotein folding: disulfide bond formation and association with calnexin. *J Virol* 70(2):778-86. 1996.
- Duesberg U, Schneiders AM, Flieger D, et al. Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C. *J Hepatol* 35(5):650-57. 2001.
- Dumonceaux J, Cormier EG, Kajumo F, et al. Expression of unmodified hepatitis C virus envelope glycoprotein-coding sequences leads to cryptic intron excision and cell surface expression of E1/E2 heterodimers comprising full-length and partially deleted E1. *J Virol* 77(24):13418-24. 2003.
- Dumoulin FL, Bach A, Leifeld L, et al. Semiquantitative analysis of intrahepatic cytokine mRNAs in chronic hepatitis C. *J Infect Dis* 175(3):681-85. 1997.
- Dumoulin FL, Wennrich U, Nischalke HD, et al. Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor  $\alpha$  and response to antiviral treatment of chronic hepatitis C. *J Hum Virol* 4(4):195-09. 2001.
- Duong FH, Filipowicz M, Tripodi M, et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. *Gastroenterology* 126(1):263-277. 2004.
- Durantel D, Carrouée-Durantel S, Branza-Nichita N, et al. Effects of interferon, ribavirin, and iminosugar derivatives on cells persistently infected with noncytopathic bovine viral diarrhea virus. *Antimicrob Agents Chemother* 48(2):497-504. 2004.

Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. *Hepatology* 19(1):13-18. 1994.

Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. *J Hepatol* 25(5):591-8. 1996.

Duvet S, Cocquerel L, Pillez A, et al. Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. *J Biol Chem* 273(48):32088-95. 1998.

Dwek RA, Butters TD, Platt FM, Zitzmann N. Targeting glycosylation as a therapeutic approach. *Nat Rev Drug Discov* 1(1):65-75. 2002.

Ebara M, Fukuda H, Hatano R, et al. Metal contents in the liver of patients with chronic liver disease caused by hepatitis C virus. Reference to hepatocellular carcinoma. *Oncology* 65(4):323-30. 2003.

Eckart MR, Selby M, Masiarz F, et al. The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. *Biochem Biophys Res Commun* 192(2):399-406. 1993.

Eckels DD, Tabatabail N, Bian TH, et al. In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: failure in IL-2 production despite proliferation. *Hum Immunol* 60(3):187-99. 1999.

Edwards-Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. *Hepatology* 30(2):526-30. 1999.

Egger D, Wölk B, Gosert R, et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. *J Virol* 76(12):5974-84. 2002.

Eigen M. Error catastrophe and antiviral strategy. *Proc Natl Acad Sci USA* 99(21):13374-76. 2002.

Einav S, Koziel MJ. Immunopathogenesis of hepatitis C virus in the immunosuppressed host. *Transpl Infect Dis* 4(2):85-92. 2002.

Einav S, Elazar M, Glenn J. A nucleotide binding motif in HCV NS4B mediates HCV RNA replication. Abstract 30A. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003a.

Einav S, Glenn JS. Prenylation inhibitors: a novel class of antiviral agents. *J Antimicrob Chemother* 52(6):883-6. 2003b.

El-Hage N, Luo G. Replication of hepatitis C virus RNA occurs in a membrane-bound replication complex containing nonstructural viral proteins and RNA. *J Gen Virol* 84(Pt 10): 2761-9. 2003.

- Emi K, Nakamura K, Yuh K, et al. Magnitude of activity in chronic hepatitis C is influenced by apoptosis of T cells responsible for hepatitis C virus. *J Gastroenterol Hepatol* 14(10):1018-24. 1999.
- Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. *J Clin Invest* 96(1):224-30. 1995.
- Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 334(2):77-81. 1996.
- Erdtmann L, Franck N, Lerat H, et al. The hepatitis C virus NS2 protein is an inhibitor of CIDE-B-induced apoptosis. *J Biol Chem* 278(20):18256-64. 2003.
- Erickson AL, Kimura Y, Igarashi S, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. *Immunity* 15(6):883-95. 2001.
- Erturk E, Ostapchuk P, Wells SI, et al. Binding of CCAAT displacement protein CDP to adenovirus packaging sequences. *J Virol* 77(11):6255-64. 2003.
- Esser MT, Marchese RD, Kierstead LS, et al. Memory T cells and vaccines. *Vaccine* 21(5-6):419-30. 2003.
- Esnouf R, Ren J, Ross C, et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. *Nat Struct Biol* 2(4):303-8. 1995.
- Esumi M, Rikihisa T, Nishimura S, et al. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. *Arch Virol* 144(5):973-80. 1999.
- Esumi M, Zhou YH, Tanoue T, et al. In vivo and *in vitro* evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralize heterologous hepatitis C virus. *Vaccine* 20(25-26):3095-103. 2002.
- Evans MJ, Rice CM. Hepatitis C virus replicons finally get to second base. *Gastroenterology* 125(6): 1892-5. 2003.
- Exley MA, He Q, Cheng O, et al. Cutting edge: Compartmentalization of T<sub>H</sub>1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. *J Immunol* 15;168(4):1519-23. 2002.
- Ezelle HJ, Markovic D, Barber GN. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. *J Virol* 76(23):12325-34. 2002.
- Failla C, Tomei L, De Francesco R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. *J Virol* 68(6):3753-60. 1994.

Failla C, Tomei L, De Francesco R. An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A. *J Virol* 69(3):1769-77. 1995.

Fairbanks LD, Bofill M, Ruckemann K, et al. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. *J Biol Chem* 270(50):29682-89. 1995.

Falcón V, Acosta-Rivero N, Chinaa G, et al. Nuclear localization of nucleocapsid-like particles and HCV core protein in hepatocytes of a chronically HCV-infected patient. *Biochem Biophys Res Commun* 310(1):54-8. 2003.

Fan Z, Yang QR, Twu JS, et al. Specific *in vitro* association between the hepatitis C viral genome and core protein. *J Med Virol* 59(2):131-34. 1999.

Fang SH, Hwang LH, Chen DS, et al. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. *J Hepatol* 33(5):791-98. 2000.

Fang SH, Lai MY, Hwang LH, et al. Ribavirin enhances interferon-gamma levels in patients with chronic hepatitis C treated with interferon- $\alpha$ . *J Biomed Sci* 8(6):484-91. 2001.

Fanning L, Kenny E, Sheehan M, et al. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. *Hepatology* 29(3):904-7. 1999.

Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. *Science* 258(5079):135-40. 1992.

Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated *in vitro* neutralization. *Proc Natl Acad Sci USA* 91(16):7792-96. 1994.

Farci P, Alter HJ, Shimoda A, et al. Hepatitis C virus-associated fulminant hepatic failure. *N Engl J Med* 335(9):631-34. 1996a.

Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. *Proc Natl Acad Sci USA* 93(26):15394-99. 1996b.

Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. *Science* 288(5464):339-44. 2000.

Fargion S, Fracanzani AL, Rossini A, et al. Iron reduction and sustained response to interferon- $\alpha$  therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. *Am J Gastroenterol* 97(5):1204-10. 2002.

Faria M, Spiller DG, Dubertret C, et al. Phosphoramidate oligonucleotides as potent antisense molecules in cells and *in vivo*. *Nat Biotechnol* 19(1):40-4. 2001.

- Farinati F, Cardin R, De Maria N, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. *J Hepatol* 22(4):449-56. 1995.
- Farinati F, Cardin R, D'Errico A, et al. Hepatocyte proliferative activity in chronic liver damage as assessed by the monoclonal antibody MIB1 Ki67 in archival material: the role of etiology, disease activity, iron, and lipid peroxidation. *Hepatology* 23(6):1468-75. 1996.
- Farinati F, Cardin R, Fiorentino M, et al. Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease. *J Viral Hepat* 8(1):34-40. 2001.
- Fattori D, Urbani A, Brunetti M, et al. Probing the active site of the hepatitis C virus serine protease by fluorescence resonance energy transfer. *J Biol Chem* 275(20):15106-13. 2000.
- Fausto N. A mouse model for hepatitis C virus infection? *Nat Med* 7(8):890-91. 2001.
- Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. *Science* 182(116):1026-28. 1973.
- Feinstone SM, Kapikian AZ, Purcell RH, et al. Transfusion-associated hepatitis not due to viral hepatitis type A or B. *N Engl J Med* 292(15):767-70. 1975.
- Feitelson MA, Larkin JD. New animal models of hepatitis B and C. *ILAR J* 42(2):127-38. 2001.
- Feitelson, MA. Hepatitis C virus: From laboratory to clinic. Cambridge, UK: Cambridge University Press, pp. 3-11. 2002.
- Feng ZH, Wang QC, Nie QH, et al. DC-SIGN: binding receptor for HCV? *World J Gastroenterol* 10(7):925-9. 2004.
- Ferenci P. Protease inhibitors for treatment of chronic hepatitis C—a new target for the magic bullet identified. *J Hepatol* 40(1):184-6. 2004.
- Fernandez J, Yaman I, Mishra R, et al. Internal ribosome entry site-mediated translation of a mammalian mRNA is regulated by amino acid availability. *J Biol Chem* 276(15):12285-91. 2001.
- Ferrari C, Valli A, Galati L, Penna A, et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. *Hepatology* 19(2):286-95. 1994.
- Fipaldini C, Bellei B, La Monica N. Expression of hepatitis C virus cDNA in human hepatoma cell line mediated by a hybrid baculovirus-HCV vector. *Virology* 255(2):302-11. 1999.
- Firpi RJ, Nelson DR, Davis GL. Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. *Liver Transpl* 9(1):57-61. 2003.



- Fischmann TO, Weber PC. Peptidic inhibitors of the hepatitis C virus serine protease within non-structural protein 3. *Curr Pharm Des* 8(28):2533-40. 2002.
- Flint M, Quinn ER, Levy S. In search of hepatitis C virus receptor(s). *Clin Liver Dis* 5(4):873-93. 2001.
- Florese RH, Nagano-Fujii M, Iwanaga Y, et al. Inhibition of protein synthesis by the nonstructural proteins NS4A and NS4B of hepatitis C virus. *Virus Res* 90(1-2):119-31. 2002.
- Fong TL, Fried MW, Clarke-Platt J. A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy. *Am J Gastroenterol* 94(4):990-3. 1999.
- Forns X, Emerson SU, Tobin GJ, et al. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. *Vaccine* 17(15-16):1992-2002. 1999.
- Forns X, Payette PJ, Ma X, et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. *Hepatology* 32(3):618-25. 2000.
- Foster GR, Finter NB. Are all type I human interferons equivalent? *J Viral Hepat* 5(3):143-52. 1998.
- Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. *Science* 300(5622):1145-48. 2003.
- FrancaVilla V, Accapezzato D, De Salvo M, et al. Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms. *Eur J Immunol* 34(2):427-37. 2004.
- Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men. *Ann Intern Med* 97(3):362-66. 1982.
- Francki RI, Fauquet CM, Knudson DL, et al. Classification and nomenclature of viruses: fifth report of the international committee on taxonomy of viruses. *Arch Virol* 2:320-326. 1991.
- François C, Duverlie G, Rebouillat D, et al. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. *J Virol* (12):5587-96. 2000.
- Frasca L, Del Porto P, Tuosto L, et al. Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells. *J Immunol* 163(2):650-8. 1999.
- Frasca L, Scotta C, Del Porto P, et al. Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes. *Hepatology* 38(3):653-63. 2003.

- Fredericksen B, Akkaraju GR, Foy E, et al. Activation of the interferon- $\beta$  promoter during hepatitis C virus RNA replication. *Viral Immunol* 15(1):29-40. 2002.
- Freed EO. Viral late domains. *J Virol* 76(10):4679-87. 2002.
- Frese M, Schwarzle V, Barth K, et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. *Hepatology* 35(3):694-03. 2002.
- Friebe P, Bartenschlager R. Genetic analysis of sequences in the 3' nontranslated region of hepatitis C virus that are important for RNA replication. *J Virol* 76(11):5326-38. 2002.
- Fujie H, Yotsuyanagi H, Moriya K, et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. *J Med Virol* 59(2):141-45. 1999.
- Fukuda R, Ishimura N, Ishihara S, et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. *Liver* 16(6):390-99. 1996.
- Fukushi S, Katayama K, Kurihara C, et al. Complete 5' noncoding region is necessary for the efficient internal initiation of hepatitis C virus RNA. *Biochem Biophys Res Commun* 199(2):425-32. 1994.
- Fukushi S, Okada M, Kageyama T, et al. Interaction of poly(rC)-binding protein 2 with the 5'-terminal stem loop of the hepatitis C-virus genome. *Virus Res* 73(1):67-79. 2001a.
- Fukushi S, Okada M, Stahl J, et al. Ribosomal protein S5 interacts with the internal ribosomal entry site of hepatitis C virus. *J Biol Chem* 276(24):20824-26. 2001b.
- Fuller MJ, Zajac AJ. Ablation of CD8 and CD4 T cell responses by high viral loads. *J Immunol* 170(1):477-86. 2003.
- Fuller MJ, Khanolkar A, Tebo AE, Zajac AJ. Maintenance, loss, and resurgence of T cell responses during acute, protracted, and chronic viral infections. *J Immunol* 172(7):4204-14. 2004.
- Gale M Jr, Blakely CM, Kwieciszewski B, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. *Mol Cell Biol* 18(9):5208-18. 1998.
- Gale M Jr, Kwieciszewski B, Dossett M, et al. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. *J Virol* 73(8):6506-16. 1999.
- Gale M Jr. Effector genes of interferon action against hepatitis C virus. *Hepatology* 37(5):975-78. 2003.
- Galle PR, Hofmann WJ, Walczak H, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. *J Exp Med* 182(5):1223-30. 1995.

- Gallois-Montbrun S, Chen Y, Dutartre H, et al. Structural analysis of the activation of ribavirin analogs by NDP kinase: comparison with other ribavirin targets. *Mol Pharmacol* 63(3):538-46. 2003.
- Gao B, Hong F, Radaeva S. Host factors and failure of interferon- $\alpha$  treatment in hepatitis C virus. *Hepatology* 39(4):880-90. 2004.
- Gao L, Tu H, Shi ST, et al. Interaction with a ubiquitin-like protein enhances the ubiquitination and degradation of hepatitis C virus RNA-dependent RNA polymerase. *J Virol* 77(7):4149-59. 2003.
- Gao L, Aizaki H, He JW, Lai MM. Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. *J Virol* 78(7):3480-8. 2004.
- Garoff H, Hewson R, Opstelten DJ. Virus maturation by budding. *Microbiol Mol Biol Rev* 62(4):1171-90. 1998.
- Geiss GK, Carter VS, He Y, et al. Gene expression profiling of the cellular transcriptional network regulated by  $\alpha$ /beta interferon and its partial attenuation by the hepatitis C virus nonstructural 5A protein. *J Virol* 77(11):6367-75. 2003.
- Geijtenbeek TB, van Kooyk Y. DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. *Curr Top Microbiol Immunol* 276:31-54. 2003.
- Gentile M, Adrian T, Scheidler A, et al. Determination of the size of HIV using adenovirus type 2 as an internal length marker. *J Virol Methods* 48(1):43-52. 1994.
- Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. *Gastroenterology* 117(4):933-41. 1999.
- Germi R, Crance JM, Garin D, et al. Rôle des glycosaminoglycanes dans l'adsorption des virus sur les cellules – hôtes. *Virologie* 5(4):255-63. 2001.
- Germi R, Crance JM, Garin D, et al. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. *J Med Virol* 68(2):206-15. 2002.
- Gewaltig J, Mangasser-Stephan K, Gartung C, et al. Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis. *Clin Chim Acta* 316(1-2):83-94. 2002.
- Ghany MG, Kleiner DE. E1 therapeutic vaccination for chronic hepatitis C: All that glitters is not gold. *Hepatology* 38(5):1092-4. 2003.
- Ghosh AK, Majumder M, Steele R, et al. Hepatitis C virus NS5A protein protects against TNF- $\alpha$  mediated apoptotic cell death. *Virus Res* 67(2):173-78. 2000.

Giladi H, Ketzinel-Gilad M, Rivkin L, et al. Small interfering RNA inhibits hepatitis B virus replication in mice. *Mol Ther* 8(5):769-76. 2003.

Giménez-Barcons M, Franco S, Suárez Y, et al. High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. *Hepatology* 34(1):158-67. 2001.

Girard S, Shalhoub P, Lescure P, et al. An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. *Virology* 295(2):272-83. 2002.

Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. *Nature* 418(6896):430-4. 2002.

Glas J, Torok HP, Simperl C, et al. The  $\Delta 32$  mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon- $\alpha$  and ribavirin. *Clin Immunol* 108(1):46-50. 2003.

Glesby MJ, Bassett R, Alston B, et al. Pilot study of low dose daily interleukin-2 plus pegylated-interferon- $\alpha$ -2b and ribavirin in patients with HCV/HIV co-infection: ACTG A5088. Abstract 818. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 2004.

Godkin A, Jeanguet N, Thursz M, et al. Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4<sup>+</sup> T cell responses in chronically infected and non-viremic patients. *Eur J Immunol* 31(5):1438-46. 2001.

Godofsky E, Afdahl N, Rustgi V, et al. First clinical results for a novel antiviral treatment for hepatitis C: a phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283. Abstract 96. 39th Annual European Association for the Study of the Liver Conference. Berlin, Germany. 2004.

Goh PY, Tan YJ, Lim SP, et al. The hepatitis C virus core protein interacts with NS5A and activates its caspase-mediated proteolytic cleavage. *Virology* 290(2):224-36. 2001.

Goldstein D, Hertzog P, Tomkinson E, et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. *J Infect Dis* 178(3):858-61. 1998.

Gong G, Waris G, Tanveer R, et al. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF- $\alpha$ B. *Proc Natl Acad Sci USA* 98(17):9599-604. 2001.

Gontarek RR, Gutshall LL, Herold KM, et al. hnRNP C and polypyrimidine tract-binding protein specifically interact with the pyrimidine-rich region within the 3'NTR of the HCV RNA genome. *Nucleic Acids Res* 27(6):1457-63. 1999.

- González-López C, Arias A, Pariente N, et al. Preextinction viral RNA can interfere with infectivity. *J Virol* 78(7):3319-24. 2004.
- Gordon SC, Bacon BR, Jacobson IM, et al. A Phase II, 12-Week Study of ISIS 14803, an Antisense Inhibitor of HCV for the Treatment of Chronic Hepatitis C. Abstract 795. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.
- Gordon SC. New insights into acute hepatitis C. *Gastroenterology* 125(1):253-56. 2003.
- Gosert R, Chang KH, Rijnbrand R, et al. Transient expression of cellular polypyrimidine-tract binding protein stimulates cap-independent translation directed by both picornaviral and flaviviral internal ribosome entry sites *In vivo*. *Mol Cell Biol* 20(5):1583-95. 2000.
- Gosert R, Egger D, Lohmann V, et al. Identification of the hepatitis C virus RNA replication complex in huh-7 cells harboring subgenomic replicons. *J Virol* 77(9):5487-92. 2003.
- Goto J, Nishimura S, Esumi M, et al. Prevention of hepatitis C virus infection in a chimpanzee by vaccination and epitope mapping of antiserum directed against hypervariable region 1. *Hepatology* 19(3):270-283. 2001.
- Goutagny N, Fatmi A, Ledinghen VD, et al. Evidence of Viral Replication in Circulating Dendritic Cells during Hepatitis C Virus Infection. *J Infect Dis* 187(12):1951-58. 2003.
- Goutagny N, Vieux C, Decullier E, et al. Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection. *J Infect Dis* 189(9):1646-55. 2004.
- Grabowska AM, Lechner F, Klenerman P, et al. Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. *Eur J Immunol* 31(8):2388-94. 2001.
- Graci JD, Cameron CE. Quasispecies, error catastrophe, and the antiviral activity of ribavirin. *Virology* 298(2):175-80. 2002.
- Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. *Clin Infect Dis* 33(4):562-69. 2001.
- Graham CS, Wells A, Liu T et al. (abstract 839) The association of hepatitis C virus (HCV)-specific immune responses with liver histology and treatment outcomes in subjects with HIV/HCV Co-infection. 10th Conference on Retroviruses and Opportunistic Illnesses. Boston, Massachusetts. 2003.
- Grakoui A, Wychowski C, Lin C, et al. Expression and identification of hepatitis C virus polyprotein cleavage products. *J Virol* 67(3):1385-95. 1993a.

- Grakoui A, McCourt DW, Wychowski C, et al. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. *J Virol* 67(5):2832-43. 1993b.
- Grakoui A, McCourt DW, Wychowski C, et al. A second hepatitis C virus-encoded proteinase. *Proc Natl Acad Sci USA* 90(22):10583-87. 1993c.
- Grakoui A, Hanson HL, Rice CM. Bad time for Bonzo? Experimental models of hepatitis C virus infection, replication, and pathogenesis. *Hepatology* 33(3):489-95. 2001.
- Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. *Science* 302(5645):659-62. 2003.
- Grande-Pérez A, Sierra S, Castro MG, et al. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. *Proc Natl Acad Sci USA* 99(20):12938-43. 2002.
- Grandvaux N, Servant MJ, tenOever B, et al. Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. *J Virol* 76(11):5532-39. 2002.
- Gremion C, Grabscheid B, Wölk B, et al. Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. *J Virol* 78(4):2152-7. 2004.
- Grenfell BT, Pybus OG, Gog JR, et al. Unifying the epidemiological and evolutionary dynamics of pathogens. *Science* 303(5656):327-32. 2004.
- Griffin SD, Beales LP, Clarke DS, et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. *FEBS Lett* 535(1-3):34-38. 2003.
- Griffin SD, Harvey R, Clarke DS, et al. A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria. *J Gen Virol* 85(Pt 2):451-61. 2004.
- Grossman Z, Meier-Schellersheim M, Sousa AE, et al. CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? *Nat Med* 8(4):319-23. 2002.
- Gruener NH, Lechner F, Jung MC, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. *J Virol* 75(12):5550-8. 2001.
- Grüner NH, Gerlach TJ, Jung MC, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. *J Infect Dis* 181(5):1528-36. 2000.

- Gu B, Gates AT, Isken O, et al. Replication studies using genotype 1a subgenomic hepatitis C virus replicons. *J Virol* 77(9):5352-59. 2003a.
- Gu B, Johnston VK, Gutshall LL, et al. Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. *J Biol Chem* 278(19):16602-7. 2003b.
- Guido M, Rugge M, Chemello L, et al. Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. *J Hepatol* 24(3):301-7. 1996.
- Guo JT, Zhu Q, Seeger C. Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons. *J Virol* 77(20):10769-79. 2003.
- Ha SJ, Kim DJ, Baek KH, et al. IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization. *J Immunol* 172(1):525-531. 2004.
- Habersetzer F, Fournillier A, Dubuisson J, et al. Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with *in vitro* binding neutralization properties. *Virology* 249(1):32-41. 1998.
- Hadlock KG, Lanford RE, Perkins S, et al. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. *J Virol* 74(22):10407-16. 2000.
- Hahm B, Kim YK, Kim JH, et al. Heterogeneous nuclear ribonucleoprotein L interacts with the 3' border of the internal ribosomal entry site of hepatitis C virus. *J Virol* 72(11):8782-8. 1998.
- Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific and public health implications. *Science* 287(5453):607-14. 2000.
- Hahn CS, Cho YG, Kang BS, et al. The HCV core protein acts as a positive regulator of fas-mediated apoptosis in a human lymphoblastoid T cell line. *Virology* 276(1):127-37. 2000.
- Hamaia S, Li C, Allain JP. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. *Blood* 98(8):2293-300. 2001.
- Harada S, Watanabe Y, Takeuchi K, et al. Expression of processed core protein of hepatitis C virus in mammalian cells. *J Virol* 65(6):3015-21. 1991.
- Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. *Blood* 103(3):966-72. 2004.
- Harvey CE, Post JJ, Palladinetti P, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. *J Leukoc Biol* 74(3):360-9. 2003.

- Hayashi N, Mita E. Fas system and apoptosis in viral hepatitis. *J Gastroenterol Hepatol* 12(9-10):S223-26. 1997.
- He L, Terunuma H, Hanabusa H, et al. Interleukin 18 and interleukin 1 $\beta$  production is decreased in HIV type 1-seropositive hemophiliacs but not in HIV type 1-seropositive nonhemophiliacs. *AIDS Res Hum Retroviruses* 16(4):345-53. 2000.
- He XS, Rehermann B, López-Labrador FX, et al. Quantitative analysis of hepatitis C virus-specific CD8<sup>+</sup> T cells in peripheral blood and liver using peptide-MHC tetramers. *Proc Natl Acad Sci USA* 96(10):5692-97. 1999.
- He Y, Tan SL, Tareen SU, et al. Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A. *J Virol* 75(11):5090-98. 2001.
- He Y, Katze MG. To interfere and to anti-interfere: the interplay between hepatitis C virus and interferon. *Viral Immunol* 15(1):95-119. 2002a.
- He Y, Nakao H, Tan SL, et al. Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. *J Virol* 76(18):9207-17. 2002b.
- He Y, Yan W, Coito C, et al. The regulation of hepatitis C virus (HCV) internal ribosome-entry site-mediated translation by HCV replicons and nonstructural proteins. *J Gen Virol* 84(Pt 3):535-43. 2003.
- Heagy W, Crumpacker C, Lopez PA, et al. Inhibition of immune functions by antiviral drugs. *J Clin Invest* 87(6):1916-24. 1991.
- Hegde RS. Targeting and beyond: new roles for old signal sequences. *Mol Cell* 10(4):697-98. 2002.
- Heile JM, Fong YL, Rosa D, et al. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. *J Virol* 74(15):6885-92. 2000.
- Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. *J Virol* 73(10):8469-75. 1999.
- Heintges T, Encke J, zu Putlitz J, Wands JR. Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor. *J Med Virol* 65(4):671-80. 2001.
- Helbling B, Stamenic I, Viani F, et al. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. *Hepatology* 35(2):447-54. 2002.
- Helenius A, Aebi M. Intracellular functions of N-linked glycans. *Science* 291(5512):2364-9. 2001.



Heller T, Sobao Y, Mizukoshi E, et al. HCV exposure in humans: stimulation of cellular, but not humoral immune responses in the absence of detectable viremia. Abstract 57. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.

Hellier S, Frodsham AJ, Hennig BJ, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. *Hepatology* 38(6):1468-76. 2003.

Hempel G, Galle PR, Lohr HF. Quantitative analysis of specific T<sub>H</sub>1/ T<sub>H</sub>2 helper cell responses and IgG subtype antibodies in interferon- $\alpha$ -treated patients with chronic hepatitis C. *J Med Virol* 64(3):340-49. 2001.

Hengge UR, Roggendorf M, Goos M. Lack of significant viral load alterations of hepatitis B virus and hepatitis C virus during treatment with IL-2 and highly active antiretroviral therapy. *AIDS* 14(16):2617-19. 2000.

Herion D, Hoofnagle JH. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same. *Hepatology* 25(3):769-71. 1997.

Hernandez LD, Hoffman LR, Wolfsberg TG, et al. Virus-cell and cell-cell fusion. *Annu Rev Cell Dev Biol* 12:627-61. 1996.

Herzer K, Falk CS, Encke J, et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. *J Virol* 77(15):8299-309. 2003.

Hickman IJ, Powell EE, Prins JB, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. *J Hepatol* 39(6): 1042-8. 2003.

Hijikata M, Kato N, Ootsuyama Y, et al. Gene mapping of the putative structural region of the hepatitis C virus genome by *in vitro* processing analysis. *Proc Natl Acad Sci USA* 88(13):5547-51. 1991.

Hijikata M, Shimizu YK, Kato H, et al. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. *J Virol* 67(4):1953-8. 1993a.

Hijikata M, Mizushima H, Akagi T, et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. *J Virol* 67(8):4665-75. 1993b.

Hilkens CM, Schlaak JF, Kerr IM. Differential responses to IFN- $\alpha$  subtypes in human T cells and dendritic cells. *J Immunol* 171(10):5255-63. 2003.

Himoudi N, Abraham JD, Fournillier A, et al. Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. *J Virol* 76(24):12735-46. 2002.

- Hino K, Okita K. Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C. *J Antimicrob Chemother* 53(1):19-22. 2004.
- Hiramatsu N, Hayashi N, Katayama K, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. *Hepatology* 19(6):1354-59. 1994.
- Hirano M, Kaneko S, Yamashita T, et al. Direct interaction between nucleolin and hepatitis C virus NS5B. *J Biol Chem* 278(7):5109-15. 2003.
- Hirowatari Y, Hijikata M, Tanji Y, et al. Two proteinase activities in HCV polypeptide expressed in insect cells using baculovirus vector. *Arch Virol* 133(3-4):349-56. 1993.
- Hjalmarsson S, Blomberg J, Grillner L, et al. Sequence evolution and cross-reactive antibody responses to hypervariable region 1 in acute hepatitis C virus infection. *J Med Virol* 64(2):117-24. 2001.
- Hoffmann RM, Diepolder HM, Zachoval R, et al. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. *Hepatology* 21(3):632-38. 1995.
- Holmes EC, Nee S, Rambaut A, et al. Revealing the history of infectious disease epidemics through phylogenetic trees. *Philos Trans R Soc Lond B Biol Sci* 349(1327):33-40. 1995.
- Holmes EC. Molecular clocks and the puzzle of RNA virus origins. *J Virol* 77(7):3893-97. 2003.
- Honda A, Arai Y, Hirota N, et al. Hepatitis C virus structural proteins induce liver cell injury in transgenic mice. *J Med Virol* 59(3):281-89. 1999.
- Honda A, Hatano M, Kohara M, et al. HCV-core protein accelerates recovery from the insensitivity of liver cells to Fas-mediated apoptosis induced by an injection of anti-Fas antibody in mice. *J Hepatol* 33(3):440-47. 2000.
- Honda M, Brown EA, Lemon SM. Stability of a stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA. *RNA* 2(10):955-68. 1996.
- Honda M, Rijnbrand R, Abell G, et al. Natural variation in translational activities of the 5' nontranslated RNAs of hepatitis C virus genotypes 1a and 1b: evidence for a long-range RNA-RNA interaction outside of the internal ribosomal entry site. *J Virol* 73(6):4941-51. 1999.
- Honda M, Kaneko S, Matsushita E, et al. Cell cycle regulation of hepatitis C virus internal ribosomal entry site-directed translation. *Gastroenterology* 118(1):152-62. 2000.
- Hong Z. The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact? *Hepatology* 38(4):807-10. 2003.

- Hoofnagle JH, Ghany MG, Kleiner DE, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. *Hepatology* 38(1):66-74. 2003.
- Horie C, Iwahana H, Horie T, et al. Detection of different quasispecies of hepatitis C virus core region in cancerous and noncancerous lesions. *Biochem Biophys Res Commun* 218(3):674-81. 1996.
- Horiike N, Hino H, Tanaka Y, et al. Combination therapy with interferon  $\alpha$  and beta to chronic hepatitis C. *Oncol Rep* 10(1):157-61. 2003.
- Hosui A, Ohkawa K, Ishida H, et al. Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-gamma stimuli. *J Biol Chem* 278(31):28562-71. 2003.
- Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. *Hepatology* 29(4):1215-19. 1999.
- Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. *Gastroenterology* 119(5):1385-96. 2000.
- Hsi B, Hsu EC, Bigam D, et al. Inducing apoptosis in hepatitis C infected Alb-uPa/SCID mice with gene therapy mechanisms. Abstract 61. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Hsieh TY, Matsumoto M, Chou HC, et al. Hepatitis C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K. *J Biol Chem* 273(28):17651-9. 1998.
- Hsiou Y, Ding J, Das K, et al. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. *Structure* 4(7):853-60. 1996.
- Hsu EC, Hsi B, Hirota-Tsuchihara M, et al. Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers. *Nat Biotechnol* 21(5):519-25. 2003.
- Hsu M, Zhang J, Flint M, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. *Proc Natl Acad Sci USA* 100(12):7271-76. 2003.
- Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. *Nat Med* 2(11):1240-3. 1996.
- Hui JM, Kench J, Farrell GC, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. *J Gastroenterol Hepatol* 17(8): 873-81. 2002.
- Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. *Gastroenterology* 125(6): 1695-704. 2003.

Hultgren C, Milich DR, Weiland O, et al. The antiviral compound ribavirin modulates the T helper (T<sub>H</sub>) 1/T<sub>H</sub>2 subset balance in hepatitis B and C virus-specific immune responses. *J Gen Virol* 79(Pt 10):2381-91. 1998.

Hunziker L, Ciurea A, Recher M, et al. Public versus personal serotypes of a viral quasispecies. *Proc Natl Acad Sci USA* 100(10):6015-20. 2003.

Hussy P, Langen H, Mous J, et al. Hepatitis C virus core protein: carboxy-terminal boundaries of two processed species suggest cleavage by a signal peptide peptidase. *Virology* 224(1):93-104. 1996.

Ibuki N, Yamamoto K, Yabushita K, et al. In situ expression of Granzyme B and Fas-ligand in the liver of viral hepatitis. *Liver* 22(3):198-204. 2002.

Idilman R, De Maria N, Colantoni A, et al. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. *J Viral Hepat* 5(5):285-99. 1998.

Iftikar R, Di Bisceglie A, Pockros PJ, et al. (abstract 790) HCV RNA and immunological responses to thymalfasin in combination with peginterferon alfa-2a in HCV non-responders: A 12-week kinetic study. American Association for the Study of Liver Disease. Boston, Massachusetts. 2002.

Iio S, Hayashi N, Mita E, et al. Serum levels of soluble Fas antigen in chronic hepatitis C patients. *J Hepatol* 29(4):517-23. 1998.

Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. *Cancer Res* 62(14):3939-44. 2002.

Iizuka N, Oka M, Yamada-Okabe H, et al. Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis. *Oncogene* 22(19):3007-14. 2003.

Ikeda F, Shimomura H, Miyake M, et al. Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN- $\beta$ . *J Interferon Cytokine Res* 20(9):831-36. 2000.

Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. *J Virol* 76(6):2997-06. 2002.

Ilan E, Arazi J, Nussbaum O, et al. The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV. *J Infect Dis* 185(2):153-61. 2002.

Imbert I, Dimitrova M, Kien F, et al. Hepatitis C virus IRES efficiency is unaffected by the genomic RNA 3'NTR even in the presence of viral structural or non-structural proteins. *J Gen Virol* 84(Pt 6):1549-57. 2003.

Ingallinella P, Fattori D, Altamura S, et al. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. *Biochemistry* 41(17):5483-92. 2002.

Inoue K, Sekiyama K, Yamada M, et al. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. *J Gastroenterol* 38(6):567-72. 2003.

Inoue Y, Miyazaki M, Ohashi R, et al. Ubiquitous presence of cellular proteins that specifically bind to the 3' terminal region of hepatitis C virus. *Biochem Biophys Res Commun* 245(1):198-203. 1998.

Isagulians MG, Ozeretskovskaya NN. Host background factors contributing to hepatitis C virus clearance. *Curr Pharm Biotechnol* 4(3):185-93. 2003.

Ishii K, Rosa D, Watanabe Y, et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. *Hepatology* 28(4):1117-20. 1998.

Ishikawa T, Shibuya K, Yasui K, et al. Expression of hepatitis C virus core protein associated with malignant lymphoma in transgenic mice. *Comp Immunol Microbiol Infect Dis* 26(2):115-24. 2003.

Isoyama T, Kamoshita N, Yasui K, et al. Lower concentration of La protein required for internal ribosome entry on hepatitis C virus RNA than on poliovirus RNA. *J Gen Virol* 80(Pt 9):2319-27. 1999.

Isoyama T, Kuge S, Nomoto A. The core protein of hepatitis C virus is imported into the nucleus by transport receptor Kap123p but inhibits Kap121p-dependent nuclear import of yeast AP1-like transcription factor in yeast cells. *J Biol Chem* 277(42):39634-41. 2002.

Ito T, Lai MM. Determination of the secondary structure of and cellular protein binding to the 3'-untranslated region of the hepatitis C virus RNA genome. *J Virol* 71(11):8698-06. 1997.

Ito T, Tahara SM, Lai MM. The 3'-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site. *J Virol* 72(11):8789-96. 1998.

Ito T, Lai MM. An internal polypyrimidine-tract-binding protein-binding site in the hepatitis C virus RNA attenuates translation, which is relieved by the 3'-untranslated sequence. *Virology* 254(2):288-96. 1999.

Itoh Y, Morita A, Nishioji K, et al. Clinical significance of elevated serum interferon-inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels. *J Viral Hepat* 8(5):341-8. 2001.

Iwawaki T, Akai R, Kohno K, Miura M. A transgenic mouse model for monitoring endoplasmic reticulum stress. *Nat Med* 10(1):98-102. 2004.

- Izumi RE, Das S, Barat B, et al. A peptide from autoantigen La blocks poliovirus and hepatitis C virus cap-independent translation and reveals a single tyrosine critical for la RNA binding and translation stimulation. *J Virol* 78(7):3763-76. 2004.
- Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. *Nat Biotechnol* 21(6):635-7. 2003.
- Jain J, Almquist SJ, Shlyakhter D, Harding MW. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. *J Pharm Sci* 90(5):625-37. 2001.
- Jain SK, Pemberton PW, Smith A, et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. *J Hepatol* 36(6):805-11. 2002.
- Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. *Nature* 421(6925):852-56. 2003.
- Jensen DM, Krawitt EL, Keeffe EB, et al. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group. *Am J Gastroenterol* 94(12):3583-88. 1999.
- Ji X, Cheung R, Cooper S, et al. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. *Hepatology* 37(3):610-21. 2003.
- Jiao X, Wang RY, Feng Z, et al. Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. *Hepatology* 37(2):452-60. 2003.
- Jinushi M, Takehara T, Kanto T, et al. Critical role of MHC class I-related chain A and B expression on IFN- $\alpha$ -stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. *J Immunol* 170(3):1249-56. 2003a.
- Jinushi M, Takehara T, Tatsumi T, et al. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. *J Immunol* 171(10):5423-9. 2003b.
- Johnston VK, Maley D, Gagnon RC, et al. Kinetic profile of a heterocyclic HCV replicon RNA synthesis inhibitor. *Biochem Biophys Res Commun* 311(3):672-7. 2003.
- Jordan R, Wang L, Graczyk TM, et al. Replication of a cytopathic strain of bovine viral diarrhea virus activates PERK and induces endoplasmic reticulum stress-mediated apoptosis of MDBK cells. *J Virol* 76(19):9588-99. 2002.
- Jubin R, Murray MG, Howe AY, et al. Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation. *J Infect Dis* 181(1):331-4. 2000.

- Jubin R. Targeting hepatitis C virus translation: stopping HCV where it starts. *Curr Opin Investig Drugs* 4(2):162-7. 2003.
- Kaito M, Watanabe S, Tsukiyama-Kohara K, et al. Hepatitis C virus particle detected by immunoelectron microscopic study. *J Gen Virol* 75(Pt 7):1755-60. 1994.
- Kakimi K, Guidotti LG, Koezuka Y, et al. Natural killer T cell activation inhibits hepatitis B virus replication *in vivo*. *J Exp Med* 192(7):921-30. 2000.
- Kakimi K, Lane TE, Chisari FV, et al. Inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver. *J Immunol* 167(12):6701-5. 2001.
- Kakizaki S, Takagi H, Yamada T, et al. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C. *J Viral Hepat* 6(4):315-19. 1999.
- Kalkeri G, Khalap N, Garry RF, et al. Hepatitis C virus protein expression induces apoptosis in HepG2 cells. *Virology* 282(1):26-37. 2001.
- Kamal SM, Rasenack JW, Bianchi L, et al. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4+ T-cell and cytokine response. *Gastroenterology* 121(3):646-56. 2001.
- Kamal SM, Fehr J, Roesler B, et al. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. *Gastroenterology* 123(4):1070-83. 2002.
- Kamal SM, Graham CS, He Q, et al. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and *Schistosoma mansoni* coinfection: relation to progression of liver fibrosis. *J Infect Dis* 189(7):1140-50. 2004.
- Kaneko T, Tanji Y, Satoh S, et al. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. *Biochem Biophys Res Commun* 205(1):320-26. 1994.
- Kanto T, Hayashi N, Takehara T, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. *J Immunol* 162(9):5584-91. 1999.
- Kantzanou M, Lucas M, Barnes E, et al. Viral escape and T cell exhaustion in hepatitis C virus infection analysed using Class I peptide tetramers. *Immunol Lett* 85(2):165-71. 2003.
- Kanzler S, Baumann M, Schirmacher P, et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. *J Viral Hepat* 8(6):430-37. 2001.
- Kao CF, Chen SY, Chen JY, Wu Lee YH. Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein. *Oncogene* 23(14):2472-83. 2004.
- Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. *Proc Natl Acad Sci USA* 100(4):2014-8. 2003.

- Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. *Nat Rev Immunol* 3(12):984-93. 2003.
- Kasahara A, Hayashi N, Mochizuki K, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. *J Hepatol* 26(3):574-83. 1997.
- Katayama K, Kasahara A, Sasaki Y, et al. Immunological response to interferon-gamma priming prior to interferon- $\alpha$  treatment in refractory chronic hepatitis C in relation to viral clearance. *J Viral Hepat* 8(3):180-85. 2001.
- Kato J, Kato N, Yoshida H, et al. Hepatitis C virus NS4A and NS4B proteins suppress translation *in vivo*. *J Med Virol* 66(2):187-99. 2002a.
- Kato J, Kato N, Moriyama M, et al. Interferons specifically suppress the translation from the internal ribosome entry site of hepatitis C virus through a double-stranded RNA-activated protein kinase-independent pathway. *J Infect Dis* 2002 Jul 15;186(2):155-63. 2002b.
- Kato N, Hijikata M, Ootsuyama Y, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc Natl Acad Sci USA* 87(24):9524-28. 1990a.
- Kato N, Hijikata M, Ootsuyama Y, et al. Sequence diversity of hepatitis C viral genomes. *Mol Biol Med* 7(6):495-501. 1990b.
- Kato N, Ootsuyama Y, Tanaka T, et al. Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. *Virus Res* 22(2):107-23. 1992a.
- Kato N, Ootsuyama Y, Ohkoshi S, et al. Characterization of hypervariable regions in the putative envelope protein of hepatitis C virus. *Biochem Biophys Res Commun* 189(1):119-27. 1992b.
- Kato N, Lan KH, Ono-Nita SK, et al. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator. *J Virol* 71(11):8856-9. 1997.
- Kato N, Shimotohno K. Systems to culture hepatitis C virus. *Curr Top Microbiol Immunol* 242:261-78. 2000a.
- Kato N, Yoshida H, Kioko Ono-Nita S, et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. *Hepatology* 32(2):405-12. 2000b.
- Kato N. Molecular virology of hepatitis C virus. *Acta Med Okayama* 55(3):133-59. 2001.
- Kato T, Miyamoto M, Furusaka A, et al. Processing of hepatitis C virus core protein is regulated by its C-terminal sequence. *J Med Virol* 69(3):357-66. 2003a.



- Kato T, Date T, Miyamoto M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. *Gastroenterology* 125(6): 1808-17. 2003b.
- Kaul R, Rowland-Jones SL, Kimani J, et al. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. *Immunol Lett* 79(1-2):3-13. 2001.
- Kawakami Y, Nabeshima S, Furusyo N, et al. Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection. *Am J Gastroenterol* 95(1):227-32. 2000.
- Kawamura T, Furusaka A, Koziel MJ, et al. Transgenic expression of hepatitis C virus structural proteins in the mouse. *Hepatology* 25(4):1014-21. 1997.
- Keeffe EB, Hollinger FB. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. *Hepatology* 26(3 Suppl 1):101S-107S. 1997.
- Kennedy NJ, Russell JQ, Michail N, et al. Liver damage by infiltrating CD8+ T cells is Fas dependent. *J Immunol* 167(11):6654-62. 2001.
- Keskinen P, Melen K, Julkunen I. Expression of HCV structural proteins impairs IFN-mediated antiviral response. *Virology* 299(2):164-71. 2002.
- Kieft JS, Zhou K, Jubin R, et al. The hepatitis C virus internal ribosome entry site adopts an ion-dependent tertiary fold. *J Mol Biol* 292(3):513-29. 1999.
- Kieft JS, Zhou K, Jubin R, et al. Mechanism of ribosome recruitment by hepatitis C IRES RNA. *RNA* 7(2):194-06. 2001.
- Kikuchi K, Umehara T, Fukuda K, et al. RNA Aptamers Targeted to Domain II of Hepatitis C Virus IRES That Bind to Its Apical Loop Region. *J Biochem (Tokyo)* 133(3):263-70. 2003.
- Kim DH, Longo M, Han Y, et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. *Nat Biotechnol* 22(3):321-5. 2004.
- Kim JL, Morgenstern KA, Griffith JP, et al. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. *Structure* 6(1):89-100. 1998.
- Kim SK, Brehm MA, Welsh RM, Selin LK. Dynamics of memory T cell proliferation under conditions of heterologous immunity and bystander stimulation. *J Immunol* 169(1):90-8. 2002.
- Kim SK, Welsh RM. Comprehensive early and lasting loss of memory CD8 T cells and functional memory during acute and persistent viral infections. *J Immunol* 172(5):3139-50. 2004.

- Kimura K, Kakimi K, Wieland S, et al. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. *J Virol* 76(21):10702-07. 2002a.
- Kimura K, Kakimi K, Wieland S, et al. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. *J Immunol* 169(9):5188-95. 2002b.
- Kitabwalla M, Ruprecht RM. RNA interference—a new weapon against HIV and beyond. *N Engl J Med* 347(17):1364-7. 2002.
- Klasse PJ, Moore JP. Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects? *Virology* 323(1):1-8. 2004.
- Klugewitz K, Blumenthal-Barby F, Schrage A, et al. Immunomodulatory effects of the liver: deletion of activated CD4+ effector cells and suppression of IFN- $\gamma$ -producing cells after intravenous protein immunization. *J Immunol* 169(5):2407-13. 2002.
- Knapp S, Yee LJ, Frodsham AJ, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. *Genes and Immunity* 4, 411-419. 2003.
- Knuchel M, Ciuffreda D, Khonkarly M, et al. (abstract 838) Pre-terminally Differentiated Hepatitis C-specific CD8+ T-cells Represent the Dominant Cell Population of Memory CD8 T-cells in Chronically Infected Patients. 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2003.
- Koch JO, Bartenschlager R. Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. *J Virol* 73(9):7138-46. 1999.
- Koev G, Duncan RF, Lai MM. Hepatitis C virus IRES-dependent translation is insensitive to an eIF2 $\alpha$ -independent mechanism of inhibition by interferon in hepatocyte cell lines. *Virology* 297(2):195-02. 2002.
- Koike K, Moriya K, Ishibashi K, et al. Expression of hepatitis C virus envelope proteins in transgenic mice. *J Gen Virol* 76(Pt 12):3031-38. 1995.
- Koike K, Moriya K, Kimura S. Role of hepatitis C virus in the development of hepatocellular carcinoma: transgenic approach to viral hepatocarcinogenesis. *J Gastroenterol Hepatol* 17(4):394-00. 2002a.
- Koike K. Hepatocarcinogenesis in hepatitis viral infection: lessons from transgenic mouse studies. *J Gastroenterol* 37 Suppl 13:55-64. 2002b.
- Kolupaeva VG, Pestova TV, Hellen CU. An enzymatic footprinting analysis of the interaction of 40S ribosomal subunits with the internal ribosomal entry site of hepatitis C virus. *J Virol* 74(14):6242-50. 2000.

- Kolykhalov AA, Agapov EV, Blight KJ, et al. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. *Science* 277(5325):570-74. 1997.
- Komurian-Pradel F, Perret M, Deiman B, et al. Strand specific quantitative real-time PCR to study replication of hepatitis C virus genome. *J Virol Methods* Mar;116(1):103-6. 2004.
- Konan KV, Giddings TH Jr, Ikeda M, et al. Nonstructural protein precursor NS4A/B from hepatitis C virus alters function and ultrastructure of host secretory apparatus. *J Virol* 77(14):7843-55. 2003.
- Kong LK, Sarnow P. Cytoplasmic expression of mRNAs containing the internal ribosome entry site and 3' noncoding region of hepatitis C virus: effects of the 3' leader on mRNA translation and mRNA stability. *J Virol* 76(24):12457-62. 2002 .
- Kono Y, Hayashida K, Tanaka H, et al. High-density lipoprotein binding rate differs greatly between genotypes 1b and 2a/2b of hepatitis C virus. *J Med Virol* 70(1):42-48. 2003.
- Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS: A new trick for an old drug? *CMAJ* 168(10):1289-92. 2003.
- Koziel MJ, Dudley D, Afdhal N, et al. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. *J Virol* 67(12):7522-32. 1993.
- Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture- adaptive mutations. *J Virol* 75(10):4614-24. 2001.
- Krönke J, Kittler R, Buchholz F, et al. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. *J Virol* 78(7):3436-46. 2004.
- Krüger M, Beger C, Welch PJ, et al. C-SPACE (cleavage-specific amplification of cDNA ends): a novel method of ribozyme-mediated gene identification. *Nucleic Acids Res* 29(19):E94. 2001a.
- Krüger M, Beger C, Welch PJ, et al. Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation. *Mol Cell Biol* 21(24):8357-64. 2001b.
- Krugman S, Giles JP, Hammond J. Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. *JAMA* 200(5):365-73. 1967.
- Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. *Hepatology* 36(5):1266-72. 2002.
- Kumar U, Monjardino J, Thomas HC. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. *Gastroenterology* 106(4):1072-5. 1994.
- Kumashiro R, Ide T, Sasaki M, et al. Interferon-gamma brings additive anti-viral environment when combined with interferon- $\alpha$  in patients with chronic hepatitis C. *Hepatol Res* 22(1):20-26. 2002.

- Kuniyasu Y, Marfani SM, Inayat IB, et al. Kupffer cells required for high affinity peptide-induced deletion, not retention, of activated CD8+ T cells by mouse liver. *Hepatology* 39(4):1017-27. 2004.
- Kunkel M, Lorinczi M, Rijnbrand R, et al. Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein. *J Virol* 75(5):2119-29. 2001.
- Kunkel M, Watowich SJ. Conformational changes accompanying self-assembly of the hepatitis C virus core protein. *Virology* 294(2):239-45. 2002.
- Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. *Science* 244(4902):362-64. 1989.
- Kwon HJ, Jang KL. Dual effects of hepatitis C virus Core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene. *J Viral Hepat* 10(4):249-55. 2003.
- Lagging LM, Meyer K, Owens RJ, et al. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. *J Virol* 72(5):3539-46. 1998.
- Lagging LM, Meyer K, Westin J, et al. Neutralization of pseudotyped vesicular stomatitis virus expressing hepatitis C virus envelope glycoprotein 1 or 2 by serum from patients. *J Infect Dis* 185(8):1165-9. 2002.
- Lahm A, Yagnik A, Tramontano A, et al. Hepatitis C virus proteins as targets for drug development: the role of bioinformatics and modelling. *Curr Drug Targets* 3(4):281-96. 2002.
- Lai MM. Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. *Gastroenterology* 122(2):568-71. 2002.
- Lai WK, Sun PJ, Zhang J, et al. Abstract 402. Human hepatic sinusoidal epithelial cells (HSEC) interact with hepatitis C virus (HCV) E2 glycoproteins via DCSIGN and LSIGN. 39th Annual Meeting of the European Association for the Study of the Liver. Berlin, Germany. 2004.
- Lake-Bakaar G, Mazzoccoli V, Ruffini L. Digital image analysis of the distribution of proliferating cell nuclear antigen in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. *Dig Dis Sci* 47(7):1644-48. 2002.
- Lalor T, Adams D. The liver: a model of organ-specific lymphocyte recruitment. *Expert Rev Mol Med* 2002:1-15. 2002.
- Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. *Nature* 426(6963):186-9. 2003.
- Lambot M, Fretier S, Op de Beeck A, et al. Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment. *J Biol Chem* 277(23):20625-30. 2002.

- Lamonaca V, Missale G, Urbani S, et al. Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: implications for vaccine development. *Hepatology* 30(4):1088-98. 1999.
- Lan KH, Sheu ML, Hwang SJ, et al. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. *Oncogene* 21(31):4801-11. 2002.
- Lan S, Wang H, Jiang H, et al. Direct interaction between alpha-actinin and hepatitis C virus NS5B. *FEBS Lett* 554(3):289-94. 2003.
- Lancaster T, Sanders E, Christie JM, et al. Quantitative and functional differences in CD8+ lymphocyte responses in resolved acute and chronic hepatitis C virus infection. *J Viral Hepat* 9(1):18-28. 2002.
- Lanford RE, Bigger C, Bassett S, et al. The chimpanzee model of hepatitis C virus infections. *ILAR J* 42(2):117-26. 2001a.
- Lanford RE, Chavez D, Guerra B, et al. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. *J Virol* 75(17):8074-81. 2001b.
- Lanford RE, Bigger C. Advances in model systems for hepatitis C virus research. *Virology* 293(1):1-9. 2002.
- Lanford RE, Guerra B, Lee H, et al. Antiviral effect and virus-host interactions in response to  $\alpha$  interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor  $\alpha$ , and ribavirin in hepatitis C virus subgenomic replicons. *J Virol* 77(2):1092-04. 2003.
- Lanford RE, Guerra B, Chavez D, et al. Cross-genotype immunity to hepatitis C virus. *J Virol* 78(3):1575-81. 2004.
- Lang KJ, Kappel A, Goodall GJ. Hypoxia-inducible factor-1 $\alpha$  mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. *Mol Biol Cell* 13(5):1792-01. 2002.
- Laporte J, Bain C, Maurel P, et al. Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. *Blood* 101(1):52-57. 2003.
- Larrat S, Stanke-Labesque F, Plages A, et al. Ribavirin quantification in combination treatment of chronic hepatitis C. *Antimicrob Agents Chemother* 47(1):124-9. 2003.
- Larrea E, Alberdi A, Castelruiz Y, et al. Expression of interferon- $\alpha$  subtypes in peripheral mononuclear cells from patients with chronic hepatitis C: a role for interferon- $\alpha$ 5. *J Viral Hepat* 8(2):103-10. 2001.
- Larsson M, Babcock E, Grakoui A, et al. Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. *J Virol* 78(12):6151-61. 2004.

- Lasarte JJ, Sarobe P, Boya P, et al. A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage. *Hepatology* 37(2):461-70. 2003.
- Laskus T, Radkowski M, Wang LF, et al. Hepatitis C virus negative strand RNA is not detected in peripheral blood mononuclear cells and viral sequences are identical to those in serum: a case against extrahepatic replication. *J Gen Virol* 78(Pt 11):2747-50. 1997.
- Laskus T, Radkowski M, Wang LF, et al. Hepatitis C virus quasispecies in patients infected with HIV-1: correlation with extrahepatic viral replication. *Virology* 248(1):164-71. 1998a.
- Laskus T, Radkowski M, Wang LF, et al. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfecting with human immunodeficiency virus type 1. *J Infect Dis* 178(4):1189-92. 1998b.
- Laskus T, Radkowski M, Piasek A, et al. Hepatitis C virus in lymphoid cells of patients coinfecting with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. *J Infect Dis* 181(2):442-48. 2000.
- Laskus T, Radkowski M, Jablonska J, et al. Human immunodeficiency virus facilitates infection/replication of hepatitis C virus in native human macrophages. *Blood* 103(10):3854-9. 2004.
- Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. *Hepatology* 35(5):1002-9. 2002.
- Lau AH, Thomson AW. Dendritic cells and immune regulation in the liver. *Gut* 52(2):307-14. 2003a.
- Lau AH, de Creus A, Lu L, Thomson AW. Liver tolerance mediated by antigen presenting cells: fact or fiction? *Gut* 52:1075-78. 2003b.
- Lauer GM, Nguyen TN, Day CL, et al. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. *J Virol* 76(6):2817-26. 2002a.
- Lauer GM, Ouchi K, Chung RT, et al. Comprehensive analysis of CD8<sup>+</sup>-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. *J Virol* 76(12):6104-13. 2002b.
- Layzer JM, McCaffrey AP, Tanner AK, et al. In vivo activity of nuclease-resistant siRNAs. *RNA* 10(5):766-71. 2004.
- Lázaro CA, Croager EJ, Mitchell C, et al. Establishment, characterization, and long-term maintenance of cultures of human fetal hepatocytes. *Hepatology* 38(5):1095-106. 2003.
- Le Bon A, Etchart N, Rossmann C, et al. Cross-priming of CD8<sup>+</sup> T cells stimulated by virus-induced type I interferon. *Nat Immunol* 4(10):1009-15. 2003.

Lechmann M, Ihlenfeldt HG, Braunschweiger I, et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. *Hepatology* 24(4):790-95. 1996.

Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. *J Exp Med* 191(9):1499-12. 2000.

Lemberg MK, Martoglio B. Requirements for signal peptide peptidase-catalyzed intramembrane proteolysis. *Mol Cell* 10(4):735-44. 2002.

Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. *Gastroenterology* 122(2):352-65. 2002.

Lerat H, Hollinger FB. Hepatitis C virus (HCV) occult infection or occult HCV RNA detection? *J Infect Dis* 189(1):3-6. 2004.

Leroy V, Vigan I, Mosnier JF, et al. Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C. *Hepatology* 38(4):829-41. 2003.

Lesburg CA, Radfar R, Weber PC. Recent advances in the analysis of HCV NS5B RNA-dependent RNA polymerase. *Curr Opin Investig Drugs* 1(3):289-96. 2000.

Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. *Nat Med* 9(7):861-6. 2003.

Levin MK, Gurjar MM, Patel SS. ATP binding modulates the nucleic acid affinity of hepatitis C virus helicase. *J Biol Chem* 278(26):23311-16. 2003.

Levin MK, Wang YH, Patel SS. The functional interaction of the hepatitis C virus helicase molecules is responsible for unwinding processivity. *J Biol Chem* 279(25):26005-26012. 2004.

Levy MT, McCaughan GW, Marinos G, et al. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. *Liver* 22(2):93-101. 2002.

Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. *Annu Rev Immunol* 16:89-109. 1998.

Li C, Candotti D, Allain JP. Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1. *J Virol* 75(24):12412-20. 2001.

Li D, Takyar ST, Lott WB, et al. Amino acids 1-20 of the hepatitis C virus (HCV) core protein specifically inhibit HCV IRES-dependent translation in HepG2 cells, and inhibit both HCV IRES- and cap-dependent translation in HuH7 and CV-1 cells. *J Gen Virol* 84(Pt 4):815-25. 2003.

- Li K, Prow T, Lemon SM, Beard MR. Cellular response to conditional expression of hepatitis C virus core protein in Huh7 cultured human hepatoma cells. *Hepatology* 35(5):1237-46. 2002.
- Li Q, Dong C, Wang J, et al. Induction of hepatitis C virus-specific humoral and cellular immune responses in mice and rhesus by artificial multiple epitopes sequence. *Viral Immunol* 16(3):321-33. 2003.
- Li X, Jeffers LJ, Shao L, et al. Identification of hepatitis C virus by immunoelectron microscopy. *J Viral Hepat* 2(5):227-34. 1995.
- Li Y, Zhang T, Douglas SD, Lai JP, et al. Morphine enhances hepatitis C virus (HCV) replicon expression. *Am J Pathol* 163(3):1167-75. 2003.
- Lian ZX, Okada T, He XS, et al. Heterogeneity of dendritic cells in the mouse liver: identification and characterization of four distinct populations. *J Immunol* 170(5):2323-30. 2003.
- Lichterfeld M, Leifeld L, Nischalke HD, et al. Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. *J Infect Dis* 185(12):1803-7. 2002.
- Lichtinghagen R, Huegel O, Seifert T, et al. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. *Clin Chem* 46(2):183-92. 2000.
- Lichtinghagen R, Michels D, Haberkorn CI, et al. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. *J Hepatol* 34(2):239-47. 2001.
- Lichtinghagen R, Bahr MJ, Wehmeier M, et al. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. *Clin Sci (Lond)* 105(3):373-82. 2003.
- Lieberman J, Song E, Lee SK, et al. Interfering with disease: opportunities and roadblocks to harnessing RNA interference. *Trends Mol Med* 9(9):397-403. 2003.
- Lin C, Lindenbach BD, Pragai BM, et al. Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. *J Virol* 68(8):5063-73. 1994a.
- Lin C, Pragai BM, Grakoui A, et al. Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics. *J Virol* 68(12):8147-57. 1994b.
- Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: Structural analysis indicates different resistance mechanisms. *J Biol Chem* 279(17):17508-14. 2004.



- Lin CC, Dadgostari S, Lau JY. Viramidine, a liver-targeting ribavirin prodrug, shows a better safety profile than ribavirin in animal safety studies. Abstract 508. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.
- Lin CC, Yeh LT, Vitarella D, Hong Z. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. *Antivir Chem Chemother* 14(3):145-52. 2003.
- Lin HJ, Seeff LB, Barbosa L, Hollinger FB. Occurrence of identical hypervariable region 1 sequences of hepatitis C virus in transfusion recipients and their respective blood donors: divergence over time. *Hepatology* 34(2):424-9. 2001.
- Lin L, Fevery J, Hiem Yap S. A novel strand-specific RT-PCR for detection of hepatitis C virus negative-strand RNA (replicative intermediate): evidence of absence or very low level of HCV replication in peripheral blood mononuclear cells. *J Virol Methods* 100(1-2):97-105. 2002.
- Lindenbach BD, Rice CM. Flaviviridae: the viruses and their replication, p. 991-1041. In Knipe DM, Howley PM, Griffin DE, et al. (ed.), *Fields virology*, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa. 2001.
- Lindenbach BD, Rice CM. Evasive maneuvers by hepatitis C virus. *Hepatology* 38(3):769-71. 2003.
- Liu C, Zhu H, Tu Z, et al. CD8+ T-cell interaction with HCV replicon cells: evidence for both cytokine- and cell-mediated antiviral activity. *Hepatology* 37(6):1335-42. 2003.
- Liu H, Andreansky S, Diaz G, et al. Quantitative analysis of long-term virus-specific CD8+-T-cell memory in mice challenged with unrelated pathogens. *J Virol* 77(14):7756-63. 2003.
- Liu J, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. *Am J Gastroenterol* 98(3):538-44. 2003.
- Liu Q, Tackney C, Bhat RA, et al. Regulated processing of hepatitis C virus core protein is linked to subcellular localization. *J Virol* 71(1):657-62. 1997.
- Llinàs-Brunet M, Bailey M, Fazal G, et al. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. *Bioorg Med Chem Lett* 10(20):2267-70. 2000.
- Lo SY, Masiarz F, Hwang SB, et al. Differential subcellular localization of hepatitis C virus core gene products. *Virology* 213(2):455-61. 1995.
- Loeb LA, Essigmann JM, Kazazi F, et al. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. *Proc Natl Acad Sci USA* 96(4):1492-7. 1999.

- Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 285(5424):110-13. 1999.
- Lohmann V, Roos A, Korner F, et al. Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. *J Viral Hepat* 7(3):167-74. 2000.
- Lohmann V, Korner F, Dobierzewska A, et al. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. *J Virol* 75(3):1437-49. 2001.
- Lohmann V, Hoffmann S, Herian U, et al. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. *J Virol* 77(5):3007-19. 2003.
- Lohr HF, Schlaak JF, Kollmannsperger S, et al. Liver-infiltrating and circulating CD4+ T cells in chronic hepatitis C: immunodominant epitopes, HLA-restriction and functional significance. *Liver* 16(3):174-82. 1996.
- Long MB, Jones JP 3rd, Sullenger BA, Byun J. Ribozyme-mediated revision of RNA and DNA. *J Clin Invest* 112(3):312-8. 2003.
- Longman RS, Talal AH, Jacobson IM, et al. Patients chronically infected with hepatitis C virus have functional dendritic cells. *Blood* 103(3):1026-9. 2004.
- Lou H, Choi YH, LaVoy JE, et al. Analysis of mutant NS5B proteins encoded by isolates from chimpanzees chronically infected following clonal HCV RNA inoculation. *Virology*. 2003 Dec 5;317(1):65-72.
- Love RA, Parge HE, Yu X, et al. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. *J Virol* 77(13):7575-81. 2003.
- Lu HH, Wimmer E. Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus. *Proc Natl Acad Sci USA* 93(4):1412-17. 1996.
- Lu JJ, Li K, Murray MG, et al. (abstract) HCV Replicon Cells Treated With the Protease Inhibitor, SCH6, Show Dramatic Disappearance of HCV Protein and RNA. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. 2003.
- Lu L, Nakano T, Orito E, et al. Evaluation of accumulation of hepatitis C virus mutations in a chronically infected chimpanzee: comparison of the core, E1, HVR1, and NS5b regions. *J Virol* 75(6):3004-9. 2001.
- Lu L, Pilot-Matias TJ, Stewart KD, et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor *in vitro*. *Antimicrob Agents Chemother* 48(6):2260-6. 2004.
- Lu W, Strohecker A, Ou Jh JH. Post-translational modification of the hepatitis C virus core protein by tissue transglutaminase. *J Biol Chem* 276(51):47993-9. 2001.

- Lucas M, Gadola S, Meier U, et al. Frequency and phenotype of circulating V $\alpha$ 24/V $\beta$ 11 double-positive natural killer T cells during hepatitis C virus infection. *J Virol* 77(3):2251-57. 2003.
- Lucas M, Vargas-Cuero AL, Lauer GM, et al. Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. *J Immunol* 172(3):1744-53. 2004.
- Luo G. Cellular proteins bind to the poly(U) tract of the 3' untranslated region of hepatitis C virus RNA genome. *Virology* 256(1):105-18. 1999.
- Lurie Y, Nevens F, Aprosina ZG, et al. A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon- $\alpha$ -2b for the treatment of chronic hepatitis C. *J Viral Hepat Sep*;9(5):346-53. 2002.
- Ma C, Marassi FM, Jones DH, et al. Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1. *Protein Sci* 11(3):546-57. 2002.
- Ma X, Fornis X, Gutierrez R, et al. DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. *Vaccine* 20(27-28):3263-71. 2002.
- Maag D, Castro C, Hong Z, et al. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. *J Biol Chem* 276(49):46094-98. 2001.
- MacCallum, FO. Homologous Serum Jaundice. *Lancet* 2:691-2. 1947.
- Macdonald A, Crowder K, Street A, et al. The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. *J Biol Chem* 278(20):17775-84. 2003.
- MacDonald AJ, Duffy M, Brady MT, et al. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. *J Infect Dis* 185(6):720-27. 2002.
- Macejak DG, Jensen KL, Jamison SF, et al. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. *Hepatology* 31(3):769-76. 2000.
- Macejak DG, Jensen KL, Pavco PA, et al. Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA. *J Viral Hepat* 8(6):400-5. 2001a.
- Macejak D, et al. Nuclease-resistant ribozymes targeting the minus strand of hepatitis C virus (HCV) RNA can inhibit the replication of a chimeric virus in cell culture. Abstract 1109. 52nd Annual Meeting of the American Association for the Study of Liver Diseases. Dallas, Texas. 2001b.

Machida K, Tsukiyama-Kohara K, Seike E, et al. Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenic mice induced to express hepatitis C viral proteins. *J Biol Chem* 276(15):12140-46. 2001.

Machida K, Cheng KT, Sung VM, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. *Proc Natl Acad Sci USA* 101(12):4262-7. 2004.

Macías J, Sánchez-Quijano A, Pineda JA, et al. Minimal liver injury in chronic hepatitis C virus infection is associated with low levels of soluble TNF- $\alpha$ /Fas receptors and acquisition in childhood. *Liver* 21(6):410-14. 2001.

MacQuillan GC, de Boer WB, Platten MA, et al. Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection. *J Med Virol* 68(2):197-205. 2002.

MacQuillan GC, Mamotte C, Reed WD, et al. Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. *J Med Virol* 70(2):219-27. 2003.

Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. *FASEB J* 11(6):428-42. 1997.

Maecker HT, Do MS, Levy S. CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. *Proc Natl Acad Sci USA* 95(5):2458-62. 1998.

Maeno T, Okumura A, Ishikawa T, et al. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. *J Gastroenterol Hepatol* 18(12): 1358-63. 2003.

Mahmood S, Kawanaka M, Kamei A, et al. Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C. *Antioxid Redox Signal* 6(1):19-24. 2004.

Maillard P, Krawczynski K, Nitkiewicz J, et al. Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. *J Virol* 75(17):8240-50. 2001.

Maillard P, Lavergne JP, Sibénil S, et al. Fc $\gamma$  receptor-like activity of hepatitis C virus core protein. *J Biol Chem* 279:2430-2437. 2004.

Mailliard RB, Son YI, Redlinger R, et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. *J Immunol* 171(5):2366-73. 2003.

Major ME, Mihalik K, Fernandez J, et al. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. *J Virol* 73(4):3317-25. 1999.

Major ME, Mihalik K, Puig M, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. *J Virol* 76(13):6586-95. 2002.

Majumder M, Ghosh AK, Steele R, et al. Hepatitis C virus NS5A protein impairs TNF-mediated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice. *Virology* 294(1):94-105. 2002.

Majumder M, Steele R, Ghosh AK, et al. Expression of hepatitis C virus non-structural 5A protein in the liver of transgenic mice. *FEBS Lett* 555(3):528-32. 2003.

Makedonas G, Bruneau J, Lin H, et al. HIV-specific CD8 T-cell activity in uninfected injection drug users is associated with maintenance of seronegativity. *AIDS* 16(12):1595-602. 2002.

Mamiya N, Worman HJ. Hepatitis C virus core protein binds to a DEAD box RNA helicase. *J Biol Chem* 274(22):15751-6. 1999.

Manabe S, Fuke I, Tanishita O, et al. Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by NS3. *Virology* 198(2):636-44. 1994.

Mangia A, Minerva N, Annese M, et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. *Hepatology* 33(4):989-93. 2001.

Manigold T, Rehmann B. Chronic hepatitis B and hepatocarcinogenesis: does prevention of "collateral damage" bring the cure? *Hepatology* 37(3):707-10. 2003.

Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. *Science* 298(5600):1912-34. 2002.

Manzin A, Solforosi L, Petrelli E, et al. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. *J Virol* 72(7):6271-6. 1998.

Markland W, McQuaid TJ, Jain J, Kwong AD. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. *Antimicrob Agents Chemother* 44(4):859-66. 2000.

Martin A, Bodola F, Sangar DV, et al. Chronic hepatitis associated with GB virus B persistence in a tamarin after intrahepatic inoculation of synthetic viral RNA. *Proc Natl Acad Sci USA* 100(17):9962-7. 2003.

Martín J, Navas S, Quiroga JA, et al. Effects of the ribavirin-interferon  $\alpha$  combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. *Cytokine* 10(8):635-44. 1998.

Martín J, Navas S, Fernández M, et al. In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients. *Antiviral Res* 42(1):59-70. 1999.

- Martinez-Sierra C, Arizcorreta A, Díaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfecting with hepatitis C virus and human immunodeficiency virus. *Clin Infect Dis* 36(4):491-98. 2003.
- Marusawa H, Hijikata M, Chiba T, et al. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor  $\alpha$ -mediated apoptosis via NF- $\kappa$ B activation. *J Virol* 73(6):4713-20. 1999.
- Masciopinto F, Freer G, Burgio VL, et al. Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. *Virology* 304(2):187-96. 2002.
- Mastroianni CM, Liuzzi GM, D'Ettorre G, et al. Matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in plasma of patients co-infected with HCV and HIV. *HIV Clin Trials* 3(4):310-15. 2002.
- Matsui M, Moriya O, Akatsuka T. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. *Vaccine* 21(15):1629-39. 2003.
- Matsumoto M, Hwang SB, Jeng KS, et al. Homotypic interaction and multimerization of hepatitis C virus core protein. *Virology* 218(1):43-51. 1996.
- Matsuura Y, Tani H, Suzuki K, et al. Characterization of pseudotype VSV possessing HCV envelope proteins. *Virology* 286(2):263-75. 2001.
- Mauro VP, Edelman GM. The ribosome filter hypothesis. *Proc Natl Acad Sci USA* 99(19):12031-36. 2002.
- McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. *Nature* 418(6893):38-9. 2002.
- McCaffrey AP, Nakai H, Pandey K, et al. Inhibition of hepatitis B virus in mice by RNA interference. *Nat Biotechnol* 21(6):639-44. 2003a.
- McCaffrey AP, Meuse L, Karimi M, et al. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. *Hepatology* 38(2):503-8. 2003b.
- McCullough AJ. Obesity and its nurturing effect on hepatitis C. *Hepatology* 38(3):557-9. 2003.
- McGuinness PH, Bishop GA, Painter DM, et al. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. *Hepatology* 23(4):676-87. 1996.
- McGuinness PH, Painter D, Davies S, McCaughan GW. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. *Gut* 46(2):260-69. 2000.

- McHutchison JG, Giannelli G, Nyberg L, et al. A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. *J Interferon Cytokine Res* 19(11):1265-70. 1999.
- McHutchison JG, Patel K. Future therapy of hepatitis C. *Hepatology* 36(5 Suppl 1):S245-52. 2002.
- McKercher G, Beaulieu PL, Lamarre D, et al. Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate. *Nucleic Acids Res* 32(2):422-31. 2004.
- McLaren RS, Caruccio N, Ross J. Human La protein: a stabilizer of histone mRNA. *Mol Cell Biol* 17(6):3028-36. 1997.
- McLauchlan J, Lemberg MK, Hope G, et al. Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. *EMBO J* 21(15):3980-88. 2002.
- Mehta AS, Gu B, Conyers B, et al.  $\alpha$ -galactosylceramide and novel synthetic glycolipids directly induce the innate host defense pathway and have direct activity against hepatitis B and C viruses. *Antimicrob Agents Chemother* 48(6):2085-2090. 2004.
- Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. *Lancet* 359(9316):1478-83. 2002.
- Meier V, Mihm S, Braun Wietzke P, et al. HCV-RNA positivity in peripheral blood mononuclear cells of patients with chronic HCV infection: does it really mean viral replication? *World J Gastroenterol* 7(2):228-34. 2001.
- Mellor J, Holmes EC, Jarvis LM, et al. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. The International HCV Collaborative Study Group. *J Gen Virol* 76(Pt 10):2493-507. 1995.
- Meng Soo H, Garzino-Demo A, Hong W, et al. Expression of a full-length hepatitis C virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES. *Virology* 303(2):253-77. 2002.
- Meola A, Sbardellati A, Bruni Ercole B, et al. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. *J Virol* 74(13):5933-38. 2000.
- Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. *Nat Med* 7(8):927-33. 2001.
- Messaoudi I, Guevara Patiño JA, Dyllal R, et al. Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense. *Science* 298(5599):1797-800. 2002.
- Michalak JP, Wychowski C, Choukhi A, et al. Characterization of truncated forms of hepatitis C virus glycoproteins. *J Gen Virol* 78(Pt 9):2299-06. 1997.

- Migliaccio G, Tomassini JE, Carroll SS, et al. Characterization of resistance to non-obligate chain terminating ribonucleoside analogs which inhibit HCV replication *in vitro*. *J Biol Chem* 278(49):49164-70. 2003.
- Mihm S, Schweyer S, Ramadori G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN- $\gamma$  and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. *J Med Virol* 70(4):562-70. 2003.
- Miller WJ, Provost PJ, McAleer WJ, et al. Specific immune adherence assay for human hepatitis A antibody application to diagnostic and epidemiologic investigations. *Proc Soc Exp Biol Med* 149(1):254-61. 1975.
- Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. *J Clin Invest* 98(3):706-14. 1996.
- Miyanari Y, Hijikata M, Yamaji M, et al. Hepatitis C virus non-structural proteins in the probable membranous compartment function in viral genome replication. *J Biol Chem* 278(50):50301-8. 2003.
- Miyasaka Y, Enomoto N, Kurosaki M, et al. Hepatitis C virus nonstructural protein 5A inhibits tumor necrosis factor-alpha-mediated apoptosis in Huh7 cells. *J Infect Dis* 188(10):1537-44. 2003.
- Mochida S, Hashimoto M, Matsui A, et al. Genetic polymorphisms in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients. *Biochem Biophys Res Commun* 313(4):1079-85. 2004.
- Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. *Nature* 427(6972):313-9. 2004.
- Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. *Gut* 52(7):1035-40. 2003.
- Moingeon P, Almond J, de Wilde M. Therapeutic vaccines against infectious diseases. *Curr Opin Microbiol* 6(5):462-71. 2003.
- Molenkamp R, Kooi EA, Lucassen MA, et al. Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins. *J Virol* 77(2):1644-48. 2003.
- Monazahian M, Bohme I, Bonk S, et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. *J Med Virol* 57(3):223-29. 1999.
- Monazahian M, Kippenberger S, Muller A, et al. Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus. *Med Microbiol Immunol (Berl)* 188(4):177-84. 2000.



- Mondelli MU, Cerino A, Lisa A, et al. Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation. *Hepatology* 30(2):537-45. 1999.
- Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. *Hepatology* 36(3): 729-36. 2002.
- Moore CB, John M, James IR, et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. *Science* 296(5572):1439-43. 2002.
- Moradpour D, Kary P, Rice CM, Blum HE. Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. *Hepatology* 28(1):192-201. 1998.
- Moradpour D, Grabscheid B, Kammer AR, et al. Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation *in vitro*. *Hepatology* 33(5):1282-7. 2001.
- Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. *Nat Rev Immunol* 2(12):957-64. 2002.
- Morgan TR, Brenner D, Everhart J, et al. Hepatitis C and alcohol: fundamental and translational research directions. *Alcohol Clin Exp Res* 27(4):726-31. 2003.
- Moriishi K, Okabayashi T, Nakai K, et al. Proteasome activator PA28 $\gamma$ -dependent nuclear retention and degradation of hepatitis C virus core protein. *J Virol* 77(19):10237-49. 2003.
- Moriya K, Yotsuyanagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. *J Gen Virol* 78(Pt 7):1527-31. 1997.
- Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nat Med* 4(9):1065-67. 1998.
- Moriya K, Todoroki T, Tsutsumi T, et al. Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. *Biochem Biophys Res Commun* 281(5):1207-12. 2001a.
- Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. *Cancer Res* 61(11):4365-70. 2001b.
- Morrish BC, Rumsby MG. The 5' untranslated region of protein kinase C $\delta$  directs translation by an internal ribosome entry segment that is most active in densely growing cells and during apoptosis. *Mol Cell Biol* 22(17):6089-99. 2002.
- Moskophidis D, Lechner F, Pircher H, et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. *Nature* 362(6422):758-61. 1993.

- Mottola G, Cardinali G, Ceccacci A, et al. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. *Virology* 293(1):31-43. 2002.
- Muerhoff AS, Leary TP, Simons JN, et al. Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis. *J Virol* 69(9):5621-30. 1995.
- Muir AJ, Sylvestre PB, Rockey DC. (abstract 107906) Interferon Gamma-1b for the Treatment of Chronic Hepatitis C Infection. Abstracts of Digestive Disease Week. Orlando, Florida. 2003.
- Munshi N, Balasubramanian A, Koziel M, et al. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. *J Infect Dis* 188(8):1192-204. 2003.
- Murakami K, Abe M, Kageyama T, et al. Down-regulation of translation driven by hepatitis C virus internal ribosomal entry site by the 3' untranslated region of RNA. *Arch Virol* 146(4):729-41. 2001.
- Murata K, Lechmann M, Qiao M, et al. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. *Proc Natl Acad Sci* 100(11):6753-8. 2003.
- Murata M, Nabeshima S, Maeda N, et al. Increased frequency of IFN- $\gamma$ -producing peripheral CD8+ T cells with memory-phenotype in patients with chronic hepatitis C. *J Med Virol* 67(2):162-70. 2002.
- Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. *FEBS Lett* 558(1-3):63-8. 2004.
- Murray EM, Grobler JA, Markel EJ, et al. Persistent replication of hepatitis C virus replicons expressing the  $\beta$ -lactamase reporter in subpopulations of highly permissive Huh7 cells. *J Virol* 77(5):2928-35. 2003.
- Nadal A, Robertson HD, Guardia J, Gómez J. Characterization of the structure and variability of an internal region of hepatitis C virus RNA for M1 RNA guide sequence ribozyme targeting. *J Gen Virol* Jun;84(Pt 6):1545-8. 2003.
- Naganuma A, Dansako H, Nakamura T, et al. Promotion of microsatellite instability by hepatitis C virus core protein in human non-neoplastic hepatocyte cells. *Cancer Res* 64(4):1307-14. 2004.
- Nakagawa M, Sakamoto N, Enomoto N, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. *Biochem Biophys Res Commun* 313(1):42-7. 2004.
- Nakamoto Y, Kaneko S, Kobayashi K. Monocyte-dependent cell death of T lymphocyte subsets in chronic hepatitis C. *Immunol Lett* 78(3):169-74. 2001.

- Nakamoto Y, Kaneko S, Kobayashi K. Increased susceptibility to apoptosis and attenuated Bcl-2 expression in T lymphocytes and monocytes from patients with advanced chronic hepatitis C. *J Leukoc Biol* 72(1):49-55. 2002.
- Nam JH, Bukh J, Purcell RH, et al. High-level expression of hepatitis C virus (HCV) structural proteins by a chimeric HCV/BVDV genome propagated as a BVDV pseudotype. *J Virol Methods* 97(1-2):113-23. 2001.
- Napoli J, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of T<sub>H</sub>1-associated cytokines. *Hepatology* 24(4):759-65. 1996.
- Narjes F, Koch U, Steinkühler C. Recent developments in the discovery of hepatitis C virus serine protease inhibitors – towards a new class of antiviral agents? *Expert Opin Investig Drugs* 12(2):153-63. 2003.
- Narumi S, Tominaga Y, Tamaru M, et al. Expression of IFN-inducible protein-10 in chronic hepatitis. *J Immunol* 158(11):5536-44. 1997.
- Nascimbeni M, Mizukoshi E, Bosmann M, et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. *J Virol* 77(8):4781-93. 2003.
- Nascimbeni M, Shin EC, Chiriboga L, et al. Peripheral CD4/CD8 double-positive T cells are differentiated effector memory cells with antiviral functions. *Blood* Mar 25 [Epub ahead of print]. 2004.
- National Center for Complementary and Alternative Medicine (NCCAM). Hepatitis C and Complementary and Alternative Medicine: 2003 Update. NCCAM Publication No. D004. 2003.
- Navas MC, Fuchs A, Schvoerer E, et al. Dendritic cell susceptibility to hepatitis C virus genotype 1 infection. *J Med Virol* 67(2):152-61. 2002.
- Neau D, Jouvencel AC, Legrand E, et al. Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients. *J Med Virol* 71(1):41-48. 2003.
- Neddermann P, Clementi A, De Francesco R. Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein. *J Virol* 73(12):9984-91. 1999.
- Negro F, Krawczynski K, Quadri R, et al. Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction. *Hepatology* 29(2):536-42. 1999.
- Negro F. Hepatitis C virus and liver steatosis: is it the virus? Yes it is, but not always. *Hepatology* 36(5):1050-52. 2002.

- Nelson DR, González-Peralta RP, Qian K, et al. Transforming growth factor-beta 1 in chronic hepatitis C. *J Viral Hepat* 4(1):29-35. 1997.
- Nelson DR, Lauwers GY, Lau JY, et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. *Gastroenterology* 118(4):655-60. 2000.
- Nelson DR, Tu Z, Soldevila-Pico C, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. *Hepatology* 38(4):859-68. 2003.
- Neuman MG, Benhamou JP, Bourliere M, et al. Serum tumour necrosis factor- $\alpha$  and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. *Cytokine* 17(2):108-17. 2002a.
- Neuman MG, Benhamou JP, Malkiewicz IM, et al. Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. *J Viral Hepat* 9(2):134-40. 2002b.
- Neuman MG, Benhamou JP, Ibrahim A, et al. Role of cytokines in the assessment of the severity of chronic hepatitis C and the prediction of response to therapy. *Rom J Gastroenterol* 11(2):97-103. 2002c.
- Neumann AU, Lam NP, Dahari H, et al. Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- $\alpha$  Therapy. *Science* 282(5386):103-7. 1998.
- Nevens F, Roskams T, Van Vlierberghe H, et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. *Hepatology* 38(5):1289-1296. 2003.
- Nguyen TT, Gates AT, Gutshall LL, et al. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. *Antimicrob Agents Chemother* 47(11):3525-30. 2003.
- Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves T<sub>H</sub>1 cytokine production but inhibits Th2 cytokine response. *J Immunol* 160(7):3487-93. 1998.
- O'Brien CB, Moonka DK, Henzel BS, et al. A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon- $\alpha$ . *Am J Gastroenterol* 96(8):2473-79. 2001.
- Odeberg J, Yun Z, Sonnerborg A, et al. Variation of hepatitis C virus hypervariable region 1 in immunocompromised patients. *J Infect Dis* 175(4):938-43. 1997.
- Odreman-Macchioli F, Baralle FE, et al. Mutational analysis of the different bulge regions of hepatitis C virus domain II and their influence on internal ribosome entry site translational ability. *J Biol Chem* 276(45):41648-55. 2001.

- Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. *Proc Natl Acad Sci USA* 88(8):3392-6. 1991.
- Ohkawa K, Yuki N, Kanazawa Y, et al. Cleavage of viral RNA and inhibition of viral translation by hepatitis C virus RNA-specific hammerhead ribozyme *in vitro*. *J Hepatol* 27(1):78-84. 1997.
- Ohkawa K, Ishida H, Nakanishi F, et al. Changes in gene expression profile by HCV core protein in cultured liver cells: analysis by DNA array assay. *Hepatol Res* 25(4):396-408. 2003.
- Ohkawa K, Ishida H, Nakanishi F, et al. Hepatitis C virus core functions as a suppressor of cyclin-dependent kinase-activating kinase and impairs cell cycle progression. *J Biol Chem* 279(12):11719-26. 2004.
- Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. *Cancer Res* 61(5):2129-37. 2001.
- Okamoto H, Kojima M, Okada S, et al. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. *Virology* 190(2):894-9. 1992.
- Okochi K, Murakami S. Observations on Australia antigen in Japanese. *Vox Sang* 15(5):374-85. 1968.
- Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. *Gastroenterology* 122(2):366-75. 2002.
- Ono K, Tanaka Y, Kusano F, et al. Fas-ligand and perforin expression in infiltrating cytotoxic T lymphocytes in the liver of chronic hepatitis C. *Hepatol Res* 23(3):153-162. 2002.
- Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics: basic principles and recent applications. *Nat Rev Drug Discov* 1(7):503-14. 2002.
- Op de Beeck A, Cocquerel L, et al. Biogenesis of hepatitis C virus envelope glycoproteins. *J Gen Virol* 82(Pt 11):2589-95. 2001.
- Op de Beeck A, Dubuisson J. Another putative receptor for hepatitis C virus. *Hepatology* 37(3):705-7. 2003.
- Op de Beeck A, Voisset C, Bartosch B, et al. Characterization of Functional Hepatitis C Virus Envelope Glycoproteins. *J Virol* 78(6):2994-3002. 2004.
- Otsuka M, Kato N, Taniguchi H, et al. Hepatitis C virus core protein inhibits apoptosis via enhanced Bcl-xL expression. *Virology* 296(1):84-93. 2002.
- Otsuka M, Aizaki H, Kato N, et al. Differential cellular gene expression induced by hepatitis B and C viruses. *Biochem Biophys Res Commun* 300(2):443-47. 2003.

Otto GA, Lukavsky PJ, Lancaster AM, et al. Ribosomal proteins mediate the hepatitis C virus IRES-HeLa 40S interaction. *RNA* 8(7):913-23. 2002

Ou R, Zhou S, Huang L, et al. Critical role for alpha/beta and gamma interferons in persistence of lymphocytic choriomeningitis virus by clonal exhaustion of cytotoxic T cells. *J Virol* 75(18):8407-23. 2001.

Ou-Yang P, Hwang LH, Tao MH, et al. Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: role of dendritic cells. *J Med Virol* 66(3):320-8. 2002.

Pallaoro M, Lahm A, Biasiol G, et al. Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein. *J Virol* 75(20):9939-46. 2001.

Palmer BE, Boritz E, Wilson CC. Effects of sustained HIV-1 plasma viremia on HIV-1 gag-specific CD4+ T cell maturation and function. *J Immunol* 172(5):3337-47. 2004.

Pan CH, Yang PM, Hwang LH, et al. T-cell antigenic determinants within hepatitis C virus non-structural protein 3 and cytokine production profiles in hepatitis C. *J Viral Hepat* 9(4):258-64. 2002.

Pancholi P, Perkus M, Tricoche N, et al. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. *J Virol* 77(1):382-90. 2003.

Pandey JP, Astemborski J, Thomas DL. Epistatic effects of immunoglobulin GM and KM allotypes on outcome of infection with hepatitis C virus. *J Virol* 78(9):4561-5. 2004.

Pandya J, Chakraborti A, Chawla Y, et al. Identification of human hepatocyte protein(s), which binds specifically to the recombinant envelope-2/non-structural-1 protein of hepatitis C virus. *Virus Res* 87(2):135-143. 2002.

Pannone BK, Xue D, Wolin SL. A role for the yeast La protein in U6 snRNP assembly: evidence that the La protein is a molecular chaperone for RNA polymerase III transcripts. *EMBO J* 17(24):7442-53. 1998.

Paolini C, De Francesco R, Gallinari P. Enzymatic properties of hepatitis C virus NS3-associated helicase. *J Gen Virol* 81(Pt 5):1335-45. 2000.

Pape GR, Gerlach TJ, Diepolder HM, et al. Role of the specific T-cell response for clearance and control of hepatitis C virus. *J Viral Hepat* 6 Suppl 1:36-40. 1999.

Pár G, Rukavina D, Podack E, et al. Decrease in CD3-negative-CD8dim+ and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection. *J Hepatol* 37(4):514. 2002.

- Paradis V, Mathurin P, Kollinger M, et al. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. *J Clin Pathol* 50(5):401-6. 1997.
- Paradis V, Dargere D, Vidaud M, et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. *Hepatology* 30(4):968-76. 1999.
- Pardo M, Castillo I, Oliva H, et al. A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. *Hepatology* 26(5):1318-21. 1997.
- Pariante N, Airaksinen A, Domingo E. Mutagenesis versus Inhibition in the Efficiency of Extinction of Foot-and-Mouth Disease Virus. *J Virol* 77(12):7131-8. 2003.
- Park CK, Park TR, Kim YB, et al. Viral loads and E2/NS1 region sequences of hepatitis C virus in hepatocellular carcinoma and surrounding liver. *Korean J Intern Med* 12(1):28-33. 1997.
- Park JS, Yang JM, Min MK. Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. *Biochem Biophys Res Commun* 267(2):581-7. 2000.
- Park JW, Gruys ME, McCormick K, et al. Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN- $\gamma$  (Mig) and chemokine responsive to  $\gamma$ -2 (Crg-2). *J Immunol* 166(6):3763-70. 2001.
- Park KJ, Choi SH, Lee SY, et al. Nonstructural 5A protein of hepatitis C virus modulates tumor necrosis factor  $\alpha$ -stimulated nuclear factor  $\kappa$ B activation. *J Biol Chem* 277(15):13122-8. 2002.
- Park KJ, Choi SH, Choi DH, et al. Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2. *J Biol Chem* 278(33):30711-8. 2003.
- Pasquinelli C, Shoenberger JM, Chung J, et al. Hepatitis C virus core and E2 protein expression in transgenic mice. *Hepatology* 25(3):719-27. 1997.
- Patzwahl R, Meier V, Ramadori G, Mihm S. Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization. *J Virol* 75(3):1332-8. 2001.
- Pavio N, Taylor DR, Lai MM. Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. *J Virol* 76(3):1265-72. 2002.
- Pavio N, Romano PR, Graczyk TM, et al. Protein synthesis and endoplasmic reticulum stress can be modulated by the hepatitis C virus envelope protein E2 through the eukaryotic initiation factor 2 $\alpha$  kinase PERK. *J Virol* 77(6):3578-85. 2003a.
- Pavio N, Lai MM. The hepatitis C virus persistence: how to evade the immune system? *J Biosci* 28(3):287-304. 2003b.

Pavlović D, Neville DC, Argaud O, et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. *Proc Natl Acad Sci USA* 100(10):6104-8. 2003.

Pawelec G, Barnett Y, Forsey R, et al. T cells and aging, January 2002 update. *Front Biosci* 7:d1056-183. 2002.

Pawlotsky JM, McHutchison JG. Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. *Hepatology* 39(2):554-67. 2004a.

Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. *Gastroenterology* 126(3):703-14. 2004b.

Pellerin M, Lopez-Aguirre Y, Penin F, et al. Hepatitis C virus quasispecies variability modulates non-structural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions. *J Virol* 78(9):4617-27. 2004.

Penin F, Dubuisson J, Rey FA, et al. Structural biology of hepatitis C virus. *Hepatology* 39:5-19. 2004.

Penna A, Missale G, Lamonaca V, et al. Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. *Hepatology* 35(5):1225-36. 2002.

Perez R, Pravia R, Artimez ML, et al. Clinical efficacy of intramuscular human interferon-beta vs interferon- $\alpha$  2b for the treatment of chronic hepatitis C. *J Viral Hepat* 2(2):103-6. 1995.

Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. *FASEB J* 16(2):185-94. 2002.

Pestova TV, Shatsky IN, Fletcher SP, et al. A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. *Genes Dev* 12(1):67-83. 1998.

Pestova TV, Kolupaeva VG, Lomakin IB, et al. Molecular mechanisms of translation initiation in eukaryotes. *Proc Natl Acad Sci USA* 98(13):7029-36. 2001.

Petit JM, Bour JB, Galland-Jos C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. *J Hepatol* 35(2): 279-83. 2001.

Petracca R, Falugi F, Galli G, et al. Structure-function analysis of hepatitis C virus envelope-CD81 binding. *J Virol* 74(10):4824-30. 2000.



- Petrik J, Parker H, Alexander GJ. Human hepatic glyceraldehyde-3-phosphate dehydrogenase binds to the poly(U) tract of the 3' non-coding region of hepatitis C virus genomic RNA. *J Gen Virol* 80 ( Pt 12):3109-13. 1999.
- Pfeiffer JK, Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. *Proc Natl Acad Sci USA* 100(12):7289-94. 2003.
- Pflugheber J, Fredericksen B, Sumpter R Jr, et al. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. *Proc Natl Acad Sci USA* 99(7):4650-5. 2002.
- Pham TN, MacParland SA, Mulrooney PM, et al. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. *J Virol* 78(11):5867-74. 2004.
- Phoon CW, Ng PY, Ting AE, et al. Biological evaluation of hepatitis C virus helicase inhibitors. *Bioorg Med Chem Lett* 11(13):1647-50. 2001.
- Pianko S, Patella S, Ostapowicz G, et al. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. *J Viral Hepat* 8(6):406-13. 2001.
- Pianko S, McHutchison JG, Gordon SC, et al. Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. *J Interferon Cytokine Res* 22(4):483-9. 2002.
- Piazzolla G, Tortorella C, Fiore G, et al. Interleukin-12 p40/p70 ratio and *in vivo* responsiveness to IFN- $\alpha$  treatment in chronic hepatitis C. *J Interferon Cytokine Res* 21(7):453-61. 2001.
- Piccininni S, Varaklioti A, Nardelli M, et al. Modulation of the hepatitis C virus RNA-dependent RNA polymerase activity by the non-structural (NS) 3 helicase and the NS4B membrane protein. *J Biol Chem* 277(47):45670-9. 2002.
- Pieroni L, Santolini E, Fipaldini C, et al. In vitro study of the NS2-3 protease of hepatitis C virus. *J Virol* 71(9):6373-80. 1997.
- Pietschmann T, Lohmann V, Rutter G, et al. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. *J Virol* 75(3):1252-64. 2001.
- Pietschmann T, Lohmann V, Kaul A, et al. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. *J Virol* 76(8):4008-21. 2002.
- Pietschmann T, Bartenschlager R. Tissue culture and animal models for hepatitis C virus. *Clin Liver Dis* 7(1):23-43. 2003.
- Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. *Science* 282(5390):938-41. 1998.

- Pockros PJ, Patel K, O'Brien C, et al. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. *Hepatology* 37(6):1368-74. 2003a.
- Pockros PJ, Schiff E, Shiffman M, et al. The first caspase inhibitor of apoptosis, IDN-6556, given orally lowers liver enzymes in HCV patients. Abstract 132A. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Podevin P, Sabile A, Gajardo R, et al. Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR- independent manner. *Hepatology* 33(6):1503-11. 2001.
- Pöhlmann S, Soilleux EJ, Baribaud F, et al. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. *Proc Natl Acad Sci USA* 98(5):2670-5. 2001.
- Pöhlmann S, Zhang J, Baribaud F, et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. *J Virol* 77(7):4070-80. 2003.
- Polakos NK, Drane D, Cox J, et al. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. *J Immunol* 166(5):3589-98. 2001.
- Polyak SJ, Khabar KS, Paschal DM, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. *J Virol* 75(13):6095-106. 2001a.
- Polyak SJ, Khabar KS, Rezeiq M, Gretch DR. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. *J Virol* 75(13):6209-11. 2001b.
- Post JJ, Pan Y, Freeman AJ, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. *J Infect Dis* 189(10):1846-55. 2004.
- Poupart MA, Cameron DR, Chabot C, et al. Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease. *J Org Chem* 66(14):4743-51. 2001.
- Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. *Hepatology* 31(4):828-33. 2000.
- Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. *J Hepatol* 38(3):257-65. 2003a.
- Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology* 38(1): 75-85. 2003b.

- Preziosi P. Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? *Nat Rev Drug Discov* 3(6):521-6. 2004.
- Priestley ES, Decicco CP. 1-Aminocyclopropaneboronic acid: synthesis and incorporation into an inhibitor of hepatitis C virus NS3 protease. *Org Lett* 2(20):3095-7. 2000.
- Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. *Proc Natl Acad Sci USA* 60(3):814-21. 1968.
- Prince AM, Brotman B, Grady GF, et al. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. *Lancet* 2(7875):241-6. 1974.
- Prince AM, Brotman B, Huima T, et al. Immunity in hepatitis C infection. *J Infect Dis* 165(3):438-43. 1992.
- Prince AM, Huima-Byron T, Parker TS, Levine DM. Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. *J Viral Hepat* 3(1):11-7. 1996.
- Promadej N, Costello C, Wernett MM, et al. Broad human immunodeficiency virus (HIV)-specific T cell responses to conserved HIV proteins in HIV-seronegative women highly exposed to a single HIV-infected partner. *J Infect Dis* 187(7):1053-63. 2003.
- Promrat K, McDermott DH, Gonzalez CM, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. *Gastroenterology* 124(2):352-60. 2003a.
- Promrat K, Liang TJ. Chemokine systems and hepatitis C virus infection: is truth in the genes of the beholders? *Hepatology* 38(6):1359-62. 2003b.
- Provost PJ, Hilleman MR. Propagation of human hepatitis A virus in cell culture *in vitro*. *Proc Soc Exp Biol Med* 160(2):213-21. 1979.
- Pudi R, Abhiman S, Srinivasan N, Das S. Hepatitis C Virus Internal Ribosome Entry Site-mediated Translation Is Stimulated by Specific Interaction of Independent Regions of Human La Autoantigen. *J Biol Chem* 278(14):12231-40. 2003.
- Pudi R, Srinivasan P, Das S. La protein binding at the GCAC near the initiator AUG facilitates the ribosomal assembly on the hepatitis C virus RNA to influence internal ribosome entry site mediated translation. *J Biol Chem* May 10 [Epub ahead of print]. 2004.
- Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfecting with hepatitis C virus and human immunodeficiency virus. *J Infect Dis* 183(1):134-7. 2001.
- Purcell AW, Gorman JJ. Immunoproteomics: Mass spectrometry-based methods to study the targets of the immune response. *Mol Cell Proteomics* 3(3):193-208. 2004.

- Pusch O, Boden D, Silbermann R, et al. Nucleotide sequence homology requirements of HIV-1-specific short hairpin RNA. *Nucleic Acids Res* 31(22):6444-9. 2003.
- Pybus OG, Charleston MA, Gupta S, et al. The epidemic behavior of the hepatitis C virus. *Science* 292(5525):2323-5. 2001.
- Pyronnet S, Pradayrol L, Sonenberg N. A cell cycle-dependent internal ribosome entry site. *Mol Cell* 5(4):607-16. 2000.
- Pyronnet S, Sonenberg N. Cell-cycle-dependent translational control. *Curr Opin Genet Dev* 11(1):13-8. 2001a.
- Pyronnet S, Dostie J, Sonenberg N. Suppression of cap-dependent translation in mitosis. *Genes Dev* 15(16):2083-93. 2001b.
- Qadri I, Iwahashi M, Capasso JM, et al. Induced oxidative stress and activated expression of manganese superoxide dismutase (MnSOD) during hepatitis C virus replication: Role of JNK, p38MAPK & AP-1. *Biochem J* 378(Pt 3):919-28. 2004.
- Qi ZT, Kalkeri G, Hanible J, et al. Stem-loop structures II-IV of the 5' untranslated sequences are required for the expression of the full-length hepatitis C virus genome. *Arch Virol* 148(3):449-67. 2003.
- Qiao M, Murata K, Davis AR, et al. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. *Hepatology* 37(1):52-9. 2003.
- Rabinovich BA, Li J, Shannon J, et al. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. *J Immunol* 170(7):3572-6. 2003.
- Racanelli V, Rehermann B. Hepatitis C virus infection: when silence is deception. *Trends Immunol* 24(8):456-64. 2003.
- Racanelli V, Behrens SE, Aliberti J, Rehermann B. Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8<sup>+</sup> T cells and antiviral immunity. *Immunity* 20(1):47-58. 2004.
- Radkowski M, Kubicka J, Kisiel E, et al. Detection of active hepatitis C virus and hepatitis G virus/GB virus C replication in bone marrow in human subjects. *Blood* 95(12):3986-9. 2000.
- Radkowski M, Wilkinson J, Nowicki M, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. *J Virol* 76(2):600-8. 2002.
- Ramalho F. Hepatitis C virus infection and liver steatosis. *Antiviral Res* 60(2): 125-7. 2003.

- Ranjith-Kumar CT, Santos JL, Gutshall LL, et al. Enzymatic activities of the GB virus-B RNA-dependent RNA polymerase. *Virology* 312(2):270-80. 2003.
- Randall G, Rice CM. Hepatitis C virus cell culture replication systems: their potential use for the development of antiviral therapies. *Curr Opin Infect Dis* 14(6):743-7. 2001.
- Randall G, Grakoui A, Rice CM. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. *Proc Natl Acad Sci USA* 100(1):235-40. 2003.
- Ratziu V, Trabut JB, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C. *Curr Gastroenterol Rep* 6(1): 22-9. 2004.
- Rawlins MD. Cutting the cost of drug development? *Nat Rev Drug Discov* 3(4):360-4. 2004.
- Ray PS, Das S. Inhibition of hepatitis C virus IRES-mediated translation by small RNAs analogous to stem-loop structures of the 5'-untranslated region. *Nucleic Acids Res* 32(5):1678-87. 2004.
- Ray RB, Lagging LM, Meyer K, et al. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. *Virus Res* 37(3):209-20. 1995.
- Ray RB, Lagging LM, Meyer K, Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. *J Virol* 70(7):4438-43. 1996a.
- Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. *Virology* 226(2):176-82. 1996b.
- Ray RB, Steele R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. *J Biol Chem* 272(17):10983-6. 1997.
- Ray S, Broor SL, Vaishnav Y, et al. Transforming growth factor beta in hepatitis C virus infection: *in vivo* and *in vitro* findings. *J Gastroenterol Hepatol* 18(4):393-403. 2003.
- Ray SC, Mao Q, Lanford RE, et al. Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. *J Virol* 74(7):3058-66. 2000.
- Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. *Clin Immunol* 101(3):284-8. 2001.
- Reddy TJ, Chan L, Turcotte N, et al. Further SAR studies on novel small molecule inhibitors of the hepatitis C (HCV) NS5B polymerase. *Bioorg Med Chem Lett* 13(19):3341-4. 2003.
- Reed KE, Grakoui A, Rice CM. Hepatitis C virus-encoded NS2-3 protease: cleavage-site mutagenesis and requirements for bimolecular cleavage. *J Virol* 69(7):4127-36. 1995.

- Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. *Curr Top Microbiol Immunol* 242:55-84. 2000.
- Reignat S, Webster GJ, Brown D, et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. *J Exp Med* 195(9):1089-101. 2002.
- Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype 1. Abstract 136. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Resti M, Azzari C, Moriondo M, et al. Injection drug use facilitates hepatitis C virus infection of peripheral blood mononuclear cells. *Clin Infect Dis* 35(3):236-9. 2002.
- Reyes GR. The nonstructural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. *J Biomed Sci* 9(3):187-97. 2002.
- Reynolds JE, Kaminski A, Kettinen HJ, et al. Unique features of internal initiation of hepatitis C virus RNA translation. *EMBO J* 14(23):6010-20. 1995.
- Rico MA, Quiroga JA, Subira D, et al. Features of the CD4+ T-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levels. *J Hepatol* 36(3):408-16. 2002.
- Rigamonti C, Andorno S, Maduli E, et al. Iron, hepatic stellate cells and fibrosis in chronic hepatitis C. *Eur J Clin Invest* 32 Suppl 1:28-35. 2002.
- Rigamonti C, Mottaran E, Reale E, et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. *Hepatology* 38(1):42-9. 2003.
- Rijnbrand R, Bredenbeek P, van der Straaten T, et al. Almost the entire 5' non-translated region of hepatitis C virus is required for cap-independent translation. *FEBS Lett* 365(2-3):115-9. 1995.
- Rispeter K, Lu M, Behrens SE, et al. Hepatitis C virus variability: sequence analysis of an isolate after 10 years of chronic infection. *Virus Genes* 21(3):179-88. 2000.
- Rivas-Estilla AM, Svitkin Y, Lopez Lastra M, et al. PKR-dependent mechanisms of gene expression from a subgenomic hepatitis C virus clone. *J Virol* 76(21):10637-53. 2002.
- Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. *Gut* 18(12):997-1003. 1977.
- Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. *Arch Virol* 143(12):2493-503. 1998.

- Robinson R. RNAi therapeutics: how likely, how soon? *PLoS Biol* 2(1):18-20. 2004.
- Roccasecca R, Folgori A, Ercole BB, et al. Induction of cross-reactive humoral immune response by immunization with mimotopes of the hypervariable region 1 of the hepatitis C virus. *Int Rev Immunol* 20(2):289-300. 2001.
- Roccasecca R, Ansuini H, Vitelli A, et al. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. *J Virol* 77(3):1856-67. 2003.
- Rodríguez-Iñigo E, Casqueiro M, Navas S, et al. Fluorescent "in situ" hybridization of hepatitis C virus RNA in peripheral blood mononuclear cells from patients with chronic hepatitis C. *J Med Virol* 60(3):269-74. 2000.
- Rollier C, Drexhage JA, Verstrepen BE, et al. Chronic hepatitis C virus infection established and maintained in chimpanzees independent of dendritic cell impairment. *Hepatology* 38(4):851-8. 2003.
- Rollier C, Depla E, Drexhage JA, et al. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. *J Virol* 78(1):187-96. 2004.
- Romero MJ, Bosch-Morell F, Romero B, et al. Serum malondialdehyde: possible use for the clinical management of chronic hepatitis C patients. *Free Radic Biol Med* 25(9):993-7. 1998.
- Romero-Gómez M, Castellano-Megias VM, Grande L, et al. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. *Am J Gastroenterol* 98(5):1135-41. 2003.
- Roque-Afonso AM, Robain M, Simoneau D, et al. Influence of CD4 cell counts on the genetic heterogeneity of hepatitis C virus in patients coinfecting with human immunodeficiency virus. *J Infect Dis* 185(6):728-33. 2002.
- Rosa D, Campagnoli S, Moretto C, et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. *Proc Natl Acad Sci USA* 93(5):1759-63. 1996.
- Rosen HR, Miner C, Sasaki AW, et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. *Hepatology* 35(1):190-8. 2002.
- Roth E, Pircher H. IFN- $\gamma$  promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells. *J Immunol* 172(3):1588-94. 2004.
- Roulot D, Durand H, Coste T, et al. Quantitative analysis of transforming growth factor beta 1 messenger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease. *Hepatology* 21(2):298-304. 1995.

- Roussel J, Pillez A, Montpellier C, et al. Characterization of the expression of the hepatitis C virus F protein. *J Gen Virol* 84(Pt 7):1751-9. 2003.
- Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. *J Hepatol* 33(1):106-15. 2000.
- Rubbia-Brandt L, Leandro G, Spahr L, et al. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. *Histopathology* 39(2):119-24. 2001.
- Rubbia-Brandt L, Taylor S, Gindre P, et al. Lack of *in vivo* blockade of Fas- and TNFR1-mediated hepatocyte apoptosis by the hepatitis C virus. *J Pathol* 197(5):617-23. 2002.
- Ruggieri A, Harada T, Matsuura Y, Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. *Virology* 229(1):68-76. 1997.
- Ruppert J, Alexander J, Snoke K, et al. Effect of T-cell receptor antagonism on interaction between T cells and antigen-presenting cells and on T-cell signaling events. *Proc Natl Acad Sci USA* 90(7):2671-5. 1993.
- Ruster B, Zeuzem S, Krump-Konvalinkova V, et al. Comparative sequence analysis of the core- and NS5-region of hepatitis C virus from tumor and adjacent non-tumor tissue. *J Med Virol* 63(2):128-34. 2001.
- Ryu KJ, Kim JH, Lee SW. Ribozyme-mediated selective induction of new gene activity in hepatitis C virus internal ribosome entry site-expressing cells by targeted trans-splicing. *Mol Ther* 7(3):386-95. 2003.
- Sabile A, Perlemuter G, Bono F, et al. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. *Hepatology* 30(4):1064-76. 1999.
- Sachs AB. Cell cycle-dependent translation initiation: IRES elements prevail. *Cell* 101(3):243-5. 2000.
- Satoi J, Murata K, Lechmann M, et al. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins. *J Virol* 75(24):12121-7. 2001.
- Saito H, Tada S, Wakabayashi K, et al. The detection of IRF-1 promoter polymorphisms and their possible contribution to T helper 1 response in chronic hepatitis C. *J Interferon Cytokine Res* 22(6):693-700. 2002.
- Saito S, Kato N, Hijikata M, et al. Comparison of hypervariable regions (HVR1 and HVR2) in positive- and negative-stranded hepatitis C virus RNA in cancerous and non-cancerous liver tissue, peripheral blood mononuclear cells and serum from a patient with hepatocellular carcinoma. *Int J Cancer* 67(2):199-203. 1996.



Sakai A, St. Claire M, Faulk K, et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. *Proc Natl Acad Sci* 100(20):11646-51. 2003.

Sakaida I, Nagatomi A, Hironaka K, et al. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy. *Am J Gastroenterol* 94(2):489-96. 1999.

Sakamoto N, Wu CH, Wu GY. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. *J Clin Invest* 98(12):2720-8. 1996.

Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. *J Virol* 69(6):3893-6. 1995.

Saksela K. Human viruses under attack by small inhibitory RNA. *Trends Microbiol* 11(8):345-7. 2003.

Sansonno D, Lotesoriere C, Cornacchiulo V, et al. Hepatitis C virus infection involves CD34<sup>+</sup> hematopoietic progenitor cells in hepatitis C virus chronic carriers. *Blood* 92(9):3328-37. 1998.

Sansonno D, Lauletta G, Nisi L, et al. Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia. *Clin Exp Immunol* 133(2):275-82. 2003.

Santolini E, Migliaccio G, La Monica N. Biosynthesis and biochemical properties of the hepatitis C virus core protein. *J Virol* 68(6):3631-41. 1994.

Sarih M, Bouchrit N, Benslimane A. Different cytokine profiles of peripheral blood mononuclear cells from patients with persistent and self-limited hepatitis C virus infection. *Immunol Lett* 74(2):117-20. 2000.

Sarnow P. Viral internal ribosome entry site elements: novel ribosome-RNA complexes and roles in viral pathogenesis. *J Virol* 77(5):2801-6. 2003.

Sarobe P, Lasarte JJ, Casares N, et al. Abnormal priming of CD4<sup>+</sup> T cells by dendritic cells "expressing hepatitis C virus core and E1 proteins. *J Virol* 76(10):5062-70. 2002.

Sarobe P, Lasarte JJ, Zabaleta A, et al. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit *in vivo* induction of cellular immune responses. *J Virol* 77(20):10862-71. 2003.

Sasaki M, Yamauchi K, Nakanishi T, et al. In vitro binding of hepatitis C virus to CD81-positive and -negative human cell lines. *J Gastroenterol Hepatol* 18(1):74-9. 2003.

Saxena S, Jonsson ZO, Dutta A. Small RNAs with imperfect match to endogenous mRNA repress translation: implications for off-target activity of siRNA in mammalian cells. *J Biol Chem* 278(45): 44312-9. 2003.

Sbardellati A, Scarselli E, Verschoor E, et al. Generation of infectious and transmissible virions from a GB virus B full-length consensus clone in tamarins. *J Gen Virol* 82(Pt 10):2437-48. 2001.

Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. *Proc Natl Acad Sci USA* 101(7):1892-7. 2004.

Scarselli E, Ansuini H, Cerino R, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. *EMBO J* 21(19):5017-25. 2002.

Schinkel J, de Jong MD, Bruning B, et al. The potentiating effect of ribavirin on interferon in the treatment of hepatitis C: lack of evidence for ribavirin-induced viral mutagenesis. *Antivir Ther* 8(6):535-40. 2003.

Schinkel J, Spaan WJM, Kroes ACM. Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions. *Antivir Ther* 9:275–286. 2004.

Schlaak JF, Schramm C, Radecke K, et al. Sustained suppression of HCV replication and inflammatory activity after interleukin-2 therapy in patients with HIV/hepatitis C virus coinfection. *J Acquir Immune Defic Syndr* 29(2):145-8. 2002.

Schneider-Schaulies J. Cellular receptors for viruses: links to tropism and pathogenesis. *J Gen Virol* 81(Pt 6):1413-29. 2000.

Scholle F, Li K, Bodola F, et al. Virus-host cell interactions during hepatitis C virus RNA replication: impact of polyprotein expression on the cellular transcriptome and cell cycle association with viral RNA synthesis. *J Virol* 78(3): 1513-24. 2004.

Schuster C, Isel C, Imbert I, et al. Secondary structure of the 3' terminus of hepatitis C virus minus-strand RNA. *J Virol* 76(16): 8058-68. 2002.

Selby MJ, Choo QL, Berger K, et al. Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome. *J Gen Virol* 74 ( Pt 6):1103-13. 1993.

Selin LK, Lin MY, Kraemer KA, et al. Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. *Immunity* 11(6):733-42. 1999.

Seo MY, Abrignani S, Houghton M, Han JH. Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. *J Virol* 77(1):810-2. 2003.

Seong YR, Choi S, Lim JS, et al. Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses. *Vaccine* 19(20-22):2955-64. 2001.

Serafino A, Valli MB, Andreola F, et al. Suggested role of the Golgi apparatus and endoplasmic reticulum for crucial sites of hepatitis C virus replication in human lymphoblastoid cells infected *in vitro*. *J Med Virol* 70(1):31-41. 2003.

Shackel NA, McGuinness PH, Abbott CA, et al. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. *Am J Pathol* 160(2):641-54. 2002.

Shata MT, Anthony DD, Carlson NL, et al. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. *J Viral Hepat* 9(6):400-10. 2002.

Shata MT, Tricoche N, Perkus M, et al. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. *Virology* 314(2):601-16. 2003.

Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. *Science* 300(5617):337-9. 2003.

Shedlofsky SI. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question? *Am J Gastroenterol* 97(5):1093-6. 2002.

Sheridan I, Pybus OG, Holmes EC, Klenerman P. High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. *J Virol* 78(7):3447-54. 2004.

Sherman KE, O'Brien J, Gutierrez AG, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. *J Clin Microbiol* 31(10):2679-82. 1993.

Sherman KE, Sickler J, Aranda-Michel J, et al. Rimantadine for treatment of hepatitis C infection in liver transplant recipients. *Liver Transpl Surg* 5(1):25-8. 1999.

Shi ST, Polyak SJ, Tu H, et al. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. *Virology* 292(2):198-210. 2002.

Shi ST, Lee KJ, Aizaki H, et al. Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2. *J Virol* 77(7):4160-8. 2003.

Shibata M, Morizane T, Uchida T, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. *Lancet* 351(9118):1773-7. 1998.

Shields PL, Morland CM, Salmon M, et al. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. *J Immunol* 163(11):6236-43. 1999.

- Shim J, Larson G, Lai V, et al. Canonical 3'-deoxyribonucleotides as a chain terminator for HCV NS5B RNA-dependent RNA polymerase. *Antiviral Res* 58(3):243-251. 2003.
- Shimakami T, Hijikata M, Luo H, et al. Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. *J Virol* 78(6):2738-48. 2004.
- Shimazaki T, Honda M, Kaneko S, et al. Inhibition of internal ribosomal entry site-directed translation of HCV by recombinant IFN- $\alpha$  correlates with a reduced La protein. *Hepatology* 35(1):199-208. 2002.
- Shimizu YK, Feinstone SM, Kohara M, et al. Hepatitis C virus: detection of intracellular virus particles by electron microscopy. *Hepatology* 23(2):205-9. 1996.
- Shimizu I. Impact of oestrogens on the progression of liver disease. *Liver Int* 23(1):63-9. 2003.
- Shimoda K, Begum NA, Shibuta K, et al. Interleukin-8 and hIRH (SDF1- $\alpha$ /PBSF) mRNA expression and histological activity index in patients with chronic hepatitis C. *Hepatology* 28(1):108-15. 1998.
- Shimoike T, Mimori S, Tani H, et al. Interaction of hepatitis C virus core protein with viral sense RNA and suppression of its translation. *J Virol* 73(12):9718-25. 1999.
- Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. *Gastroenterology* 126(3):840-8. 2004.
- Shiratori Y, Perelson AS, Weinberger L, et al. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon- $\beta$ . *J Hepatol* 33(2):313-22. 2000.
- Shirota Y, Luo H, Qin W, et al. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. *J Biol Chem* 277(13):11149-55. 2002.
- Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. *J Exp Med* 197(12):1645-55. 2003.
- Shoukry NH, Sidney J, Sette A, Walker CM. Conserved Hierarchy of Helper T Cell Responses in a Chimpanzee during Primary and Secondary Hepatitis C Virus Infections. *J Immunol* 172(1):483-92. 2004.
- Silvestri G, Feinberg MB. Turnover of lymphocytes and conceptual paradigms in HIV infection. *J Clin Invest* 112(6):821-4. 2003.
- Silvestri L, Sonzogni L, De Silvestri A, et al. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. *Int J Cancer* 104(3):310-7. 2003.

- Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. *Hepatology* 19(5):1321-4. 1994a.
- Simmonds P, Smith DB, McOmish F, et al. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. *J Gen Virol* 75 ( Pt 5):1053-61. 1994b.
- Simmonds P. The origin and evolution of hepatitis viruses in humans. *J Gen Virol* 82(Pt 4):693-712. 2001.
- Simons JN, Leary TP, Dawson GJ, et al. Isolation of novel virus-like sequences associated with human hepatitis. *Nat Med* 1(6):564-9. 1995a.
- Simons JN, Pilot-Matias TJ, Leary TP, et al. Identification of two flavivirus-like genomes in the GB hepatitis agent. *Proc Natl Acad Sci USA* 92(8):3401-5. 1995b.
- Simpson KJ, Henderson NC, Bone-Larson CL, et al. Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles. *Clin Sci (Lond)* Jan;104(1):47-63. 2003.
- Sintchak MD, Nimmesgern E. The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors. *Immunopharmacology* 47(2-3):163-84. 2000.
- Sjogren MH, Holtzmuller K, Smith M, et al. Sustained Antiviral Response with Consensus Interferon (CIFN) Plus Ribavirin or Interferon Alfa-2b (INF Alfa-2b) Plus Ribavirin in Treatment Naïve Subjects with Chronic Hepatitis C. A Pilot Study. Abstract 100345. *Hepatology* ID 593 (oral session). *Hepatology* Vol 36, No 4, Part 2 of 2. October 2002.
- Sledz CA, Holko M, de Veer MJ, et al. Activation of the interferon system by short-interfering RNAs. *Nat Cell Biol* 5(9):834-9. 2003.
- Smith DB, Simmonds P. Review: molecular epidemiology of hepatitis C virus. *J Gastroenterol Hepatol* 12(7):522-7. 1997.
- Smith MW, Yue ZN, Geiss GK, et al. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. *Cancer Res* 63(4):859-64. 2003a.
- Smith MW, Yue ZN, Korth MJ, et al. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. *Hepatology* 38(6): 1458-67. 2003b.
- Snell NJ. Ribavirin—current status of a broad spectrum antiviral agent. *Expert Opin Pharmacother* 2(8):1317-24. 2001.
- Sobao Y, Tomiyama H, Nakamura S, et al. Visual demonstration of hepatitis C virus-specific memory CD8+ T-cell expansion in patients with acute hepatitis C. *Hepatology* 33(1):287-94. 2001.

- Sobue S, Nomura T, Ishikawa T, et al. T<sub>H</sub>1/ T<sub>H</sub>2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. *J Gastroenterol* 36(8):544-51. 2001.
- Soguero C, Joo M, Chianese-Bullock KA, et al. Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. *J Virol* 76(18):9345-54. 2002.
- Soilleux EJ, Morris LS, Rushbrook S, et al. Expression of human immunodeficiency virus (HIV)-binding lectin DC-SIGNR: Consequences for HIV infection and immunity. *Hum Pathol* 33(6):652-9. 2002.
- Soilleux EJ. DC-SIGN (dendritic cell-specific ICAM-grabbing non-integrin) and DC-SIGN-related (DC-SIGNR): friend or foe? *Clin Sci (Lond)* 104(4):437-46. 2003.
- Somsouk M, Lauer GM, Casson D, et al. Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. *Gastroenterology* 124(7):1946-9. 2003.
- Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. *Nat Med* 9(3):347-51. 2003.
- Song J, Fujii M, Wang F, et al. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon. *J Gen Virol* 80 ( Pt 4):879-86. 1999.
- Sonzogni L, Silvestri L, De Silvestri A, et al. Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. *Hepatology* 36(1):195-201. 2002.
- Soo HM, Garzino-Demo A, Hong W, et al. Expression of a full-length hepatitis C virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES. *Virology* 303(2):253-77. 2002.
- Soza A, Heller T, Doo E, et al. Pilot Study of Interferon Gamma for Chronic Hepatitis C. Abstract 106774. Digestive Disease Week. Orlando, Florida. 2003.
- Spahn CM, Kieft JS, Grassucci RA, et al. Hepatitis C virus IRES RNA-induced changes in the conformation of the 40s ribosomal subunit. *Science* 291(5510):1959-62. 2001.
- Spångberg K, Schwartz S. Poly(C)-binding protein interacts with the hepatitis C virus 5' untranslated region. *J Gen Virol* 80 ( Pt 6):1371-6. 1999.
- Spångberg K, Wiklund L, Schwartz S. Binding of the La autoantigen to the hepatitis C virus 3' untranslated region protects the RNA from rapid degradation *in vitro*. *J Gen Virol* 82(Pt 1):113-20. 2001.
- Sperandio D, Gangloff AR, Litvak J, et al. Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease. *Bioorg Med Chem Lett* 12(21):3129-33. 2002.
- Sreekumar R, Rosado B, Rasmussen D, et al. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. *Hepatology* 38(1):244-51. 2003.

Sreenarasimhaiah J, Jaramillo A, Crippin J, et al. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon- $\alpha$  and ribavirin treatment for chronic hepatitis C virus infection. *Hum Immunol* 64(5):497-504. 2003.

Stein I, Itin A, Einat P, et al. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. *Mol Cell Biol* 18(6):3112-9.

Steinhauer DA, Domingo E, Holland JJ. Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. *Gene* 122(2):281-8. 1992.

Stoneley M, Chappell SA, Jopling CL, et al. c-Myc protein synthesis is initiated from the internal ribosome entry segment during apoptosis. *Mol Cell Biol* 20(4):1162-9. 2000.

Street A, Macdonald A, Crowder K, Harris M. The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase dependent survival signalling cascade. *J Biol Chem* 279(13):12232-41. 2004.

Stuyver LJ, Whitaker T, McBrayer TR, et al. Ribonucleoside analogue that blocks replication of bovine viral diarrhoea and hepatitis C viruses in culture. *Antimicrob Agents Chemother* 47(1):244-54. 2003a.

Stuyver LJ, McBrayer TR, Tharnish PM, et al. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. *J Virol* 77(19):10689-94. 2003b.

Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. *Proc Natl Acad Sci USA* 99(24):15669-74. 2002.

Su HL, Liao CL, Lin YL. Japanese encephalitis virus infection initiates endoplasmic reticulum stress and an unfolded protein response. *J Virol* 76(9):4162-71. 2002.

Sugimoto K, Stadanlick J, Ikeda F, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. *Hepatology* 37(3):590-9. 2003a.

Sugimoto K, Ikeda F, Stadanlick J, et al. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. *Hepatology* 38:1437-1448. 2003b.

Sugimoto Y, Kuzushita N, Takehara T, et al. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. *J Viral Hepat* 9(5):377-84. 2002.

Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. *J Hepatol* 33(4):616-22. 2000.

Summa V, Petrocchi A, Pace P, et al. Discovery of  $\alpha,\gamma$ -diketo acids as potent selective and reversible inhibitors of Hepatitis C Virus NS5b RNA-dependent RNA polymerase. *J Med Chem* 47(1):14-7. 2004.

- Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. *Science* 300(5617):339-42. 2003.
- Sung VM, Shimodaira S, Doughty AL, et al. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus *in vivo* and *in vitro*: the apoptotic effects of virus infection. *J Virol* 77(3):2134-46. 2003.
- Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. *Semin Liver Dis* 24(1):77-88. 2004.
- Suzuki F, Chayama K, Tsubota A, et al. Twice-daily administration of interferon- $\beta$  for chronic hepatitis C is not superior to a once-daily regimen. *J Gastroenterol* 36(4):242-7. 2001.
- Suzuki R, Matsuura Y, Suzuki T, et al. Nuclear localization of the truncated hepatitis C virus core protein with its hydrophobic C terminus deleted. *J Gen Virol* 76 ( Pt 1):53-61. 1995.
- Szabó E, Páska C, Kaposi Novák P, et al. Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. *Pathol Oncol Res* 10(1):5-11. 2004.
- Szmunn W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. *N Engl J Med* 303(15):833-41. 1980.
- Tagashira M, Yamamoto K, Fujio K, et al. Expression of perforin and Fas ligand mRNA in the liver of viral hepatitis. *J Clin Immunol* 20(5):347-53. 2000.
- Tai DI, Tsai SL, Chen YM, et al. Activation of nuclear factor  $\kappa$ B in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. *Hepatology* 31(3):656-64. 2000.
- Takaku S, Nakagawa Y, Shimizu M, et al. Induction of hepatic injury by hepatitis C virus-specific CD8+ murine cytotoxic T lymphocytes in transgenic mice expressing the viral structural genes. *Biochem Biophys Res Commun* 301(2):330-7. 2003.
- Takamizawa A, Mori C, Fuke I, et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. *J Virol* 65(3):1105-13. 1991.
- Takikawa S, Ishii K, Aizaki H, et al. Cell fusion activity of hepatitis C virus envelope proteins. *J Virol* 2000 Jun;74(11):5066-74. 2000.
- Talal AH et al. Effect of hepatitis C virus and HIV-1 on hepatic parenchymal and mononuclear cell proliferation and apoptosis. Abstract 183 at Digestive Disease Week 2000; May 21-24, 2000; San Diego, California. 2000.
- Tallet-Lopez B, Aldaz-Carroll L, Chabas S, et al. Antisense oligonucleotides targeted to the domain III<sub>d</sub> of the hepatitis C virus IRES compete with 40S ribosomal subunit binding and prevent *in vitro* translation. *Nucleic Acids Res* 31(2):734-42. 2003.



- Tam RC, Pai B, Bard J, et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. *J Hepatol* 30(3):376-82. 1999.
- Tam RC, Ramasamy K, Bard J, et al. The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels. *Antimicrob Agents Chemother* 44(5):1276-83. 2000.
- Tan SL, Nakao H, He Y, et al. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. *Proc Natl Acad Sci USA* 1999 96(10):5533-8. 1999.
- Tan SL, Katze MG. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. *Virology* 2001 284(1):1-12. 2001.
- Tan SL, Pause A, Shi Y, Sonenberg N. Hepatitis C therapeutics: current status and emerging strategies. *Nat Rev Drug Discov* 1(11):867-81. 2002.
- Tanabe Y, Sakamoto N, Enomoto N, et al. Synergistic Inhibition of Intracellular Hepatitis C Virus Replication by Combination of Ribavirin and Interferon- $\alpha$ . *J Infect Dis* 189(7):1129-39. 2004.
- Tanaka Y, Shimoike T, Ishii K, et al. Selective binding of hepatitis C virus core protein to synthetic oligonucleotides corresponding to the 5' untranslated region of the viral genome. *Virology* 2000 270(1):229-36. 2000.
- Tanaka Y, Furuta T, Suzuki S, et al. Impact of interleukin-1 $\beta$  genetic polymorphisms on the development of hepatitis C virus-related hepatocellular carcinoma in Japan. *J Infect Dis* 187(11):1822-5. 2003.
- Tanji Y, Hijikata M, Satoh S, et al. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. *J Virol* 69(3):1575-81. 1995.
- Tardif KD, Mori K, Siddiqui A. Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway. *J Virol* 76(15):7453-9. 2002.
- Tardif KD, Siddiqui A. Cell surface expression of major histocompatibility complex class I molecules is reduced in hepatitis C virus subgenomic replicon-expressing cells. *J Virol* 77(21):11644-50. 2003.
- Tardif KD, Mori K, Kaufman RJ, Siddiqui A. Hepatitis C virus suppresses the IRE1-XBP1 pathway of the unfolded protein response. *J Biol Chem* 279(17):17158-64. 2004.
- Taylor DR, Shi ST, Romano PR, et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. *Science* 285(5424):107-10. 1999.

Taylor DR, Tian B, Romano PR, et al. Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain. *J Virol* 75(3):1265-73. 2001a.

Taylor DR. Hepatitis C virus and interferon resistance: it's more than just PKR. *Hepatology* 33(6):1547-9. 2001b.

Tedeschi V, Akatsuka T, Shih JW, et al. A specific antibody response to HCV E2 elicited in mice by intramuscular inoculation of plasmid DNA containing coding sequences for E2. *Hepatology* 25(2):459-62. 1997.

Tellinghuisen TL, Rice CM. Interaction between hepatitis C virus proteins and host cell factors. *Curr Opin Microbiol* 5(4):419-27. 2002.

Temiz NA, Bahar I. Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. *Proteins* 49(1):61-70. 2002.

Terada R, Yamamoto K, Hakoda T, et al. Stromal cell-derived factor-1 from biliary epithelial cells recruits CXCR4-positive cells: implications for inflammatory liver diseases. *Lab Invest* 83(5):665-72. 2003.

Thibault V, Delaugerre C, Calvez V, et al. Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial. *Hepatology* 35(1):238-9. 2002.

Thibeault D, Maurice R, Pilote L, et al. In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus. *J Biol Chem* 276(49):46678-84. 2001.

Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. *J Exp Med* 194(10):1395-406. 2001.

Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. *Proc Natl Acad Sci USA* 99(24):15661-8. 2002.

Thimme R, Wieland S, Steiger C, et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. *J Virol* 77(1):68-76. 2003.

Thio CL, Thomas DL, Goedert JJ, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. *J Infect Dis* 184(1):16-21. 2001.

Thio CL, Gao X, Goedert JJ, et al. HLA-Cw\*04 and hepatitis C virus persistence. *J Virol* 76(10):4792-7. 2002.

Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. *J Infect Dis* 174(4):690-5. 1996.

- Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. *JAMA* 2000 284(4):450-6. 2000.
- Thomson M, Nascimbeni M, Havert MB, et al. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. *J Virol* 77(2):862-70. 2003.
- Thomssen R, Bonk S, Propfe C, et al. Association of hepatitis C virus in human sera with  $\beta$ -lipoprotein. *Med Microbiol Immunol (Berl)* 181(5):293-300. 1992.
- Thomssen R, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of  $\beta$ -lipoproteins and immunoglobulins. *Med Microbiol Immunol (Berl)* 182(6):329-34. 1993.
- Thorburn D, Curry G, Spooner R, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. *Gut* 50(2):248-52. 2002.
- Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. *Nat Genet* 31(4):339-46. 2002.
- Thuluvath PJ, Maheshwari A, Mehdi J, et al. Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naive patients with chronic hepatitis C. *Gut* 53(1):130-5. 2004.
- Tobler LH, Busch MP. History of posttransfusion hepatitis. *Clin Chem* 43(8 Pt 2):1487-93. 1997.
- Togashi H, Shinzawa H, Matsuo T, et al. High content of lipid hydroperoxides in livers from patients with chronic hepatitis C. *J Med* 31(1-2):3-14. 2000.
- Tomei L, Failla C, Santolini E, et al. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. *J Virol* 67(7):4017-26. 1993.
- Tomei L, Altamura S, Bartholomew L, et al. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. *J Virol* Dec;77(24):13225-31. 2003.
- Tomei L, Altamura S, Bartholomew L, et al. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. *J Virol* 78(2):938-46. 2004.
- Tong MJ, Blatt LM, Resser KJ, et al. Treatment of chronic hepatitis C virus infection with recombinant consensus interferon. *J Interferon Cytokine Res* 18(2):81-6. 1998.
- Tordjmann T, Soulie A, Guettier C, et al. Perforin and granzyme B lytic protein expression during chronic viral and autoimmune hepatitis. *Liver* 18(6):391-7.
- Tossing G. Merimepodib (vertex). *Idrugs* 6(4):372-6. 2003.

- Toubi E, Kessel A, Goldstein L, et al. Enhanced peripheral T-cell apoptosis in chronic hepatitis C virus infection: association with liver disease severity. *J Hepatol* 35(6):774-80. 2001.
- Toulmé JJ. New candidates for true antisense. *Nat Biotechnol* 19(1):17-8. 2001.
- Toulmé JJ, Darfeuille F, Kolb G, et al. Modulating viral gene expression by aptamers to RNA structures. *Biol Cell* 95(3-4):229-38. 2003.
- Triyatni M, Saunier B, Maruvada P, et al. Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. *J Virol* 76(18):9335-44. 2002.
- Trobonjaca Z, Leithäuser F, Möller P, et al. Activating immunity in the liver. I. Liver dendritic cells (but not hepatocytes) are potent activators of IFN- $\gamma$  release by liver NKT cells. *J Immunol* 167(3):1413-22. 2001.
- Trobonjaca Z, Kröger A, Stober D, et al. Activating immunity in the liver. II. IFN- $\beta$  attenuates NK cell-dependent liver injury triggered by liver NKT cell activation. *J Immunol* 168(8):3763-70. 2002.
- Trowsdale J, Parham P. Defense strategies and immunity-related genes. *Eur J Immunol* 34(1):7-17. 2004.
- Trozzi C, Bartholomew L, Ceccacci A, et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. *J Virol* 77(6):3669-79. 2003.
- Tsai SL, Liaw YF, Chen MH, et al. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. *Hepatology* 25(2):449-58. 1997.
- Tsai SL, Chen YM, Chen MH, et al. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. *Gastroenterology* 115(4):954-65. 1998.
- Tseng CT, Miskovsky E, Houghton M, et al. Characterization of liver T-cell receptor  $\gamma\delta^+$  T cells obtained from individuals chronically infected with hepatitis C virus (HCV): evidence for these T cells playing a role in the liver pathology associated with HCV infections. *Hepatology* 33(5):1312-20. 2001.
- Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. *J Exp Med* 195(1):43-9. 2002.
- Tsuchihara K, Tanaka T, Hijikata M, et al. Specific interaction of polypyrimidine tract-binding protein with the extreme 3'-terminal structure of the hepatitis C virus genome, the 3'X. *J Virol* 71(9):6720-6. 1997.
- Tsuchihara K, Hijikata M, Fukuda K, et al. Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. *Virology* 258(1):100-7. 1999.

Tsukiyama-Kohara K, Iizuka N, Kohara M, et al. Internal ribosome entry site within hepatitis C virus RNA. *J Virol* 66(3):1476-83. 1992.

Tsushima H, Kawata S, Tamura S, et al. Reduced plasma transforming growth factor- $\beta$ 1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. *J Hepatol* 30(1):1-7. 1999.

Tsutsumi T, Suzuki T, Shimoike T, et al. Interaction of hepatitis C virus core protein with retinoid X receptor  $\alpha$  modulates its transcriptional activity. *Hepatology* 35(4):937-46. 2002a.

Tsutsumi T, Suzuki T, Moriya K, et al. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. *Virology* 304(2):415-24. 2002b.

Tsutsumi T, Suzuki T, Moriya K, et al. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. *Hepatology* 38(4):820-8. 2003.

Tu H, Gao L, Shi ST, et al. Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein. *Virology* 263(1):30-41. 1999.

Uberti-Foppa C, De Bona A, Morsica G, et al. Recombinant interleukin-2 for treatment of HIV reduces hepatitis C viral load in coinfecting patients. *AIDS* 13(1):140-1. 1999.

Ulsenheimer A, Gerlach JT, Gruener NH, et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. *Hepatology* 37(5):1189-98. 2003.

Urbani S, Uggeri J, Matsuura Y, et al. Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens. *Hepatology* 33(6):1533-43. 2001.

Valdez H, Anthony D, Farukhi F, et al. Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfecting patients. *AIDS* 14(15):2239-46. 2000.

Valdez H, Metcalf JA, Gripshover BM, et al. Effect of IL-2 therapy on plasma hepatitis C virus-RNA levels in HIV/hepatitis C virus co-infected patients. *AIDS* 15(5):661-2. 2001.

Valdez H, Carlson NL, Post AB, et al. HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. *AIDS* 16(8):1113-8. 2002.

Valgimigli M, Valgimigli L, Trere D, et al. Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. *Free Radic Res* 36(9):939-48. 2002.

VanCompernelle SE, Wiznycia AV, Rush JR, et al. Small molecule inhibition of hepatitis C virus E2 binding to CD81. *Virology* 314(1):371-80. 2003.

- van der Most RG, Murali-Krishna K, Lanier JG, et al. Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation. *Virology* 315(1):93-102. 2003.
- van Doorn LJ, Capriles I, Maertens G, et al. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. *J Virol* 69(2):773-8. 1995.
- van Doorn LJ, van Hoek K, de Martinoff G, et al. Serological and molecular analysis of hepatitis C virus envelope regions 1 and 2 during acute and chronic infections in chimpanzees. *J Med Virol* 52(4):441-50. 1997.
- van Kooyk Y, Geijtenbeek TB. DC-SIGN: escape mechanism for pathogens. *Nat Rev Immunol* 3(9):697-709. 2003.
- Varaklioti A, Vassilaki N, Georgopoulou U, Mavromara P. Alternate translation occurs within the core coding region of the hepatitis C viral genome. *J Biol Chem* 277(20):17713-21. 2002.
- Vargason JM, Szittyá G, Burgyán J, Tanaka Hall TM. Size selective recognition of siRNA by an RNA silencing suppressor. *Cell* 115(7):799-811. 2003.
- Vassilaki N, Mavromara P. Two alternative translation mechanisms are responsible for the expression of the HCV ARFP/F/core+1 coding open reading frame. *J Biol Chem* 278(42):40503-13. 2003.
- Vejbaesya S, Songsivilai S, Tanwandee T, et al. HLA association with hepatitis C virus infection. *Hum Immunol* 61(3):348-53. 2000.
- Villa E, Trande P, Grottola A, et al.  $\alpha$  but not  $\beta$  interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study. *Dig Dis Sci* 1996 Jun;41(6):1241-7. 1996.
- Vlahakis S, Villasis-Keever A, Gomez T, et al. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. *J Infect Dis* 188(10):1455-60. 2003.
- Vollmer J, Rankin R, Hartmann H, et al. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. *Antimicrob Agents Chemother* 48(6):2314-7. 2004.
- von Herrath MG, Fujinami RS, Whitton JL. Microorganisms and autoimmunity: making the barren field fertile? *Nat Rev Microbiol* 1(2):151-7. 2003.
- Vrolijk JM, Kwekkeboom J, Janssen HL, et al. Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection. *J Infect Dis* 188(10):1528-32. 2003.

- Vukmanović S, Neubert TA, Santori FR. Could TCR antagonism explain associations between MHC genes and disease? *Trends Mol Med* 9(4):139-46. 2003.
- Vyas J, Elia A, Clemens MJ. Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA. *RNA* 9(7):858-870. 2003.
- Wack A, Soldaini E, Tseng C, et al. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. *Eur J Immunol* 31(1):166-75. 2001.
- Wagner CE, Mohler ML, Kang GS, et al. Synthesis of 1-boraadamantaneamine derivatives with selective astrocyte vs C6 glioma antiproliferative activity. A novel class of anti-hepatitis C agents with potential to bind CD81. *J Med Chem* 46(14):2823-33. 2003.
- Wakita T, Katsume A, Kato J, et al. Possible role of cytotoxic T cells in acute liver injury in hepatitis C virus cDNA transgenic mice mediated by Cre/loxP system. *J Med Virol* 62(3):308-17. 2000.
- Walewski JL, Keller TR, Stump DD, et al. Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. *RNA* 7(5):710-21. 2001.
- Walker MP, Hong Z. HCV RNA-dependent RNA polymerase as a target for antiviral development. *Curr Opin Pharmacol* 2(5):534-40. 2002.
- Wang C, Sarnow P, Siddiqui A. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. *J Virol* 67(6):3338-44. 1993.
- Wang C, Sarnow P, Siddiqui A. A conserved helical element is essential for internal initiation of translation of hepatitis C virus RNA. *J Virol* 68(11):7301-7. 1994.
- Wang C, Le SY, Ali N, et al. An RNA pseudoknot is an essential structural element of the internal ribosome entry site located within the hepatitis C virus 5' noncoding region. *RNA* 1(5):526-37. 1995.
- Wang C, Pflugheber J, Sumpter R Jr, et al.  $\alpha$  interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. *J Virol* 77(7):3898-912. 2003.
- Wang H, Eckels DD. Mutations in immunodominant T cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T cell recognition. *J Immunol* 162(7):4177-83. 1999.
- Wang H, Bian T, Merrill SJ, Eckels DD. Sequence variation in the gene encoding the nonstructural 3 protein of hepatitis C virus: evidence for immune selection. *J Mol Evol* 54(4):465-73. 2002.
- Wang M, Ng KK, Cherney MM, et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. *J Biol Chem* 278(11):9489-95. 2003.

- Wang T<sub>H</sub>, Rijnbrand RC, Lemon SM. Core protein-coding sequence, but not core protein, modulates the efficiency of cap-independent translation directed by the internal ribosome entry site of hepatitis C virus. *J Virol* 74(23):11347-58. 2000.
- Wang Y, Kato N, Hoshida Y, et al. Interleukin-1 $\beta$  gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. *Hepatology* 37(1):65-71. 2003.
- Ward S, Lauer G, Isba R, et al. Cellular immune responses against hepatitis C virus: the evidence base 2002. *Clin Exp Immunol* 128(2):195-203. 2002.
- Waris G, Tardif KD, Siddiqui A. Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF- $\kappa$ B and STAT-3. *Biochem Pharmacol* 64(10):1425-30. 2002.
- Waris G, Livolsi A, Imbert V, et al. Hepatitis C virus NS5A and subgenomic replicon activate NF- $\kappa$ B via tyrosine phosphorylation of I $\kappa$ B $\alpha$  and its degradation by calpain protease. *J Biol Chem* 278(42):40778-87. 2003.
- Waris G, Sarker S, Siddiqui A. Two-step affinity purification of the hepatitis C virus ribonucleoprotein complex. *RNA* 10:321-329. 2004.
- Wasmuth HE, Werth A, Mueller T, et al. CC chemokine receptor 5  $\Delta$ 32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia. *J Mol Med* 82(1):64-69. 2004.
- Watanabe H, Iwata K, Sohda T, et al. Interferon  $\beta$  induction/interferon  $\alpha$  therapy in patients with interferon-resistant chronic hepatitis C. *Hepatology* 24(4):355-360. 2002.
- Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. *Hepatology* 38(5):1282-8. 2003a.
- Watashi K, Hijikata M, Tagawa A, et al. Modulation of retinoid signaling by a cytoplasmic viral protein via sequestration of Sp110b, a potent transcriptional corepressor of retinoic acid receptor, from the nucleus. *Mol Cell Biol* 23(21):7498-509. 2003b.
- Watashi K, Shimotohno K. The roles of hepatitis C virus proteins in modulation of cellular functions: A novel action mechanism of the HCV core protein on gene regulation by nuclear hormone receptors. *Cancer Sci* 94(11):937-43. 2003c.
- Watson MW, Jaksic A, Price P, et al. Interferon- $\gamma$  response by peripheral blood mononuclear cells to hepatitis C virus core antigen is reduced in patients with liver fibrosis. *J Infect Dis* 188(10):1533-6. 2003.
- Waxman L, Whitney M, Pollok BA, et al. Host cell factor requirement for hepatitis C virus enzyme maturation. *Proc Natl Acad Sci USA* 98(24):13931-5. 2001.



- Wedemeyer H, Mizukoshi E, Davis AR, et al. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. *J Virol* 75(23):11392-400. 2001.
- Wedemeyer H, He XS, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. *J Immunol* 169(6):3447-58. 2002.
- Wedemeyer H, Erhardt A, Schmiegel W, et al. Abstract 294. Safety and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, and liver cirrhosis. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2003.
- Weihofen A, Binns K, Lemberg MK, et al. Identification of signal peptide peptidase, a presenilin-type aspartic protease. *Science* 296(5576):2215-8. 2002.
- Weiner AJ, Brauer MJ, Rosenblatt J, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. *Virology* 180(2):842-8. 1991.
- Weiner A, Erickson AL, Kansopon J, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. *Proc Natl Acad Sci USA* 92(7):2755-9. 1995.
- Weiner AJ, Paliard X, Selby MJ, et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. *J Virol* 75(15):7142-8. 2001.
- Weinman SA, Belalcazar LM. Hepatitis C: A metabolic liver disease. *Gastroenterology* 126(3):917-9. 2004.
- Weiss G, Umlauf F, Urbanek M, et al. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. *J Infect Dis* 180(5):1452-8. 1999.
- Welch PJ, Tritz R, Yei S, et al. A potential therapeutic application of hairpin ribozymes: *in vitro* and *in vivo* studies of gene therapy for hepatitis C virus infection. *Gene Ther* 3(11):994-1001. 1996.
- Welch PJ, Yei S, Barber JR. Ribozyme gene therapy for hepatitis C virus infection. *Clin Diagn Virol* 10(2-3):163-71. 1998.
- Wellnitz S, Klumpp B, Barth H, et al. Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. *J Virol* 76(3):1181-93. 2002.
- Welsh RM. Assessing CD8 T cell number and dysfunction in the presence of antigen. *J Exp Med* 193(5):F19-22. 2001.

- Wertheimer AM, Miner C, Lewinsohn DM, et al. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. *Hepatology* 37(3):577-89. 2003.
- Westin J, Nordlinder H, Lagging M, et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. *J Hepatol* 37(6):837-42. 2002.
- Wherry EJ, Blattman JN, Murali-Krishna K, et al. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. *J Virol* 77(8):4911-27. 2003.
- Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. *J Virol* 78(11):5535-45. 2004.
- Whitney M, Stack JH, Darke PL, et al. A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity. *J Biomol Screen* 7(2):149-54. 2002.
- Wiklund L, Spångberg K, Schwartz S. Positive and negative effects on translation of the hepatitis C virus 3' untranslated region. *J Hum Virol* 5(1):8-16. 2002.
- Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. *Am J Gastroenterol* 97(3):700-6. 2002.
- Wilson JA, Jayasena S, Khvorova A, et al. RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. *Proc Natl Acad Sci USA* 100(5):2783-8. 2003.
- Wodarz D. Hepatitis C virus dynamics and pathology: the role of CTL and antibody responses. *J Gen Virol* 84(Pt 7):1743-50. 2003.
- Woitars RP, Lechmann M, Jung G, et al. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. *J Immunol* 159(2):1012-8. 1997.
- Woitars RP, Rockstroh JK, Beier I, et al. Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients. *AIDS* 13(11):1313-22. 1999.
- Woitars RP, Ahlenstiel G, Iwan A, et al. Frequency of the HIV-protective CC chemokine receptor 5- $\Delta$ 32/ $\Delta$ 32 genotype is increased in hepatitis C. *Gastroenterology* 122(7):1721-8. 2002.
- Wolfe ND, Escalante AA, Karesh WB, et al. Wild primate populations in emerging infectious disease research: the missing link? *Emerg Infect Dis* 4(2):149-58. 1998.
- Wolfe MS, Selkoe DJ. Intramembrane proteases--mixing oil and water. *Science* 296(5576):2156-7. 2002.

- Wong DK, Dudley DD, Afdhal NH, et al. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. *J Immunol* 160(3):1479-88. 1998.
- Wong DK, Dudley DD, Dohrenwend PB, et al. Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV. *J Virol* 75(3):1229-35. 2001.
- Wood J, Frederickson RM, Fields S, Patel AH. Hepatitis C virus 3'X region interacts with human ribosomal proteins. *J Virol* 75(3):1348-58. 2001.
- Woollard DJ, Grakoui A, Shoukry NH, et al. Characterization of HCV-specific Patr class II restricted CD4+ T cell responses in an acutely infected chimpanzee. *Hepatology* 38(5):1297-306. 2003.
- Wright M, Goldin R, Hellier S, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. *Gut* 52(8):1206-1210. 2003.
- Wu JZ. Internally located signal peptides direct hepatitis C virus polyprotein processing in the ER membrane. *IUBMB Life* 51(1):19-23. 2001.
- Wu JZ, Walker H, Lau JY, Hong Z. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. *Antimicrob Agents Chemother* 47(1):426-31. 2003.
- Wu V. Beefing up replication of the hepatitis C virus. *Hepatology* 33(6):1550-1. 2001.
- Wünschmann S, Medh JD, Klinzmann D, et al. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. *J Virol* 74(21):10055-62. 2000.
- Xie ZC, Riezu-Boj JI, Lasarte JJ, et al. Transmission of hepatitis C virus infection to tree shrews. *Virology* 244(2):513-20. 1998.
- Xu Z, Choi J, Yen TS, et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. *EMBO J* 20(14):3840-8. 2001.
- Yamaguchi K, Tanaka E, Higashi K, et al. Adaptation of hepatitis C virus for persistent infection in patients with acute hepatitis. *Gastroenterology* 106(5):1344-8. 1994.
- Yamanaka T, Uchida M, Doi T. Innate form of HCV core protein plays an important role in the localization and the function of HCV core protein. *Biochem Biophys Res Commun* 294(3):521-7. 2002.
- Yanagi M, Purcell RH, Emerson SU, Bukh J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. *Proc Natl Acad Sci USA* 94(16):8738-43. 1997.

- Yanagiya A, Ohka S, Hashida N, et al. Tissue-specific replicating capacity of a chimeric poliovirus that carries the internal ribosome entry site of hepatitis C virus in a new mouse model transgenic for the human poliovirus receptor. *J Virol* 77(19):10479-87. 2003.
- Yang SH, Lee CG, Lee CW, et al. Hepatitis C virus core inhibits the Fas-mediated p38 mitogen activated kinase signaling pathway in hepatocytes. *Mol Cells* 13(3):452-62. 2002.
- Yao N, Weber PC. Helicase, a target for novel inhibitors of hepatitis C virus. *Antivir Ther* 3(Suppl 3):93-7. 1998.
- Yao ZQ, Nguyen DT, Hiotellis AI, et al. Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway. *J Immunol* 167(9):5264-72. 2001.
- Yao ZQ, Eisen-Vandervelde A, Waggoner SN, et al. Direct binding of hepatitis C virus core to gC1qR on CD4+ and CD8+ T cells leads to impaired activation of Lck and Akt. *J Virol* 78(12):6409-19. 2004.
- Yasui K, Wakita T, Tsukiyama-Kohara K, et al. The native form and maturation process of hepatitis C virus core protein. *J Virol* 72(7):6048-55. 1998.
- Ye J, Wang C, Sumpter R Jr, et al. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. *Proc Natl Acad Sci USA* 100(26):15865-70. 2003.
- Ye K, Malinina L, Patel DJ. Recognition of small interfering RNA by a viral suppressor of RNA silencing. *Nature* 426(6968):874-8. 2003.
- Yee LJ, Tang J, Herrera J, et al. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. *Genes Immun* 1(6):386-90. 2000.
- Yee LJ, Tang J, Gibson AW, et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. *Hepatology* 33(3):708-12. 2001.
- Yee LJ, Perez KA, Tang J, et al. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. *J Infect Dis* 187(8):1264-71. 2003.
- Yeh CT, Hwang DR, Lai HY, Hsu JT. Inhibition of authentic hepatitis C virus replication by sodium stibogluconate. *Biochem Biophys Res Commun* 310(2):537-41. 2003.
- Yeung KS, Meanwell NA, Qiu Z, et al. Structure-activity relationship studies of a bisbenzimidazole-based, Zn<sup>2+</sup>-dependent inhibitor of HCV NS3 serine protease. *Bioorg Med Chem Lett* 11(17):2355-9. 2001.
- Yi M, Lemon SM. 3' nontranslated RNA signals required for replication of hepatitis C virus RNA. *J Virol* 77(6): 3557-68. 2003a.

- Yi M, Lemon SM. Structure-function analysis of the 3' stem-loop of hepatitis C virus genomic RNA and its role in viral RNA replication. *RNA* 9(3): 331-45. 2003b.
- Yokota T, Sakamoto N, Enomoto N, et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. *EMBO Rep* 4(6):1-7. 2003.
- Yoshida H, Kato N, Shiratori Y, et al. Hepatitis C virus core protein activates nuclear factor  $\kappa$ B-dependent signaling through tumor necrosis factor receptor-associated factor. *J Biol Chem* 276(19):16399-405. 2001.
- Yoshida T, Hanada T, Tokuhisa T, et al. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. *J Exp Med* 196(5):641-53. 2002.
- You LR, Chen CM, Lee YH. Hepatitis C virus core protein enhances NF- $\kappa$ B signal pathway triggering by lymphotoxin- $\beta$  receptor ligand and tumor necrosis factor  $\alpha$ . *J Virol* 73(2):1672-81. 1999.
- You S, Stump DD, Branch AD, Rice CM. A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. *J Virol* 78(3): 1352-66. 2004.
- Youn JW, Park SH, Cho JH, Sung YC. Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization. *J Virol* 77(21):11596-602. 2003.
- Younes SA, Yassine-Diab B, Dumont AR, et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4<sup>+</sup> T cells endowed with proliferative capacity. *J Exp Med* 198(12):1909-22. 2003.
- Young KC, Lin PW, Hsiao WC, et al. Variation of hepatitis C virus load, hypervariable region 1 quasispecies and CD81 hepatocyte expression in hepatocellular carcinoma and adjacent non-cancerous liver. *J Med Virol* 68(2):188-96. 2002.
- Young KC, Lindsay KL, Lee KJ, et al. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. *Hepatology* 38(4):869-78. 2003.
- Yu SH, Nagayama K, Enomoto N, et al. Intrahepatic mRNA expression of interferon-inducible antiviral genes in liver diseases: dsRNA-dependent protein kinase overexpression and RNase L inhibitor suppression in chronic hepatitis C. *Hepatology* 32(5):1089-95. 2000.
- Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. *J Exp Med* 188(12):2205-13. 1998.
- Zech B, Kurtenbach A, Krieger N, et al. Identification and characterization of amphiphysin II as a novel cellular interaction partner of the hepatitis C virus NS5A protein. *J Gen Virol* 84(Pt 3):555-60. 2003.

- Zein NN, Li H, Persing DH. Humoral immunity in acute and chronic hepatitis C infection. *Gastroenterology* 117(2):510. 1999.
- Zein NN, et al. A phase II randomized, double blind, placebo controlled study of tumor necrosis factor antagonist (Etanercept, Enbrel®) as an adjuvant to Interferon and Ribavirin in naïve patients with chronic hepatitis C. Abstract 566. 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. 2002.
- Zemel R, Gerechet S, Greif H, et al. Cell transformation induced by hepatitis C virus NS3 serine protease. *J Viral Hepat* 8(2):96-102. 2001.
- Zender L, Hutker S, Liedtke C, et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. *Proc Natl Acad Sci USA* 100(13):7797-802. 2003.
- Zender L, Kubicka S. siRNA based strategies for inhibition of apoptotic pathways *in vivo*—analytical and therapeutic implications. *Apoptosis* 9(1):51-4. 2004.
- Zeuzem S, Hopf U, Carreno V, et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. *Hepatology* 29(4):1280-87. 1999.
- Zeuzem S, Teuber G, Naumann U, et al. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. *Hepatology* 32(4 Pt 1):835-41. 2000.
- Zhang J, Yamada O, Yoshida H, et al. Autogenous translational inhibition of core protein: implication for switch from translation to RNA replication in hepatitis C virus. *Virology* 293(1):141-50. 2002.
- Zhang J, Randall G, Higginbottom A, et al. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. *J Virol* 78(3): 1448-55. 2004.
- Zhang X, Schmitt AC, Jiang W, et al. Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease. *Bioorg Med Chem Lett* 13(6):1157-60. 2003.
- Zhang ZX, Milich DR, Peterson DL, et al. Interferon- $\alpha$  treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy. *J Infect Dis* 175(6):1294-301. 1997.
- Zhang ZX, Lazdina U, Chen M, et al. Characterization of a monoclonal antibody and its single-chain antibody fragment recognizing the nucleoside Triphosphatase/Helicase domain of the hepatitis C virus nonstructural 3 protein. *Clin Diagn Lab Immunol* 7(1):58-63. 2000.
- Zhao WD, Lahser FC, Wimmer E. Genetic analysis of a poliovirus/hepatitis C virus (HCV) chimera: interaction between the poliovirus cloverleaf and a sequence in the HCV 5' nontranslated region results in a replication phenotype. *J Virol* 74(13):6223-26. 2000.

- Zhao WD, Wimmer E. Genetic analysis of a poliovirus/hepatitis C virus chimera: new structure for domain II of the internal ribosomal entry site of hepatitis C virus. *J Virol* 75(8):3719-30. 2001.
- Zhao X, Tang ZY, Klumpp B, et al. Primary hepatocytes of *Tupaia belangeri* as a potential model for hepatitis C virus infection. *J Clin Invest* 109(2):221-32. 2002.
- Zhou S, Liu R, Baroudy BM, et al. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. *Virology* 310(2):333-42. 2003.
- Zhou YH, Moriyama M, Esumi M. Multiple sequence-reactive antibodies induced by a single peptide immunization with hypervariable region 1 of hepatitis C virus. *Virology* 256(2):360-70. 1999.
- Zhou YH, Shimizu YK, Esumi M. Monoclonal antibodies to the hypervariable region 1 of hepatitis C virus capture virus and inhibit virus adsorption to susceptible cells *in vitro*. *Virology* 269(2):276-83. 2000.
- Zhou YH, Takekoshi M, Maeda F, et al. Recombinant antibody Fab against the hypervariable region 1 of hepatitis C virus blocks the virus adsorption to susceptible cells *in vitro*. *Antiviral Res* 56(1):51-9. 2002a.
- Zhou YH, Sugitani M, Esumi M. Sequences in the hypervariable region 1 of hepatitis C virus show only minimal variability in the presence of antibodies against hypervariable region 1 during acute infection in chimpanzees. *Arch Virol* 147(10):1955-62. 2002b.
- Zhu F, Eckels DD. Functionally distinct helper T-cell epitopes of HCV and their role in modulation of NS3-specific, CD8+/tetramer positive CTL. *Hum Immunol* 63(9):710-8. 2002.
- Zhu J, Wang CL, Zhu LX, et al. DNA immunization with recombinant HCV E2 expression plasmids. *Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai)* 34(4):445-51. 2002.
- Zhu N, Khoshnan A, Schneider R, et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. *J Virol* 72(5):3691-97. 1998.
- Zhu N, Ware CF, Lai MM. Hepatitis C virus core protein enhances FADD-mediated apoptosis and suppresses TRADD signaling of tumor necrosis factor receptor. *Virology* 283(2):178-87. 2001.
- Zhu Q, Guo JT, Seeger C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. *J Virol* 77(17):9204-10. 2003.
- Zibert A, Meisel H, Kraas W, et al. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. *Hepatology* 25(5):1245-49. 1997.
- Zinkernagel RM. Immunity, immunopathology and vaccines against HIV? *Vaccine* 20(15):1913-7. 2002.
- Zinkernagel RM. On natural and artificial vaccinations. *Annu Rev Immunol* 21:515-46. 2003.